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2
Acknowledgments
With all my heart I want to thank the following people who supported me in realizing
this project:
• My doctoral advisor Prof. Dr. Jürgen Hubbuch for mentoring, pushing, hiring and
inspiring me during the last years. His great lectures literally forced me into joining
our Biomolecular Separation Engineering group and it was him who raised my in-
terest in high-throughput screening and virus-like particles. With great discussions,
his open mind, his support for conference participations as well as academic and
industrial collaborations, he allowed me to expand my horizon and to develop pro-
ject ideas and this thesis. Thank you for giving me this great opportunity to work
as a PhD student in your group.
• Prof. Dr.-Ing. Udo Reichl for being the second referee of my thesis, for taking the
long way from Magdeburg to Karlsruhe for my dissertation defense, for giving me
the opportunity to give my first conference talk (ENVVP2013) and for great dis-
cussions on virus-like particle vaccines.
• Dr.-Ing. Stefan Oelmeier for introducing me to high-throughput experimentation,
aqueous two-phase extraction and scientific writing, presenting and working. Wi-
thout your support and mentoring skills this thesis would probably not exist.
• All project members for their material, financial and scientific support. My special
thanks go to Prof Dr. Anton Middelberg for introducing me to the world of virus-
like particles and giving me the great opportunity to visit his group in Brisbane.
Dr. Heike Schwarz, Dr. Richard Kneusel and Dr. Iris Asen from Diarect for their
support on insect cells, parvo-VLPs and inviting me to Freiburg, Kim Erickson and
Prof Dr. Robert Garcea from the University of Colorado for their help with protein
expression in E.coli, Dr. Louis Villain, Katrin Töppner and Dr. Martin Leuthold
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Numerous human drugs have emerged over the last decades by the implementation of
biopharmaceutical manufacturing processes. Continuous improvements and innovations
in genetic, biomolecular and bioprocess engineering have created versatile prospects for
pharmaceutical drug design. Biopharmaceutical processes utilizing recombinant DNA
technology have evolved from the production of comparably small biomolecules (anti-
biotics, hormones, enzymes) into manufacturing of large biomolecules (monoclonal anti-
bodies, virus-like particles, nucleic acids) allowing treatment of cancer as well as infec-
tious, autoimmune and cardiovascular diseases. However, the production in genetically
modified organisms requires a long and complex process chain of upstream processing
(USP), downstream processing (DSP) and formulation of the desired target molecule.
During USP, the biomolecules are produced in bioreactors and are subsequently puri-
fied during DSP to remove undesired process- and product-related impurities that might
impact drug safety and efficacy. It is evident that an increasing complexity and size of
target molecules challenges the design of biopharmaceutical processes. Hence, the scope
of this doctoral thesis was to develop novel systematic procedures for the process design
of large biomolecular entities. Apart from monoclonal antibodies (mAbs) another fast
growing class of biologics represented the key issue of this work: recombinant protein-
based virus-like particles (VLPs).
VLPs are highly ordered protein assemblages covering a size range of 20-200 nm. Due to
their pathogen-associated molecular patterns and the lack of viral nucleic acids, VLPs
represent promising bionanoparticles for vaccine applications, generating new prospects
for untreated infectious diseases and emerging pandemic threats. An increasing multitu-
de of VLPs have been developed in different recombinant production systems and were
approved for vaccination against cervical cancer, hepatitis B, hepatitis E and malaria.
Novel VLP structures and vaccine candidates in clinical studies were reviewed in the
first section of this doctoral thesis highlighting current trends, process limitations and
state-of-the-art unit operations for purification. With regard to an economic and rapid
process, aqueous two-phase extraction (ATPE), precipitation and membrane chromato-
graphy were identified as promising DSP unit operations for VLPs. For rapid and robust
process development, high-throughput experimentation (HTE) and mechanistic modeling
approaches were implemented and applied for industrially relevant biological feedstocks.
In general, this doctoral thesis is divided into four major topics aiming at accelerating,
innovating and intensifying processing of VLPs. Whereas the first section focuses on the
development of HTE-based proceedings for low-cost and rapid VLP processes, the second
approach deals with the in silico design of a membrane process, the third section covers
the HTE-based development of an alternative VLP upstream process and the last section
concludes with the development of a high-throughput (HT) assay for the characterization
of VLPs.
The evaluation of ATPE for mAbs and VLPs is the first central topic of this thesis. Cha-
racterization of polyethylene glycol (PEG)-salt aqueous two-phase systems (ATPSs) and
partitioning studies were realized by automated screenings on a robotic liquid handling
station. HT-compatible analytics were conducted in microtiter plates by implementing
an ultra-high performance liquid chromatography (UHPLC) method and automated pro-
tein and DNA assays. More than twenty PEG-salt ATPS phase diagrams were generated
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and a variety of system compositions were screened and ranked for mAbs and VLPs in
terms of attained recovery, capacity and purity. The ultimate goals were to elucidate
optimal design spaces and critical process attributes of an ATPS capture step. The mole-
cular weight of PEG, the pH value and the salt type were identified as main parameters
affecting the partitioning of mAbs and VLPs. In order to gain a more profound pro-
cess understanding, the partitioning patterns were successfully correlated with solubility
curves for mAbs, VLPs and host-cell proteins (HCPs) indicating that the distribution
was primarily dictated by solubility limitations in ATPS phases. Hence, a systematic
solubility-guided screening procedure was followed for the design of ATPS processes. Ca-
se studies for several human IgG1 antibodies derived from Chinese hamster ovary (CHO)
cells and human B19 parvovirus-like particles derived from Spodoptera frugiperda insect
cells highlighted the benefit of the solubility-guided HTS-based approach. The proposed
capture steps for mAbs and VLPs allowed high loading capacities in the ATPS top phases
approaching capacities of chromatographic stationary phases. Regarding VLP purificati-
on, the developed process incorporated clearance of cell debris and host-cell DNA while
concentrating VLPs in the top phase.
For further optimization of the separation efficiency by ATPE, centrifugal partition chro-
matography (CPC) was assessed as scalable multi-stage extraction method. A ’Design
of Experiments’ (DoE) approach was applied for determining the effect of operating and
system conditions on the separation of VLPs and mAbs from HCPs. Low flow rates and
elevated rotation speeds lead to an increased resolution of target and contaminant com-
ponents. These findings were successfully correlated with the retention of stationary phase
in the CPC. Optimum operating conditions and ATPS compositions were identified for
both mAbs and VLPs demonstrating the general feasibility of the CPC technology for
purification of biopharmaceuticals. An operation procedure referred to as ’Dual Mode’
revealed the best process performance for mAbs by stripping HCPs through inversion of
mobile and stationary phases during the run.
In order to meet required purity levels for biopharmaceuticals with more simple purifi-
cation procedures, alternative two step processes incorporating a combination of ATPE
and precipitation were developed for mAbs and VLPs demanding only minimal invest-
ments for hardware. Process integration of a single-stage PEG-salt ATPE in accordance
with subsequent steps was pursued by precipitation of target molecules from ATPS top
phases. For process development, a HTS method was established allowing miniaturized
and automated precipitation, solid-liquid separation and resolubilization of biomolecules.
Hence, straightforward non-chromatographic downstream processes for mAbs and VLPs
were designed by HTE obtaining protein purities in the range of 90 to 98%. In parti-
cular, the demonstrated orthogonal separation mechanisms of ATPE and precipitation
depicted important findings. Whereas cell debris and host cell DNA were cleared from
VLP feedstocks by ATPE, HCPs were depleted by precipitating VLPs with PEG. Results
by Fourier transform infrared spectroscopy (FTIR) for mAbs and transmission electron
microscopy (TEM) as well as immuno dot blots for VLPs confirmed the preservation of
the native protein and particle structure of processed target substances.
The focus of the second topic of this thesis lies on the implementation of a process model
for membrane adsorbers allowing in silico design of VLP purification procedures with
minimal experimental effort. The scope of this approach was to develop a bind-and-elute
anion-exchange membrane chromatography step for the isolation of human B19 parvovi-
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rus VLPs from a complex insect cell lysate. Hydrodynamic mass transfer in a spiral wound
membrane module was modeled using a lumped rate model adapted to radial flow. Mo-
deling of ion-exchange for the complex VLP feedstock was performed with a scaled steric
mass action model using UV absorption-based modeling. All process model equations
were integrated in the in-house chromatography software package ChromX. The software
allowed automation of model parameter estimations and of process optimizations based
on evolutionary algorithms. For process simulations the feedstock was virtually split into
17 subcomponents. Model parameters were estimated for each subcomponent based on
experimental calibration runs and utilized to generate a design space and process solu-
tion for maximum product recovery and purity in a simple salt step elution procedure.
Binding conditions for VLPs were optimized by HTE-based approaches using DoE and
micro-scale membrane formats. The hybrid approach of HTE and mechanistic modeling
resulted in a membrane process with a high dynamic binding capacity and purity.
Major obstacles impairing the performance of VLP processes are the large size and com-
plexity of the bionanoparticles. A method to avoid upstream and downstream processing
of such large particles is the production of VLP subunits. The murine polyomavirus (Mu-
PyV) protein VP1 is a capsid protein capable of forming VLPs by in vitro self-assembly
under controlled buffer conditions. MuPyV VLPs have been evaluated in multiple pre-
clinical studies for generation of tailored chimeric vaccines presenting surface-exposed
foreign antigenic epitopes. The third section of this thesis deals with the HTE-based op-
timization of an alternative low-cost microbial production platform for MuPyV VLPs.
The development approach included codon optimization of the VP1 insert, strain and
vector selection, miniaturized upstream development, HT cell lysis and HT-compatible
analytics by capillary gel electrophoresis. During micro-scale cultivations in 48-well format
the temperature, shaker speed, pH value and induction conditions were varied according
to a DoE set-up. Obtained product titers for the optimum conditions exceeded all so far
reported VLP yields at shaker flask scale and reached the highest levels at the optimum
growth temperature for E.coli (37 ◦C), decreased pH (pH 6), and low oxygen supply at
a shaker speed of 600 rpm. In addition, a scalable purification procedure based on mem-
brane chromatography and size-exclusion chromatography was suggested with a final in
vitro assembly step creating homogeneous spherical bionanoparticles. In summary, the
developed alternative production process comprises a promising and industrially feasible
option for tailored VLP vaccines.
The last section of this thesis focuses predominantly on the development of a rapid and
generic characterization method for VLPs. Therefore, different commercial size-exclusion
chromatography columns were evaluated on a UHPLC system for the separation of VLPs
and VLP aggregates. Subsequent to the identification of a promising chromatographic
support, the method was accelerated by performing interlaced sample injections. This
procedure allowed the establishment of a VLP characterization method with a through-
put of 20 samples per hour outperforming traditional analytical VLP methods with one
or two samples per hour. The developed assay was successfully applied for the charac-
terization of five VLP vaccine candidates including human papillomavirus (HPV) VLPs,
human enterovirus 71 (EV71) VLPs, MuPyV VLPs, human B19 parvovirus VLPs, and
chimeric hepatitis B core antigen (HBcAg) VLPs. This highlights the generic applicabili-
ty of the assay for VLPs. The method was furthermore supported and complemented by
dynamic light scattering and TEM measurements. In order to deploy the analytical tool
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for HTE case studies, the assay was used to track VLP aggregates during downstream
processing and stability studies.
In summary, the HTE methods and process models established in this doctoral thesis re-
present novel powerful tools for the design of VLP processes and have laid the foundation
for an improved understanding and control of the applied unit operations.
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Zusammenfassung
In den vergangen Jahrzehnten wurden weltweit zunehmend mehr Arzneimittel auf Basis
von biopharmazeutischen Herstellungsverfahren entwickelt und produziert. Die großtech-
nische Produktion neuartiger biopharmazeutischer Wirkstoffe beruht dabei vor allem auf
Fortschritten in der Entwicklung und Optimierung gentechnischer, molekularbiologischer
und verfahrenstechnischer Methoden. Biopharmazeutische Herstellprozesse beschränkten
sich in der Vergangenheit zunächst noch auf vergleichsweise kleine Biomoleküle wie Anti-
biotika, Hormone oder Enzyme. Heutzutage werden rekombinante DNA-Techniken auch
zur Produktion großer Biomoleküle wie monoklonaler Antikörper, Virus-ähnlicher Par-
tikel oder Nukleinsäuren eingesetzt. Hierdurch sind unter anderem neue Möglichkeiten
zur Therapie und Prävention von Krebs, Infektionskrankheiten, Autoimmunerkrankun-
gen und Herz-Kreislauf-Erkrankungen entstanden. Die Wirkstoffproduktion in gentech-
nisch veränderten Organismen erfordert jedoch eine lange und komplexe Prozesskette von
Kultivierungsverfahren (Upstream Processing), Aufarbeitungs- (Downstream Processing)
und Formulierungsschritten bis zum fertigen Produkt. Die Herstellung von Biomolekülen
wird über die Kultivierung gentechnisch veränderter Expressionswirte in Bioreaktoren
realisiert. Im Anschluss daran werden bei der Aufarbeitung unerwünschte prozess- und
produktbedingte Verunreinigungen abgetrennt, die die Arzneimittelsicherheit und Wirk-
samkeit beeinträchtigen können. Es ist offensichtlich, dass eine zunehmende Komplexität
und Größe von Biomolekülen die Auslegung biopharmazeutischer Prozesse zusätzlich er-
schwert. Das Ziel der vorliegenden Dissertation war es daher die Entwicklung neuer syste-
matischer Verfahren für die Prozessauslegung großer Biomoleküle voranzutreiben. Neben
der Betrachtung monoklonaler Antikörper (engl. monoclonal antibodies (mAbs)) lag der
Fokus dabei vor allem auf einer zunehmend wichtiger werdenden biopharmazeutischen
Produktklasse: Virus-ähnliche Partikel (engl. virus-like particles (VLPs)).
VLPs sind hochorganisierte Bionanopartikel im Größenbereich von 20-200 nm, die sich
aus einer Vielzahl von Proteinuntereinheiten zusammensetzen. Aufgrund ihrer pathogen-
assoziierten Struktur und fehlender viraler Nukleinsäuren stellen die Partikel eine vielver-
sprechende Alternative für Impfstoffanwendungen dar. Hierdurch entstehen neue Möglich-
keiten für die Prävention bislang nicht oder nur schwer therapierbarer Infektionserkran-
kungen wie Ebola, HIV oder Malaria. In den letzten Jahren wurde eine Vielzahl an VLP-
Strukturen in verschiedenen rekombinanten Systemen hergestellt und teilweise bereits in
Vakzinformulierungen zugelassen. Impfstoffe gegen Gebärmutterhalskrebs, Hepatitis B,
Hepatitis E und Malaria basieren beispielsweise auf pathogen-assoziierten VLPs. Im ers-
ten Abschnitt der vorliegenden Dissertation wurden neuartige VLPs und VLPs in klini-
schen Studien genauer betrachtet und aktuelle Trends, Prozesslimitierungen und Verfah-
rensschritte für die Aufarbeitung von VLPs evaluiert. Dabei wurden die wässrige Zweipha-
senextraktion, Präzipitation sowie Membranchromatographie als vielversprechende Ver-
fahren für kostengünstige und schnelle VLP- Prozesse ausgemacht. Für eine schnelle und
robuste Prozessentwicklung wurden zwei verschiedene Ansätze implementiert und für in-
dustriell relevante biopharmazeutische Produkte angewandt: Hochdurchsatz-Experimente
(HTE) sowie die mechanistische Prozessmodellierung.
Die vorliegende Dissertation ist in vier Themenbereiche untergliedert, die darauf ab-
zielen die Prozessierung von VLPs zu beschleunigen, zu intensivieren und innovative
Lösungsansätze zu generieren. Im ersten Teil der Arbeit liegt der Fokus auf der Entwick-
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lung von HTE-basierten Ansätzen für kostengünstige und schnelle VLP-Aufarbeitungs-
prozesse. Im zweiten Themenbereich wird die Implementierung mechanistischer Modelle
zur in silico Auslegung von Membranverfahren für VLPs behandelt. In den letzten beiden
Kapiteln werden neuentwickelte Methoden für einen alternativen VLP-Herstellprozess
und eine Hochdurchsatz-kompatible Analytikmethode für die Charakterisierung von VL-
Ps vorgestellt.
Das erste zentrale Thema der Dissertation ist die Evaluierung der wässrigen Zweipha-
senextraktion für die Aufarbeitung von mAbs und VLPs. Die Charakterisierung von Po-
lyethylenglykol (PEG)-Salz-Systemen sowie Verteilungsstudien wurden hierfür über au-
tomatisierte Screenings auf einer Pipettierroboterplatform realisiert. Hochdurchsatzkom-
patible analytische Verfahren wurden im Mikrotiterplatten-Maßstab durchgeführt. Da-
bei kamen sowohl Ultra-Hochleistungsflüssigkeitschromatographie (UHPLC)-Methoden
als auch automatisierte farbstoffbasierte Methoden für die Gesamtprotein- sowie DNA-
Quantifizierung zum Einsatz. Mehr als zwanzig Phasendiagramme für PEG-Salz-basierte
wässrige Zweiphasensysteme wurden generiert und eine Vielzahl von Systemzusammen-
setzungen wurde für die Aufarbeitung von mAbs und VLPs evaluiert. Die Hauptkrite-
rien bei der Auswahl geeigneter Systemzusammensetzungen waren die Ausbeute, Ka-
pazität und Reinheit. Im Vordergrund standen bei der Prozessentwicklung vor allem
die Auslegung optimaler Prozessfenster sowie die Identifizierung kritischer Prozessattri-
bute bei der wässrigen Zweiphasenextraktion. Die Hauptparameter, die die Verteilung
von mAbs sowie VLPs in wässrigen Zweiphasensystemen beeinflussten, waren das Mo-
lekulargewicht des eingesetzten Polymers, der pH-Wert sowie die Salzart. Um ein fun-
dierteres Prozessverständnis zu generieren, wurden die erhaltenen Verteilungsmuster mit
Löslichkeitskurven für mAbs, VLPs und Wirtszellproteine (HCPs) korreliert. Die Ergeb-
nisse zeigten deutlich, dass die Verteilung hauptsächlich durch Löslichkeitsgrenzen in den
ATPS-Phasen bestimmt wurde. Über ein löslichkeitsbasiertes Screening-Verfahren konn-
te die Zusammensetzung der wässrigen Zweiphasensysteme daher so optimiert werden,
dass in den Oberphasen für mAbs und VLPs sehr hohe Kapazitäten in der Nähe von
Bindekapazitäten von Chromatographiematerialien erreicht wurden. Bei der wässrigen
Zweiphasenextraktion der VLPs konnten ein Großteil der Zellbruchstücke und Wirtszell-
DNA abgetrennt und die VLPs in der Oberphase konzentriert werden.
Eine weitere Optimierung der wässrigen Zweiphasenextraktion wurde über mehrstufige
Extraktionen mit Hilfe der zentrifugalen Verteilungschromatographie (engl. centrigual
partition chromatography (CPC)) evaluiert. Der Einfluss von Betriebs- sowie Systempa-
rametern auf die Trennung von VLPs und mAbs von HCPs wurde über einen Design
of Experiments (DoE) Ansatz untersucht. Dabei wurde fesgestellt, dass geringe Flussra-
ten und erhöhte Rotordrehzahlen zu einer verbesserten Trennung von Zielkomponenten
und HCPs führten. Die Ergebnisse konnten erfolgreich mit der Retention der stationären
Phase in der CPC korreliert werden. Sowohl für mAbs als auch für VLPs wurden op-
timale Betriebsbedingungen und Zusammensetzungen der wässrigen Zweiphasensysteme
entwickelt, die zeigten, dass es sich bei der CPC-Technologie um eine vielversprechende
Aufarbeitungsmethode für Biopharmazeutika handelt. Vor allem die Anwendung der ’Du-
al Mode’-Verfahrensweise, bei der HCPs über den Wechsel von mobiler und stationärer
Phase abgereichert wurden, führte bei der Aufarbeitung von mAbs zu der höchsten Rein-
heit. Um die regulatorischen Reinheitsvorgaben für Biopharmazeutika wie mAbs und
VLPs mit möglichst einfachen Prozessen und minimalen Investitionskosten zu erfüllen,
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wurde ein zweistufiges Verfahrenskonzept entwickelt. Die Prozessintegration eines Ex-
traktionsschrittes sollte hierfür über die Präzipitation der Zielmoleküle aus der Oberphase
umgesetzt werden. Für die Prozessentwicklung wurde eine HTE-basierte Methode entwor-
fen, mit der miniaturisierte und automatisierte Fällungen mit gekoppelter Fest-Flüssig-
Trennung und Wiederauflösung präzipitierter Biomoleküle untersucht werden sollten. Die
Methodik ermöglichte eine schnelle Entwicklung nicht-chromatographischer hochselek-
tiver Reinigungsprozesse für VLPs sowie mAbs mit erzielten Proteinreinheiten von 90
bis 98%. Insbesondere die gezeigte Orthogonalität der Trennmechanismen der wässrigen
Zweiphasenextraktion und Präzipitation stellt eine wichtige Erkenntnis der Arbeit dar.
Während Zellbruchstücke und Wirtszell-DNA primär im ersten Verfahrensschritt über die
wässrige Zweiphasenextraktion abgetrennt wurden, wurde die Abreicherung von HCPs
vor allem über die Präzipitation der VLPs mit PEG erreicht. Untersuchungen basierend
auf der Fourier-Transformations-Infrarotspektroskopie (FTIR) für mAbs und der Trans-
missionselektronenmikroskopie (TEM) sowie Immunoblot-Analyse für VLPs bestätigten
in beiden Fällen den Erhalt der nativen Struktur der Zielmoleküle.
Der Schwerpunkt des zweiten Themenbereichs der Arbeit ist die Implementierung eines
Prozessmodells für Membranadsorber, das die in silico Auslegung chromatographischer
Aufarbeitungsverfahren für VLPs mit minimalem experimentellen Aufwand ermöglichen
soll. Ziel hierbei war die Entwicklung eines Chromatographieverfahrens für die Bin-
dung und Elution humaner Parvovirus B19 VLPs aus einem Insektenzelllysat mittels
Anionenaustauscher-Membranadsorbern. Der hydrodynamische Stofftransport in einem
spiralförmig gewundenen Membranadsorbermodul wurde unter Verwendung des ’Lumped
Rate’-Modells bei radialer Anströmung modelliert. Für die Modellierung der Stofftrans-
portvorgänge von Komponenten aus einem komplexen Spodoptera frugiperda Lysat war
es notwendig die Modellgleichungen mit UV-Absorptionskoeffizienten so zu modifizieren,
dass Berechnungen auf Basis von UV-Signalen möglich wurden. Für die Beschreibung
der Adsorption und Desorption über Ionenaustauschvorgänge wurde das Steric-Mass-
Action-Modell verwendet. Alle Modellgleichungen wurden in die am Lehrstuhl entwickelte
Chromatographiesoftware ChromX integriert. Die Software ermöglicht die automatisierte
Schätzung von Modellparametern und optimalen Prozessbedingungen basierend auf ge-
netischen Algorithmen. Für Prozesssimulationen wurde das Ausgangsmaterial basierend
auf dem Elutionsverhalten einzelner Spezies in 17 Komponentengruppen unterteilt. Für
jede Teilkomponente wurden basierend auf experimentellen Kalibrierungsläufen die Mo-
dellparameter geschätzt und im Anschluss verwendet, um Prozessfenster und Lösungen
für eine maximale Produktausbeute und Reinheit bei einer stufenweisen Salzelution zu
generieren. Bindungsbedingungen für VLPs wurden durch HTE-basierte Ansätze mittels
DoE und miniaturisierten Membranformaten optimiert. Der kombinatorische Ansatz von
HTE und mechanistischer Prozessmodellierung ermöglichte es in kurzer Zeit und mit
minimalem Probenverbrauch einen Membranprozess mit hohen dynamischen Bindekapa-
zitäten und Produktreinheiten auszulegen.
Die Effizienz von VLP-Prozessen wird im Wesentlichen von der Größe und Komple-
xität der Partikel beeinflusst. Die Produktion von VLP-Untereinheiten stellt einen An-
satz dar, bei dem statt ganzen Partikel einzelne Virusproteine prozessiert werden. Zum
Ende des Prozesses hin können die Virusproteine unter definierten Pufferbedingungen
dann zu VLPs zusammengebaut werden. Eine vielversprechende VLP-Plattform, die in
mehreren präklinischen Studien zur Erzeugung maßgeschneiderter chimärer Impfstoffe
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verwendet wurde, ist die Herstellung von murinen Polyomavirus (MuPyV) VLPs. Der
dritte Teil dieser Arbeit beschäftigt sich mit der HTE-basierten Optimierung einer al-
ternativen mikrobiellen Produktionsplattform für MuPyV VLPs. Der Entwicklungsan-
satz umfasste dabei die Codon-Optimierung der Gensequenz des Haupt-Kapsidproteins
VP1, die Stamm- und Vektorauswahl, miniaturisierte Kultivierungsexperimente, eine
Hochdurchsatz-Zellaufschlussmethode und eine Hochdurchsatz-Analytik mittels Kapillar-
Gelelektrophorese. In miniaturisierten Kultivierungsversuchen im 48-Well Format wurden
die Temperatur, die Schüttelgeschwindigkeit, der pH-Wert und die Induktionsbedingun-
gen mittels DoE-Ansatz variiert. Die erzielten Produkttiter für die optimalen Expres-
sionsbedingungen übertrafen alle bislang veröffentlichten VLP-Ausbeuten im Schüttel-
kolbenmaßstab und waren bei der optimalen Wachstumstemperatur für E.coli (37◦C),
einem leicht sauren pH-Wert (pH 6) und einem geringen Sauerstoffeintrag bei einer
Schüttlergeschwindigkeit von 600 rpm am höchsten. Nach der Optimierung der Expres-
sionsbedingungen wurde zudem ein Prozess zur Aufarbeitung der Virusproteine entwi-
ckelt. Für die Herstellung homogener, kugelförmiger Partikel wurden die Virusproteine
zunächst per Membranchromatograhie und Größenausschlusschromatographie aufgerei-
nigt und anschließend per in vitro Assemblierung zu VLPs zusammengelagert. Insgesamt
konnte somit eine vielversprechende und industriell anwendbare Prozessalternative für
neuartige VLP-Produkte entwickelt werden.
Der letzte Teil dieser Arbeit konzentriert sich hauptsächlich auf die Entwicklung einer
schnellen und generischen Methode zur Qualitätskontrolle von VLPs. Hierfür wurden
an einem UHPLC-System verschiedene analytische Größenausschlusschromatographie-
Säulen im Hinblick auf die Trennleistung von VLPs und VLP-Aggregaten evaluiert. Die
Analysezeit für die vielversprechendste analytische Säule konnte über vorgeschaltetete
(engl. interlaced) Probeninjektionen drastisch verkürzt werden. Dadurch wurde ein ana-
lytischer Durchsatz für die Charakterisierung von VLPs mit bis zu 20 Probeninjektionen
pro Stunde erreicht. Die entwickelte Methode wurde erfolgreich zur Charakterisierung von
fünf VLP-Impfstoff-Kandidaten einschließlich humaner Papillomavirus (HPV) VLPs, hu-
maner Enterovirus 71 (EV71) VLPs, MuPyV VLPs, humaner Parvovirus B19 VLPs und
chimärer Hepatitis-B-Core-Antigen (HBcAg) VLPs eingesetzt. Dies unterstreicht die ge-
nerische Anwendbarkeit der Methode für VLPs. Die Methode wurde weiterhin durch dy-
namische Lichtstreuungs- und TEM-Messungen gestützt und ergänzt. Die Anwendung in
zwei HTE-Fallstudien zeigte, dass mit der Methode VLP-Aggregate während der Entwick-
lung von Aufarbeitungsprozessen und in Stabilitätsstudien nachverfolgt werden konnten.
Zusammenfassend stellen die in dieser Doktorarbeit etablierten Hochdurchsatzmethoden
und Modelle neue und wichtige Werkzeuge für die Auslegung von VLP-Prozessen dar und
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Over the last century, the global health infrastructure and pharmaceutical industry have
been drastically changing. The average human life span was dramatically increased
by improvements in global sanitation and hygiene, and the introduction of antibiotics
and vaccines (Cooper et al., 2002). The rise of novel pathogens, cancer, infectious,
metabolic, neurodegenerative and cardiovascular diseases represent today’s major public
health threats. The majority of current pharmaceutical drugs is based on small molecules
derived from chemical synthesis or natural material. However, advances in biomolecu-
lar, genetic and bioprocess engineering have created essential healthcare prospects in the
last decades by enabling the industrial-scale production of larger molecules: biologics.
Biologics summarize a large number of therapeutic and prophylactic drugs derived from
living organisms including enzymes, hormones, growth factors, blood factors, monoclonal
antibodies (mAbs) and vaccines. The molecular variety and tailor-made design of bi-
ologics have generated a broad range of target indications such as therapies of cancer,
autoimmune diseases, infectious diseases or hormone and enzyme deficiencies. Hence,
biopharmaceutical products account for the fastest growing segment in the global phar-
maceutical industry (Love et al., 2013) and are steadily creating novel therapy approaches
such as gene or cell therapies. Numerous clinical and postlicensing successes of thera-
pies with biopharmaceutical products have heightened the enthusiasm for the future of
biologics. Nevertheless, despite these successes, there are a lot of constraints linked to
the development and manufacturing of biopharmaceutical products. Especially the high
costs of biologics resulting in limited accessibility for developing countries and increasing
burdens for global health insurances represent a critical issue. The high expenditure of
biopharmaceutical products is predominantly generated by time-intensive product devel-
opment phases and cost-intensive manufacturing processes.
Manufacturing processes of biologics are generally divided into upstream processing (USP),
downstream processing (DSP), formulation, and filling and packaging of a biopharma-
ceutical drug product. In a typical USP of a biologic drug, eukaryotic or prokaryotic cells
expressing the target molecule are cultured in bioreactors. Subsequently, in the DSP, the
target molecule is separated from host cell impurities (process-related impurities) includ-
ing host cell proteins (HCPs), endotoxins or DNA and product variants (product-related
impurities) by a series of unit operations such as centrifugation, chromatography and
filtration. Finally, during formulation, the drug substance is transferred into the final
buffer at the desired concentration and filled and packaged for administration yielding
the drug product. Required capital investments for production facilities, reactors, tanks
and all unit operations are accompanied by high operating costs for cell culture media,
chromatography media, buffer consumption and facility operation. Hence, it is evident
that a reduction of manufacturing costs can only be obtained for a biopharmaceutical
drug if the yield of product is increased, if the number of process steps and process time
is lowered or if the consumption of raw materials is decreased. The definition, design and
optimization of the operating instruments, procedures and conditions is set during pro-
cess development. This underlines the impact of process development tools and strategies
on the overall costs and timelines of biopharmaceutical products.
In the following section, the design and manufacturing of a biopharmaceutical product
will be discussed in the case of virus-like particles, which represent the central topic of
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this thesis. Subsequently, downstream processing of large biomolecules will be focused,
describing theory and concepts of membrane chromatography and aqueous two-phase ex-
traction in the lights of process intensification and process integration. At the end of this
section, current process development approaches will be introduced and discussed.
1.1 Virus-like Particles (VLPs)
Virus-like particles (VLPs) comprise non-infectious assemblages of viral structural pro-
teins capable of mimicking viruses and presenting antigen epitopes. Due to the absence of
viral nucleic acids, the pathogen-associated molecular patterns, the highly repetitive sur-
faces and particle sizes from 20 to over 200 nm (Vicente et al., 2011) VLPs combine ideal
characteristics for activating T cells and B cells required for cell-mediated and humoral
immune responses (Link et al., 2012). The high variety and complexity of VLPs have
lead to a vast and steadily increasing number of medical applications. Up to date, the
majority of VLPs is used for vaccination against viral pathogens such as hepatitis B virus
(Lacson et al., 2005) and human papillomavirus (HPV) (Dochez et al., 2014). Among
the top five vaccine manufacturers by 2014 revenue (GlaxoSmithKline, Merck & Co, No-
vartis, Pfizer, and Sanofi Pasteur), each company has either initiated development or
production of VLP vaccines in recent years (Chandramouli et al., 2013, Dochez et al.,
2014, Farlow et al., 2015, Fiers et al., 2009, Sharma et al., 2011). In addition, novel tar-
get indications have recently advanced enormously such as vaccination against malaria
(Vekemans et al., 2009) and bacterial pathogens (Rivera-Hernandez et al., 2013), gene
therapy (Keswani et al., 2015, Tegerstedt et al., 2005) as well as immunotherapy of cancer
(Klamp et al., 2011), metabolic diseases (Spohn et al., 2014), chronic diseases (Bachmann
and Whitehead, 2013) and Alzheimer’s disease (Chackerian, 2010, Farlow et al., 2015).
This ongoing progress can only be realized by designing adequate VLP structures for the
desired application.
1.1.1 Structure of VLPs
In 1982, Valenzula et al. (Valenzula et al., 1982) were the first reporting the successful
production and characterization of recombinant protein-based VLPs using Saccharomyces
cerevisiae yeast cells. The surface antigen of hepatitis B virus (HBsAg) was expressed and
assembled to spherical particles revealing similar structural and functional properties as
the 22 nm hepatitis viruses secreted by human cells (Valenzula et al., 1982). Meanwhile,
HBsAg VLPs are licensed as hepatitis B vaccines (Lacson et al., 2005) and the prospects
for VLP design have become more diverse than ever before. The phenomenon of particle
assembly from proteins to VLPs depends on the applied virus protein structure, the
chemical environment and the production host. VLPs of mammalian viruses are usually
not assembled in prokaryotic cells and post-translational modifications such as protein
glycosylation require expression in eukaryotic hosts. In general, VLPs are classified as
non-enveloped and enveloped particles. Fig. 1 gives a schematic overview of different VLP
structures. In contrast to non-enveloped capsid-based VLPs, enveloped VLPs consist of
proteins enclosed by a lipid layer. The lipid layer is derived from the membrane of
the expression host and embeds glycoproteins. Depending on the parental virions and
the structural stability, VLPs consist of single or multiple proteins building single or
16
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Figure 1: Classification of recombinant protein-virus-like particles (VLPs). Particles are assembled
by one or multiple proteins building single or multilayered structures. Both lipid enveloped and non-
enveloped VLPs can be used for antigen presentation and packaging of DNA (Keswani et al., 2013),
proteins (Kaczmarczyk et al., 2011) or small molecules (Garcea and Gissmann, 2004).
multilayered protein shells. Hence, structurally simple viruses such as non-enveloped
HPV can be mimicked by expressing a single capsid protein (e.g. papillomavirus L1
(Neeper et al., 1996)), whereas more complex VLPs composed of four or more proteins
such as influenza (Pushko et al., 2011), rotavirus (Palomares and Ramı́rez, 2009) or
cytomegalovirus VLPs (Wellnitz et al., 2014) can be assembled using recombinant protein
expression systems. The spherical and highly ordered structure of VLPs is generated by
attractive interactions between virus proteins due to hydrophobic as well as charged amino
acid groups. For instance the large size of HPV VLPs with a hydrodynamic diameter of
60 nm is based on the assembly of 72 pentameric capsomeres composed of a single virus
protein L1 (Zhao et al., 2005). VLPs designed with highly similar structures as their
native viruses are mostly used to target molecules based on single or multicomponent
capsids. Other designs involve the presentation of foreign antigens or tumor-associated
cell line markers on VLP surfaces to target molecules of foreign pathogens or tumor
cells. Antigen presentation can be achieved by genetic fusion or chemical conjugation
of epitopes to capsid proteins or glycoproteins, or in case of enveloped VLPs also by
insertion of foreign glycoproteins (Lua et al., 2014). Moreover, VLPs can be designed as
delivery vehicles for packaging of molecules such as nucleic acids (Keswani et al., 2013),
proteins (Kaczmarczyk et al., 2011) or small molecules (Garcea and Gissmann, 2004).
1.1.2 Bioengineering of VLPs
Today’s diversity of VLP structures could only be realized by the development and opti-
mization of recombinant expression systems, genome sequencing and structure determi-
nation of viruses. Designing or ’bioengineering’ of VLPs requires primarily a definition
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of the desired application: immunization against a specific virus pathogen, immunization
against different virus serotypes or non-viral pathogens, targeting of tumor cells, or deliv-
ery of drug or gene substances. The application defines the necessitated complexity of the
VLP structure and therefore the selection of the production host. VLPs for vaccination
purposes against a specific virus are usually designed by expressing the major proteins of
the native virus.
Structurally simple VLPs based on a single protein are mostly generated by protein
expression in Escherichia coli or yeast cells providing high expression yields and easy
scalability (Lua et al., 2014). For protein expression, the tailored gene sequence of the
desired protein is cloned into a DNA plasmid which is transferred into the production
host cell line. During fermentation of transformed E.coli or yeast cells virus proteins
are expressed and in some cases assembled in vivo to VLPs. In vivo VLP assembly in
yeast cells occurs for instance upon expression of the major HPV capsid protein L1, the
basic subunit of Merck & Co.’s cervical cancer vaccine Gardasil R© (Neeper et al., 1996).
Another example for in vivo assembly of single protein-based VLPs is the expression
of the hepatitis B core antigen (HBcAg) in E.coli (Holmes et al., 2015). HBcAg VLPs
are currently evaluated for the immunotherapy of chronic hepatitis B (Al-Mahtab et al.,
2013), foreign epitope presentation (Karpenko et al., 2000) and drug delivery (Lu et al.,
2015). Recombinant expression of HBsAg in yeast cells yields in VLPs budding from
cells as lipid enveloped particles which are successfully used as human hepatitis B vac-
cines (Lacson et al., 2005).
More complex VLPs composed of multiple proteins can be produced in insect or mam-
malian cells. A widely spread expression system is the baculovirus expression vector
(BEVS)/insect cell (IC) system. The system relies on recombinant baculoviruses with
inserted gene sequences for the desired virus proteins. The baculoviruses carrying single
or multiple foreign genes infect the insect cells during the exponential cell growth phase
(Vicente et al., 2011), and induce both expression and in vivo assembly of virus proteins
to corresponding VLPs. The BEVS/IC system is for instance used for the production of
several non-enveloped VLP-based vaccine candidates consisting of multiple proteins such
as human B19 parvovirus VLPs (Bernstein et al., 2011), human enterovirus 71 VLPs (Lin
et al., 2015), and human rotavirus VLPs (Palomares and Ramı́rez, 2009).
Enveloped VLPs such as bilayered influenza VLPs (Hahn et al., 2013), HIV-1 gag VLPs
(Cervera et al., 2013) or filamentous ebola-VLPs Sun et al. (2009) are produced either in
insect or mammalian cells allowing appropriate protein folding and glycosylation. Mim-
icking of complex viruses with a high architectural consistency can be realized using
insect or mammalian cell culture systems. However, scalability, yields, process time and
costs represent major challenges and bottlenecks in comparison to bacterial or yeast cell
processes. Therefore, another more flexible VLP class has attracted increased attention
in recent years: chimeric VLPs.
Chimeric VLPs are tailor-made nanocarriers presenting foreign epitopes or antigens on
their surfaces to elicit immune responses against foreign pathogens or cells. Several
chimeric VLP platforms have been developed and evaluated in preclinical and clinical
phases: the bacteriophage Qβ (Bachmann and Whitehead, 2013, Riviere et al., 2014),
HBcAg (Fiers et al., 2009, Klamp et al., 2011), HBsAg (Bouchie, 2013, Vekemans et al.,
2009), the woodchuck hepadnavirus core protein (WHcAg) (Whitacre et al., 2010), the
murine polyoma virus protein VP1 (Middelberg et al., 2011) or the papaya mosaic virus
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(PapMV) system (Baz et al., 2008). Table 1 gives an overview of chimeric VLPs gener-
ated for vaccination and immunotherapy. While feasible antigen length and complexity
vary for each chimeric VLP platform, all carrier systems rely on a single virus protein
and a simple production host using either E.coli or S.cerevisiae cells. Apart from genetic
engineering, epitopes can also be fused to VLPs by chemical conjugation (Smith et al.,
2013). This covalent binding approach was for instance used for the fusion of the influenza
peptide M2e to cowpea chlorotic mottle virus (CCMV) VLPs by conjugation to surface
exposed cysteines and lysines (Cantin et al., 2011). Major advantages of chimeric VLPs
are the rapid adaptability of processes for novel antigens, the simple production hosts,
and the possibility to create artificial pathogen-like particles for non-viral pathogens or
viruses incapable of forming VLPs. Hence, this approach constitutes a powerful tool for
the generation of future vaccine platforms based on peptide design as demonstrated re-
cently by the approval of a chimeric VLP-based malaria vaccine (RTS,S/ MOSQUIRIX R©)
(Umeh et al., 2014).
Table 1: Overview of chimeric vaccines generated by epitope presentation on VLP-based nanocarriers.
Aβ: amyloid β; Claudin18: gastric epithelium-associated lineage marker; CS: Malaria P. falciparum
circumsporozoite protein; GH1: globular head domain of hemagglutinin (HA); HBcAg: hepatitis B core
antigen; HBsAg: hepatitis B surface antigen; Her2: human epidermal growth factor receptor 2; M2e:
ectodomain of influenza matrix protein 2; J8i: Group A streptococcus peptide antigen; MuPyV: murine
polyomavirus; PapMV: papaya mosaic virus; WHcAg: woodchuck hepadnavirus core protein.
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In addition, Table 1 demonstrates that chimeric VLPs are moving towards applications
beyond vaccination against infectious diseases such as therapy of cancer and Alzheimer’s
disease. However, constraints remain due to possible carrier specific immune responses,
limited length and number of fused surface epitopes, and epitope dependent biophysical
stability and process fluctuations. Another promising application, VLPs as vectors for
packaging and delivery, can be realized by exploiting the assembly and disassembly mech-
anism of VLPs. This approach was for instance implemented in in vivo studies for the
delivery of small molecules, proteins and nucleic acids using MuPyV VLPs produced in
insect cells (Tegerstedt et al., 2005). An advantage of MuPyV VLPs as delivery vehicles
is the lack of human pre-existing immunity. In contrast to vaccines, gene vector agents
need to fulfill requirements such as increased bioavailability, reduced immunogenicity,
and efficient targeted cell delivery. Hybrid delivery vectors consisting of retrovirus VLPs
produced in mammalian cells and synthetic lipid or polymer layers have shown promising
results for gene delivery to human embryonic kidney cells and human oral carcinoma
cells (Keswani et al., 2015, 2013). Increased bioavailability and reduced immunogenicity
were achieved by retarded dissociation of lipids or polymers and the absence of retroviral
envelope proteins. Using VLPs as vehicles for gene therapy avoids the potential danger
of activating viral oncogenes and offers novel prospects for the prevention, treatment and
elimination of diseases.
1.1.3 Manufacturing of VLPs
Manufacturing conditions for VLPs are tied to the definition of the product and the re-
quired degree of VLP complexity. Processes and production sites should be designed
following ’current good manufacturing practice’ (cGMP) guidelines given by regula-
tory agencies such as the US Food and Drug Administration (FDA) and the European
Medicines Agency (EMA) to ensure safe and effective products in humans (Marshall and
Baylor, 2011). In contrast to viral vaccines, a major advantage of VLP processes is the
lower biosafety risk elicited by non-infectious recombinant virus proteins (Grabherr and
Reichl, 2015). The utilization of recombinant protein expression systems generates dif-
ferent manufacturing process schemes than the production of viral vaccines.
Fig. 2 depicts process schemes of two manufacturing processes for VLP-based vaccines. In
Fig. 2a the production of enveloped influenza A (H7N9) VLPs at Novavax is illustrated.
In vivo assembled VLPs are expressed with the BEVS/IC culture system, purified by
a series of chromatography, ultracentrifugation and filtration steps, formulated into the
final formulation buffer and filled into glass vials. In contrast to traditional biopharma-
ceutical manufacturing, the entire process applies single use technologies allowing more
flexible production facilities and reduced contamination risks (Nestola et al., 2015). The
reported total batch production time was three months from virus genomic sequences to
the release of the first vaccine doses (Hahn et al., 2013). In comparison, Fig. 2b shows
the manufacturing process of the multivalent cervical cancer vaccine Gardasil R© based on
non-enveloped HPV VLPs. VLPs are produced in S. cerevisiae cells in stainless steel
fermenters, purified by a series of filtration and chromatography steps and a controlled in
vitro disassembly and re-assembly step before formulation of the drug substance including
adsorption to an aluminium-containing adjuvant (Cook, 2003, Josefsberg and Buckland,
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2012, Zhao et al., 2012). To obtain multivalent vaccines each HPV serotype VLP is pro-
duced according to the presented process scheme and merged in the final formulation
steps yielding the drug product Gardasil R©.
(a) Influenza A (H7N9) VLP vaccine process
(b) Human papilloma VLP vaccine process
Figure 2: Process schemes of manufacturing processes for virus-like particle vaccines. Process flow-
sheets were designed in SuperPro Designer R© 8.5 (Intelligen Inc., Scotch Plains, NJ, USA). Processes are
classified into upstream processing (’blue’ ), downstream processing (’black’ ) and formulation (’green’ ).
a) Production process of an insect-cell derived enveloped VLP vaccine against avian influenza A (H7N9)
virus according to Hahn et al. (2013). b) Production of the yeast-cell derived non-enveloped VLP vaccine
Gardasil R© against cervical cancer with subsequent purification and formulation steps according to Cook
(2003) and Zhao et al. (2012).
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1.2 Downstream Processing (DSP) of Large Biomolecules
Downstream processing (DSP) of human protein or vaccine products can be subdivided
into four process steps: clarification, capturing, intermediate purification, and polishing
of the target molecule. A variety of unit operations are available for these process steps to
remove process- and product-related contaminants and to ensure safe and effective drug
products. The most prevalent technique for capturing, intermediate purification and
polishing steps in biopharmaceutical manufacturing processes is liquid chromatography
(Close et al., 2014). However, the large size of complex therapeutic targets such as VLPs,
viruses, plasmid DNA or stem cells represents a challenge for DSP design affecting the
economic feasibility of novel vaccine candidates as well as gene and cell therapy products
(Willoughby, 2009). Two promising approaches for purification of larger biomolecules
have attracted increased attention in recent years: membrane chromatography and aque-
ous two-phase extraction (ATPE).
1.3 Membrane Chromatography
Membrane processes are widely used as separation techniques in pharmaceutical, food
and chemical industry. In recent years, novel membrane designs have been steadily devel-
oped for adsorptive separations entailing new prospects for bioprocesses as cost-effective
alternatives to column chromatography (Orr et al., 2013). Membrane chromatography
represents an integrated process combining filtration and chromatography in a single unit
operation. Support matrices of commercial membranes are mostly based on regenerated
cellulose due to lower costs and reduced non-specific protein binding in comparison to
synthetic polymers such as nylon or polyethersulfone (PES) (Orr et al., 2013). Adsorp-
tive membrane interactions with biomolecules can be realized by surface immobilization
of basically all ligand chemistries that are used in packed bed chromatography: cation-
exchange, anion-exchange, hydrophobic interaction, mixed-mode or affinity ligands. Ad-
ditional spacer arms (e.g. polypeptide, polyamine, polyether, etc.) are often included
between support matrix and ligand molecules to ensure a good ligand accessibility (Suen
et al., 2003).
1.3.1 The Prospects of Large Pores
Membrane pore structures are typically designed in the micrometer range to allow high
flow rates with a reduced pressure drop and decreased mass transfer resistance. Since
large pore sizes imply a reduced surface and binding capacity in comparison to porous
chromatography resins, membranes are most often used towards the end of protein down-
stream processes for polishing and flow-through procedures. On the other hand, mem-
branes generate unique prospects for processing of large biomolecules such as VLPs.
Major advantages are the large pore sizes, reduced diffusional path lengths, ease of
scale-up, avoidance of column packing, and the operation in ready-to-use disposable de-
vices. Membrane adsorbers have been successfully applied for purification of numerous
large biomolecules including plasmid DNA, adenoviruses, influenza viruses, retroviruses,
rotavirus-like particles and modified vaccinia ankara virus (McNally et al., 2014, Nestola
et al., 2014, Opitz et al., 2007, Orr et al., 2013, Vicente et al., 2008, Wolff and Reichl,
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2008, Wolff et al., 2010). Reported utilization of membranes as capture step from bio-
logical feedstocks, for product concentration or in flow-through mode at small and large
scales underline the relevance of this technique for integrated processing of VLPs.
1.3.2 Geometric and Processing Formats of Membrane Adsorbers
Several geometries of membrane chromatography devices have been developed and com-
mercialized in recent years. Fig. 3 shows an overview of the most prevalent designs
according to Ghosh (2002) and Suen et al. (2003). The most widely-used modules for
membrane chromatography are based on stacked flat-sheet or spiral wound geometries
(Ghosh, 2002). While the mobile phase in stacked flat-sheet membranes is introduced in
axial flow direction normal to the membrane surface, the liquid in spiral wound mem-
branes flows in radial direction. The two flow patterns have different effects on mass
transport phenomena of membrane processes as presented in the subsequent passage.
Figure 3: Schematic illustration of membrane chromatography modules adapted from Ghosh (2002)
and Suen et al. (2003). (A) Stacked flat-sheet, (B) spiral wound, (C) tangential flow flat-sheet, and (D)
hollow-fiber geometry.
1.3.3 Mass Transfer in Membrane Adsorbers
Similar to packed bed chromatography, the following mechanisms describe the molecular
transport within membrane adsorbers (van Beijeren et al., 2013):
• Convection within the mobile phase
• Axial dispersion within the mobile phase
• Film diffusion from the mobile phase into the stationary phase
• Pore diffusion within the stationary phase
• Surface diffusion along the membrane surface
• Adsorption and desorption kinetics at the membrane surface
Several models with different levels of complexity have been developed for mass balances
of molecules in the mobile and stationary phase. Hydrodynamic models are usually one-
dimensional neglecting effects normal to the flow direction and assuming homogeneous
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membranes and fluids. The most detailed model incorporating all above mentioned trans-
port phenomena is the general rate model (Gu et al., 1991, van Beijeren et al., 2013).
The following description of the general rate model for membrane adsorbers is based on
the research article of van Beijeren et al. (2013).
The calculation of the interstitial linear velocity u in a stacked flat-sheet module is iden-
tical to axial chromatography columns given the volumetric flow rate F , the membrane





In contrast, the frontal area Afront for a spiral wound geometry is defined by the radial
position x and the membrane height H. Hence, the interstitial velocity u increases








The continuity equation for the mobile phase in a stacked flat sheet module in axial
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kL,iav (ci − cp,i) i = 1 . . . N (3)
The change of the concentration ci of component i within the mobile phase is modeled
by three terms. The first term considers convective transport affected by the interstitial
velocity u. The middle term describes the hydrodynamic dispersion determined by the
dispersion coefficient Dax. The last term incorporates the transport of component i
between bulk and membrane pore volume ci − cp,i for the membrane porosity εpores, the
liquid film diffusion coefficient kL,i and the specific surface area av.
The continuity equation for the mobile phase in a spiral wound module in radial direction
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The algebraic sign of the convective transport term is positive for inward flow and neg-
ative for outward flow. Modeling of mass transport phenomena in the stationary phase
requires information of the membrane structure and the adsorption mechanism. The
majority of membrane adsorbers is modified with grafted polymer layers to increase the
specific surface areas. These hydrogels are incorporated in model equations by assuming
a homogeneous layer present on the pore walls with a porosity εhydrogel. Hence, the mass
balance for the stationary phase considering accumulation and mass transport within
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i = 1 . . . N (6)
The first term in Eq.(5) describes the pore diffusion within the stationary phase influenced
by the pore diffusion coefficient kp,i, while the second terms in Eq.(5) and Eq.(6) consider
the accumulation in the solid volume of the stationary phase due to binding on immo-
bilized ligands. The binding mechanism is characterized by an adsorption coefficient
kads,i, a desorption coefficient kdes,i, an accumulated concentration qi and a maximum
binding capacity qmax,i. The diffusion at the membrane surface is described by the solid
film diffusion coefficient kS,i. The adsorption of biomolecules on membrane adsorbers
can be characterized with different models depending on the driving interaction forces
and the desired complexity. In this thesis, ion-exchange (IEX) membranes were used
for purification of biomolecules. Adsorption models for IEX interactions are for instance
the Freundlich (Freundlich, 1906), Langmuir (Langmuir, 1916), Brunauer-Emmett-Teller
(Brunauer et al., 1938), and steric mass-action (SMA) isotherm (Brooks and Cramer,
1992). The steric mass action model which is applied in this thesis is a semi-mechanistic
approach that considers stoichiometric ion-exchange reactions of biomolecules with mul-
tiple binding sites on a chromatographic solid phase. The isotherm accounts the compe-
tition between salts and proteins for available binding places limited by the total ionic
capacity Λ, and incorporates a component specific characteristic charge νi and a shielding
factor σi. The kinetic form of the SMA isotherm describes the accumulation in the solid
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Eq. (8) describes the mass balance for salt ions attached to the IEX adsorbent:




1.4 Aqueous Two-Phase Extraction (ATPE)
A unit operation that has gained increased attention in recent years for downstream pro-
cessing of large biomolecules such as monoclonal antibodies, nucleic acids, viruses and
cells is aqueous two-phase extraction (ATPE) (Jue et al., 2014, Kepka et al., 2009, Richter
et al., 2014, Rosa et al., 2013a, Tsukamoto et al., 2009, Vijayaragavan et al., 2014). While
liquid extraction processes have been widely used for decades in the pharmaceutical in-
dustry for isolation and separation of small molecules such as natural drug products,
antibiotics, vitamins, and other active pharmaceutical ingredients (APIs) (Crowell, 1997,
Hanson, 2013, Voeste et al., 2012), the ATPE technique has hardly been implemented for
large scale purifications of biopharmaceutical products. In contrast to traditional biphasic
systems (e.g. organic-aqueous systems) used for extraction processes, aqueous two-phase
systems (ATPSs) provide mild process conditions for biologics using hydrophilic solutes
such as polymers or salts. However, current major drawbacks of ATPSs impeding indus-
trial applications are attributed to the high experimental effort during process develop-
ment, limited mechanistic understanding, low loading capacities, unfavourable physical
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properties for scale-up, and unknown compatibility with preceding or subsequent unit
operations. The scope of this section is to introduce the basic concept of ATPS, depict
strategies for process integration and present scalable options for multi-stage extraction.
1.4.1 The Formation of Aqueous Two-Phase Systems (ATPSs)
ATPSs can be formed by a variety of polymers, salts, ionic liquids or non-ionic surfactants
(Albertsson, 1971, Fischer et al., 2013). The most common ATPSs considered for bio-
pharmaceutical processes contain polyethylene glycol (PEG) and inorganic salts (Reschke
et al., 2014). Fig. 4 shows the illustration of a typical binary phase diagram for a PEG-salt
ATPS. Similar to traditional biphasic systems, ATPSs are characterized by equilibrium
binodal curves and tie-lines. Binodal curves reflect the components’ critical transition
concentrations for the formation of two immiscible aqueous phases (Hatti-Kaul, 2000).
Systems with concentrations above the binodal curve separate into a PEG-rich top phase
and a salt-rich bottom phase. The exact phase compositions are given by the intersection
points of binodal curve and tie-line. Along the same tie-line coordinates compositions
of top and bottom phases remain constant. In contrast, volume ratios of top to bottom
phases change for different system compositions along the tie-line as illustrated in Fig. 4.























Figure 4: Schematic phase diagram of a PEG-salt aqueous two-phase system (ATPS). The system point
SP separates into a PEG-rich top phase TP and a salt-rich bottom phase BP .
1.4.2 Partitioning in ATPSs
Purification of biomolecules by ATPE can be realized by exploiting differences in parti-
tioning trends of the target component and contaminants. A characteristic value to rank
partitioning trends of molecules is the ratio of top phase to bottom phase concentration,
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Several model approaches have been developed to correlate the partition coefficient of pro-
teins with ATPS phase properties and molecular descriptors such as molecular weight,
surface charge, and hydrophobicity (Albertsson, 1971, Andrews and Asenjo, 2010, An-
drews et al., 2005, Asenjo, 1994). Models focused on hydrophobic properties of proteins
revealed the most promising correlations using either hydrophobicities calculated from
the primary amino acid sequence, surface hydrophobicities derived from molecular dy-
namic simulations of three dimensional protein structures or experimentally determined
hydrophobicity values (Andrews and Asenjo, 2010, Dismer et al., 2013). Incorporation of
ATPS phase properties in model approaches was for instance accomplished by character-
ization with solvatochromic dyes (Madeira et al., 2013, Nuno et al., 2015), by molecular
dynamic simulations of PEG and salt molecules (Dismer et al., 2013, Oelmeier et al.,
2012a) or by description with the electrolyte fluid theory (ePC-SAFT) developed by Gross
and Sadowski (2001) (Reschke et al., 2014). Nevertheless, reliable mechanistic modeling
of ATPSs has not yet been realized since current model approaches fail to include effects
of varying biomolecule concentrations, saturation of phases and three-dimensional struc-
tures of large biomolecules such as antibodies, viruses or VLPs. An alternative empirical
approach to shorten development times for ATPS selection is solubility-guided process
development that was for instance implemented for the pre-selection of promising ATPSs
for industrial mAbs (Oelmeier et al., 2012b). The approach is based on the correlation
of solubility curves of biomolecules for increasing phase component concentrations with
ATPS compositions in top and bottom phases.
1.4.3 ATPE of Large Biomolecules
Regarding the size effect of large biomolecules on partitioning in ATPSs, Luechau et al.
(2010) developed a model for interfacial partitioning combining the theory of Brownian
motion (Boltzmann constant k (1.381×10−23JK−1), absolute temperature T ), the cross-
sectional area of a bioparticle π/4d2p and the surface tension γTP between top and bottom
phase. The theory assumes that a particle can only adsorb to the interface between
top and bottom phase if the particle motion from one phase to the other decreases the





Hence, the critical particle diameter at which interfacial adsorption might occur can be







According to calculations from Luechau et al. (2010), bioparticles with diameters above
50 nm have a high tendency to adsorb to ATPS interfaces and can hardly be distributed
into top or bottom phases. Interfacial adsorption of particles was for instance observed for
cells, cell debris, nanoparticles, protein aggregates, and viruses and offers the possibility
to integrate both a capture and solid-liquid separation into one unit operation (Oelmeier
et al., 2012b, Rito-Palomares and Lyddiatt, 2002, Selvakumar et al., 2010, Targovnik
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et al., 2012, Tsukamoto et al., 2009). This highlights the suitability of ATPE for the
initial purification of biomolecules from crude cell culture broths (Builder et al., 1995,
Hayenga and Valex, 2002, Tran et al., 2011, Van et al., 2011). Apart from solid-liquid
separation and capturing, interfacial partitioning has also been used for concentrating
biomolecules such as viruses (Jue et al., 2014). However, interfacial adsorption of target
molecules is undesirable for capture processes aiming at separating cells, and is further-
more linked to the precipitation of biomolecules (Guo et al., 2012). Vijayaragavan et al.
(2014) pointed out that top phase partitioning of large biomolecules can only be realized
if hydrophobic forces promoting partitioning into PEG-rich phases outperform the sur-
face tension of ATPSs.
Since ATPE is not considered as high-resolution separation technique, subsequent purifi-
cation procedures are needed to meet required purity levels for biopharmaceuticals. For
direct processing of PEG-rich or salt-rich phases, precipitation, filtration, hydrophobic
interaction (HIC) and mixed-mode (MM) chromatography have been evaluated for mAbs,
and other proteins (Azevedo et al., 2008, Diederich et al., 2015, Tran et al., 2011). The
main obstacle impeding direct processing by chromatographic unit operations is the high
viscosity of ATPSs causing diffusive limitations, pumping difficulties, and compression
of packed chromatography beds. Hence, integration of ATPS into an overall manufac-
turing process is easier to realize using micro- or macroporous chromatographic supports
such as membranes or monoliths (Lee et al., 1995, Vargas et al., 2015). A reduction of
viscosity is obtained by buffer exchange separating polymers by means of precipitation
or diafiltration procedures. Another procedure to increase the separation efficiencies of
ATPS processes is multi-stage extraction.
1.4.4 Multi-stage Extractors for Biopharmaceutical Processes
The goal of multi-stage ATPE is to increase the number of theoretical stages for a sepa-
ration problem. The number of theoretical stages obtainable with a multi-stage extractor
depends on operating conditions, physical properties of the biphasic system, and the de-
sign of the apparatus. In general, extractor configurations and types are classified into
three main groups: mixer-settler units, column contactors, and liquid-liquid chromatogra-
phy systems. Fig. 5 shows an overview of different extraction instruments. Mixer-settler
units possess the most simple apparatus design consisting of multiple units of mixing
stages coupled to settling and separating units (Espitia-Saloma et al., 2014). An accel-
erated mass transfer and phase separation for large scale applications is obtained with
centrifugal extractors as demonstrated by Richter et al. (2014) at Boehringer Ingelheim
for industrial scale purification of monoclonal antibodies. In column contactors top and
bottom phases are pumped in vertical direction using two separate inlets and outlets
for the lighter and heavier phase. Thus, the phase separation is realized by gravity,
while the mass transfer between the phases can be promoted by diverse mechanisms such
as spray mechanisms, rotating vanes or discs, pulsed caps, packing material or mixers
(Espitia-Saloma et al., 2014). A benefit making multi-stage extractors attractive for the
biopharmaceutical industry is the compatibility with continuous processes (Rosa et al.,
2013b).
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Figure 5: Illustration of multi-stage extraction instruments: (A) Mixer-settler units, (B) Column
extractors, (C) Centrifugal partition chromatography.
1.4.5 Centrifugal Partition Chromatography
An adaptation of extraction processes to a more chromatography-like unit operation and
to common chromatography periphery set-ups is feasible with liquid-liquid chromatog-
raphy devices. There are two types of centrifugal liquid-liquid chromatography systems:
hydrodynamic and hydrostatic counter-current chromatography (CCC). In both set-ups
one phase of an ATPS is used as stationary phase while the other phase is pumped through
the column as mobile phase. The retention of the stationary phase is achieved by different
mechanisms. The equilibrium in hydrodynamic CCC is based on the Archimedean Screw
effect generated by a combination of a coiled tube configuration and a rotating force field
with planetary motion. The technique is termed hydrodynamic since the phases redis-
tribute to the ends of the coil if the flow is stopped (Sutherland, 2007).
The first hydrodynamic CCC was designed in the 1960s by Ito et al. (1966). Since
then, the technology has been steadily advanced with novel designs such as the ’J’ type
coil planet centrifuge, multilayer toroidal coil chromatography, and centrifugal parti-
tion chromatography (CPC) (Ito and Bowman, 1977, Sumner, 2011, Sutherland et al.,
2011, Sutherland, 2007). In this thesis, CPC was evaluated for purification of large
biomolecules. Phase mixing and separation in CPC is implemented by the design of se-
rially interconnected chambers mounted circumferentially on rotating disks. Due to the
centrifugal force field, the heavier phase is distributed to the bottom while the lighter
phase is moved towards the top of each chamber. To minimize backmixing effects, the
top of one chamber is always connected to the bottom of the next by capillaries. CPC
is also referred to as hydrostatic CCC since the phases remain in the chambers if the
flow is stopped (Sutherland, 2007). CPC can be operated in ascending mode with the
heavier phase as stationary phase or in descending mode using the lighter phase as sta-
tionary phase and the heavier as mobile phase. A third operation procedure is dual mode,
a combination of ascending and descending mode, that is realized by switching the di-
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rection of flow during the process. Up to date, only few CPC case studies have been
published on the purification of proteins and other large biomolecules from cell culture
broths (Grudzien et al., 2013, Oelmeier et al., 2012b). Most reported studies on ATPS-
based CPC dealt with the separation of model proteins (Bezold et al., 2015, Chen et al.,
1999, Schwienheer et al., 2014, Sutherland et al., 2008). However, due to centrifugally
aided phase separation and a high number of theoretical stages of 200-600 (Hopmann and
Minceva, 2012), CPC is considered as an ideal extraction instrument for challenging sep-
arations in biphasic systems with low interfacial tension, low density differences and high
viscosities such as ATPSs (Adelmann and Schembecker, 2011, Schwienheer et al., 2014).
In general, the resolution in CPC predominantly depends on the retention of station-
ary phase which is influenced by operating conditions and system properties Sutherland
(2007). A higher volume of stationary phase creates narrower peaks and higher peak
resolution as demonstrated in hydrodynamic CPC models and case studies (de Folter
and Sutherland, 2009, Oelmeier et al., 2012b). Critical process parameters affecting the
stationary phase retention are the flow rate, the centrifugal speed, the chamber geometry
and the operation mode (Adelmann and Schembecker, 2011).
1.5 Process Development Tools for Biopharmaceuticals
According to Pronker et al. (2011) the average development period for a biopharmaceuti-
cal product from idea to market launch is 12 years generating research and development
costs of US$ 200-800 million (Andre, 2002, DiMasi et al., 2003). Along this develop-
ment time line molecular design, process design, preclinical in vivo studies, clinical phase
studies and ongoing process optimizations are realized. Process development for manu-
facturing of a novel drug candidate is already initiated in the discovery phase in order
to supply enough material for preclinical and clinical tests. The final process scheme for
full manufacture must be set before start of phase III clinical trials (Rathore and Win-
kle, 2009, Werner, 2004). At this stage, production processes such as those presented in
section 1.1.3 for VLP vaccines are not allowed to be changed substantially according to
FDA and EMA requirements (Yu, 2008). This applies especially to production hosts, unit
operations and process buffer solutions (Werner, 2004). In the light of ’time-to-market’
demands in the pharmaceutical industry, this circumstance enhances additional time
pressure on the process development of drug candidates. Hence, strategies for supporting
manufacturing and process development of biologics should provide systematic, rapid and
flexible tools. Traditionally, biopharmaceutical processes were designed and optimized by
one-factor-at-a time approaches and heuristic or knowledge-based approaches. Consid-
ering the diversity and high number of drug candidates in preclinical and early-stage
clinical phases, such development strategies prolong pharmaceutical development times
and result in suboptimal process conditions, which remain critical at later development
stages due to regulatory obstacles for process adjustments (Nfor et al., 2009).
The introduction of ’Quality by Design’ (QbD) in the biopharmaceutical industry has
recently changed the requirements for process development (Herwig et al., 2015, Rathore
and Winkle, 2009). The basic tenet of QbD is to assess the effect of deviations in man-
ufacturing processes on product quality attributes. For robust and rapid identification
of critical process parameters and definition of process design spaces, novel development
approaches rely on statistical methodologies, high-throughput experimentation (HTE)
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and mechanistic modeling. An ongoing trend has been initiated moving from rules of
thumb to improved understanding and sophisticated characterization of processes (Nfor
et al., 2009).
1.5.1 High-throughput Process Development (HTPD)
Automation, parallelization and miniaturization of unit operations and entire manufac-
turing processes by HTE approaches facilitate and accelerate the generation of a wide
range of experimental data enormously (Bhambure et al., 2011, Hubbuch, 2012). In
recent years, the majority of downstream process unit operations such as chromatogra-
phy, filtration, precipitation and aqueous two-phase extraction have been implemented
on robotic liquid handling stations at microtiter-plate scale (Berg et al., 2012, Bhambure
et al., 2011, Gibson et al., 2011, Wiendahl et al., 2008, 2007, 2009). Many biopharma-
ceutical companies have already established HTE routines for upstream and downstream
process development and couple the screening methods to statistical tools such as Design
of Experiments (DoE) or evolutionary search algorithms (Coffman et al., 2008, Hansen
and Oelmeier, 2012, Treier et al., 2012). While the throughput for robotic screenings of
single unit operations has been reduced to a couple of hours, novel bottlenecks arise in
analytics and data handling (Hubbuch, 2012).
1.5.2 Model-based Process Development
Further reduction of sample consumption and experimental effort is obtained by applying
mathematical models and numerical simulations for process development and optimiza-
tions (Close et al., 2014, Nfor et al., 2009). Predictive model approaches rely either
on empirical correlations or fundamental mathematical descriptions of physico-chemical
processes. Molecular dynamics (MD) simulations and quantitative structure-property
relationship (QSPR) are for instance development tools used for prediction of process
behaviour based on structural properties of biomolecules under defined buffer conditions
(Dismer et al., 2013, Ladiwala et al., 2005, Schaller et al., 2014, Zhang and Sun, 2010).
For liquid chromatography processes, several hydrodynamic and mechanistic models have
been developed as depicted in section 1.3.3 for membrane adsorbers. Thermodynamic
models describing ion-exchange, hydrophobic interaction and mixed-mode chromatog-
raphy have been implemented and applied for modeling of protein separations (Huuk
et al., 2014, Mollerup, 2008, Mollerup et al., 2008, Osberghaus et al., 2012). The devel-
opment of chromatography modeling software packages (Hahn et al., 2015a, Mehay and
Gu, 2014) incorporating hydrodynamic models, adsorption models and algorithms has
moved model-based approaches further towards industrial process development (Hahn
et al., 2015b). However, the estimation of model parameters in the presence of crude
material such as cell debris, complex feedstocks including HCPs, DNA or cell culture
medium components represents a challenge for predicting processes and defining design
spaces in silico.
In this thesis the application and development of HTE-based and model-based devel-






Virus-like particles (VLPs) have recently gained increased attention as innovative molec-
ular entities for vaccination and gene therapy. Due to the large size and complexity, the
design of recombinant protein-based VLP products represents a challenge for upstream,
downstream and analytical process development. This research work is part of the project
’Optimization of an industrial process for the production of cell-culture-based seasonal
and pandemic influenza vaccines’. Within the scope of future influenza vaccines, VLPs
are assessed as alternative vaccine platforms in collaboration with project partners from
academia and industry. The entire research consortium addresses four core areas dealing
with the design of vaccine processes: Process integration, development of novel methods,
continuous processing and aggregation (Fig. 6).
Figure 6: Overview of the project ’Optimization of an industrial process for the production of cell-
culture-based seasonal and pandemic influenza vaccines’.
The focus of this thesis is laid on the implementation of integrated bioprocesses and the
development of novel methods. In contrast to protein therapeutics such as mAbs, produc-
tion and purification procedures, chromatographic supports and analytical assays have
not yet been adapted and standardized for VLPs. Rational development strategies based
on high-throughput experimentation, statistical design and model approaches are rarely
applied. Current process development predominantly relies on heuristic approaches. The
selection of suboptimal unit operations and process conditions during DSP has lead to
dramatically low process yields and high manufacturing costs for VLP vaccines. To coun-





For realization of an economic design of future VLP processes, DSP unit operations re-
quiring minimal investment for hardware such as aqueous two-phase extraction (ATPE),
precipitation and membrane chromatography will be assessed for purification. The huge
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number of process parameters in ATPE depicts a major obstacle hindering industrial im-
plementation. The lack of mechanistic models drives process development for ATPE into
heuristic or trial-and-error experimentation. Within the scope of this thesis, accelerated
process development and improved process understanding for ATPE of large biomolecules
will be sought by coupling robotic HTE with heuristics, solubility correlations, design of
experiments and HTS-compatible analytical methods. The aim of this development strat-
egy will be to identify critical process parameters for the ATPE of mAbs and VLPs and
to define robust design spaces for purification. Another approach to reduce costs of VLP
processes will focus on the upstream part using a low-cost microbial production host:
Escherichia coli . The goal will be to optimize the process of an alternative carrier plat-
form for antigens based on the murine polyoma virus protein VP1. The murine polyoma
VLP platform is currently evaluated in preclinical trials for presentation of pathogen epi-
topes, but lacks an economic and industrially feasible production process.
As a second focus, implementation of innovative process concepts will be aspired by eval-
uation and integration of alternative unit operations. While the industrial purification
of mAbs is based on so called platform processes incorporating multiple chromatography
steps, VLPs are most often purified by ultracentrifugation. VLP or mAb purification by a
single ATPE step will not provide a sufficient purity for clinical applications. Hence, one
key aspect will be to develop a simple procedure for process integration of ATPE. With
regards to industrial relevance, the integrated process should start with a crude mAb or
VLP feedstock and end with a purified target under compatible process conditions for
subsequent steps. The realization of this approach will be attempted by evaluating pre-
cipitation and centrifugal partition chromatography (CPC) in combination with ATPE.
The development of adequate miniaturized methods and a systematic process procedure
will first of all be established in a case study on mAbs derived from mammalian cell
culture.
As a third focus, several approaches will be implemented to accelerate process develop-
ment and overall process time for VLP products. A reduction of upstream process time
is intended by using microbial cells for VLP production, while the downstream process
time is planned to be minimized by reducing the number of intermediate unit operations
and applying ATPE and precipitation for purification. Concerning speed-up of process
development and analytics, novel HTS and model-based design tools are required. HTS
tools need to be developed for miniaturized precipitation and resolubilization screenings,
automated binding screenings with membrane adsorbers, cell lysis and process analytical
techniques for VLPs.
In summary, this thesis aims to generate straightforward production, purification and
analytical procedures for VLPs by adapting and advancing rational design tools for large
biomolecules.
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1. Next Generation Vaccines and Vectors: Designing Downstream Pro-
cesses for Recombinant Protein-based Virus-like Particles
C. Ladd Effio, J. Hubbuch
Biotechnol. J. (2015), doi:10.1002/biot.201400392
Virus-like particles are protein assemblages produced in recombinant systems and
represent a new platform for vaccines and gene vectors requiring robust purifica-
tion processes. In this review article, recent advances in the design of downstream
processes and unit operations for recombinant based virus-like particles are pre-
sented. A special focus is placed on regulatory requirements, and novel strategies
for reducing manufacturing costs and development times for VLP-based products.
2. Alternative Separation Steps for Monoclonal Antibody Purification: Com-
bination of Centrifugal Partition Chromatography and Precipitation
S. A. Oelmeier, C. Ladd Effio, J. Hubbuch
J. Chrom. A (2013), doi:10.1016/j.chroma.2013.10.043
This article discusses the purification of the most prominent class of large bio-
molecules: monoclonal antibodies. A column-free process for human IgG1 is pre-
sented combining ATPE and precipitation. HTS methods were implemented to
identify optimal conditions for ATPE, precipitation and re-dissolution of antibod-
ies. For multi-stage ATPE, scale-up to a 500 mL centrifugal partition chromatogra-
phy system was performed investigating the effect of sample, system and operating
conditions on the isolation of antibodies from a Chinese hamster ovary supernatant.
For integration into a traditional protein purification process, antibodies were pre-
cipitated and re-dissolved incorporating a virus inactivation step. Preservation of
the native secondary protein structure was demonstrated by Fourier transform in-
frared spectroscopy (FTIR).
3. Downstream Processing of Virus-like Particles: Single-stage and Multi-
stage Aqueous Two-Phase Extraction
C. Ladd Effio, L. Wenger, O. Oetes, S. A. Oelmeier, R. Kneusel, J. Hubbuch
J. Chrom. A (2015), doi:10.1016/j.chroma.2015.01.007
This article describes the design of an ATPE process for human B19 parvo VLPs
derived from insect cells. Reversed-phase ultra-high performance chromatography
(RP-UHPLC) was established as high-throughput analytical tool for tracking VLPs
and host-cell proteins (HCPs). Promising ATPS conditions for VLP capturing, and
separation of host-cell DNA and cell debris were identified using HTS methods. A
systematic approach for VLP partitioning trends was developed by correlation with
solubility curves. HCP separation was realized by multi-stage extraction with a
centrifugal partition chromatography instrument. Gel electrophoresis, transmission
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electron microscopy (TEM) and binding assays with human patient sera demon-
strated the purity, homogeneity and antigen reactivity of processed VLPs.
4. Modeling and Simulation of Anion-Exchange Membrane Chromatogra-
phy for Purification of Sf 9 Insect Cell-derived Virus-like Particles
C. Ladd Effio, T. Hahn, J. Seiler, S. A. Oelmeier, I. Asen, C.Silberer, L. Villain, J.
Hubbuch
J. Chrom. A (2015), doi:10.1016/j.chroma.2015.12.006
This article deals with the application of a hybrid development approach combining
high-throughput experimentation and mechanistic modeling for the design of an
anion-exchange membrane chromatography process. Optimal binding conditions
for VLPs derived from insect cells were identified by membrane binding screenings
using design of experiments. A model for radial flow membrane chromatography
was implemented, calibrated and applied for simulating a bind-and-elute process.
Using UV absorption-based modeling a design space for an optimized salt elution
step of VLPs was developed in silico enhancing yield and purity.
5. High-throughput Process Development of an Alternative Platform for
the Production of Virus-like Particles in Escherichia coli
C. Ladd Effio‡, P. Baumann‡, C. Weigel, P. Vormittag, A. Middelberg and J. Hub-
buch (‡: Contributed equally)
J. Biotechnol. (2016), doi:10.1016/j.jbiotec.2015.12.018
This article describes the development of an upstream and downstream process
for murine polyoma VLPs in Escherichia coli. USP development was realized by
codon optimization for the major capsid protein VP1 and a HTS procedure con-
sisting of high-throughput cultivations in 48-well format, HTS cell disruption and
capillary gel electrophoresis as HTS-compatible analytical tool. A simple two-step
purification process was developed using membrane and size-exclusion chromatog-
raphy. Analysis of assembled VLPs by TEM revealed the presence of homogeneous
spherical particles.
6. High-throughput Characterization of Virus-like Particles by Interlaced
Size-Exclusion Chromatography
C. Ladd Effio, S. A. Oelmeier, J. Hubbuch
Vaccine (2016), doi:10.1016/j.vaccine.2016.01.035
This article depicts the development of a rapid analytical tool for virus-like particles.
A size-exclusion UHPLC method was designed for assessing the dispersity of VLPs.
Assay time was reduced to a few minutes by performing interlaced sample injections.
The final method was applied for characterization of five VLP vaccine candidates
and allowed tracking of VLP aggregates during DSP development and stability
studies.
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Abstract
In recent years, the development of novel recombinant virus-like particles (VLPs) has been
generating new perspectives for the prevention of untreated and arising infectious diseases.
However, cost-reduction and acceleration of manufacturing processes for VLP-based vaccines or
vectors are key challenges for the global health system. In particular, the design of rapid and
cost-efficient purification processes is a critical bottleneck. In this review, we describe and eval-
uate new concepts, development strategies and unit operations for the downstream processing
of VLPs. A special focus is placed on purity requirements and current trends, as well as chances
and limitations of novel technologies. The discussed methods and case studies demonstrate the
advances and remaining challenges in both rational process development and purification tools
for large biomolecules. The potential of a new era of VLP-based products is highlighted by the
progress of various VLPs in clinical phases.
Keywords: High-throughput screening, Modeling, Purification, Vaccine, VLP
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Virus-like particles (VLPs) represent new molecular toolboxes for the control and containment
of infectious diseases[1]. VLPs are protein assemblages composed of one or several types of
viral proteins. Lacking viral nucleic acids, they mimic the virus they are derived from in
size and morphology. In recent years, the assemblies of numerous virus-like structures have
been realized using recombinant VLP technology approaches. In addition, VLPs have been
used as carrier systems for the presentation of foreign antigen epitopes to design new tailored
vaccine candidates. Examples are the development of VLP-based vaccine candidates against
malaria [2, 3], diseases attributed to group A Strepptococcus infections [4], Alzheimer’s disease
[5, 6, 7], asthma [8, 9], diabetes [10], tumor growth [11, 12] and the design of packaged VLPs
for the delivery of anti-cancer reagents [13]. Thus, VLP technology paves new ways for further
medical applications such as immunotherapy of cancer, Alzheimer’s disease, metabolic and
chronic diseases [14].
The production of VLPs is achieved by recombinant protein expression. Viral structural proteins
are expressed in systems such as bacteria, yeast, mammalian, insect or plant cells. In eukaryote
cells the assembly into empty capsids occurs in vivo, while upstream processes with prokaryotic
cells require most often an in vitro assembly step [15]. More complex VLPs composed of several
viral proteins and a lipid envelope require a eukaryotic host. A detailed overview and comparison
of expression systems for VLPs has been reviewed elsewhere [16, 17, 18, 19, 20]. The advances
in virus structure determination, genetic engineering, and bioengineering have generated a high
and steadily increasing number of VLP-based vaccine candidates which are now evaluated in
preclinical and clinical studies [16, 17]. VLP-based vaccines have contributed significantly to the
prevention of cervical cancer and hepatitis B [21, 22]. Table 1 gives an overview of some vaccine
candidates in clinical phases, and licensed products using the VLP technology approach.
A challenge slowing down manufacturing processes and the development of new VLP-based
products is the design and scale-up of downstream processes. Purification of VLPs produced
in genetically modified cells is essential for the generation of safe human vaccines. Host cell
impurities have shown to increase reactogenicity, induce secondary immune responses, and thus
generate preventable risks for human patients [51, 52, 42]. Classical chromatography devices and
matrices for downstream processing of biopharmaceuticals were initially developed for smaller
biomolecules such as peptides and proteins. Therefore, the most widely used technique for VLP
purification is still ultracentrifugation. For decades, this technique has proven to be a valuable
platform technology for purifying and concentrating all kinds of VLPs or viruses in lab scale.
Drawbacks arise due to low product yields, limited separation efficiencies, difficult scalability,
and long process times [15]. The purpose of this review paper is to sum up new technologies,
trends, and approaches for purification of VLPs at different stages of a downstream process.
Guidelines, challenges, and strategies for the design of a VLP downstream process are presented.
2 Purity Guidelines for Virus-like Particles
VLP production in recombinant systems comes along with the generation of numerous impurities
which are summarized into two subgroups: process-related and product-related contaminants
[53]. Process-related contaminants are predominantly attributed to host cell impurities such
as cells, cell debris, host cell proteins (HCPs), DNA, proteases, endotoxins, polysaccharides,
and lipids. Further impurities dedicated to the production process are media components,
anti-foam reagents, and other potential hazards supplemented during upstream or downstream
processing such as stabilizers, excipients, proteases, and nucleases. A list of inactive ingre-
dients allowed in final drug formulations is provided by the Food and Drug Administration
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Table 1 Development stages of virus-like particle based vaccines.
Development stage Virus/ pathogen/ disease
Preclinical Chikungunyavirus [23], Coxsackievirus B3 [24], Cytomegalovirus [25],
Denguevirus [26], Enterovirus 71 [27, 28], Group A Streptococcus [4],
Human B19 parvovirus [29], Human immunodeficiency virus [30, 31],
Human papillomavirus [32], Rotavirus [33]
Phase 1 Allergenic rhinitis/ Asthma (anti IgE Qβ-VLP), Chikungunyavirus [34],
Ebolavirus a [35], Influenza H1N1 [36, 37], Influenza H7N9 [38], Respri-
ratory syncytial virus [39]
Phase 2 Alzheimer disease (amyloid Qβ-VLP) [14, 40, 41], Human B19 par-
vovirus [42], Influenza H1N1 [43], Influenza H5N1 [37], Norovirus [44],
Phase 3 Human papillomavirus [45, 46], Malaria P. falciparum (RTS,S) [47]
Licensed Human papillomavirus (Gardasil R©, Cervarix R©) [48], Hepatitis B virus
(Recombivax HB R©, Engerix-B R©) [49] , Hepatitis E virus (Hecolin R©)
[50]
a Novavax initiated phase-1 clinical trials with Ebola-VLPs in Feb 2015
(http://ir.novavax.com/phoenix.zhtml?c=71178&p=irol-newsArticle&ID=2016192).
(FDA) (http://www.accessdata.fda.gov/scripts/cder/iig/index.cfm). According to the
World Health Organization (WHO), quality monitoring of final VLP-based vaccine bulks should
include, among others [54]:
• Testing for sterility (bacteria, fungi);
• Testing for virus clearance;
• Summary of vaccine composition (protein, lipid, polysaccharides);
• Control of residual DNA, protein and endotoxin content;
• Determination of protein purity (by SDS-PAGE or similar); and
• Description of residual chemicals.
Industry is required to set specifications for contaminants during the process of product de-
velopment. Residual contaminant levels should not exceed values found in vaccine lots shown
to be safe in clinical trials [55]. The US Food and Drug Administration provides guidelines
concerning acceptable ranges of DNA content in vaccine doses and recommends to measure the
amount and size distribution of residual DNA. Residual host cell or viral DNA might be a risk
due to oncogenicity and infectivity potentials. Therefore, maximum residual amounts of DNA
depend on the host system, but should be below 10 ng per dose, with the DNA size being below
200 base pairs for parenterally administered vaccines [56].
Furthermore, residual HCPs and endotoxins strongly affect the safety of human vaccines and
can elicit immunogenic responses and reactogenicity in humans [51, 52]. Recently, the WHO
recommended a protein purity of at least 95% for the late-stage VLP-based malaria vaccine
candidate RTS,S (GlaxoSmithKline plc) [55, 57]. Vaccine manufacturers do not release their
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lot specifications on DNA, HCP, and endotoxin levels. However, Brito et al. [58] from Novartis
Vaccines and Diagnostics recommended an endotoxin level below 20 EU/mL for recombinant
subunit vaccines. Purity data for a patented VLP downstream process developed by Merck
Research Laboratories was reported by Cook et al.[59]: protein purity according to SDS-PAGE
was 98% and residual DNA content was 0.84 ng/mL in the final human papilloma-VLP vac-
cine bulk. For comparison, acceptable HCP and DNA levels for therapeutic biopharmaceutical
products such as monoclonal antibodies are usually set below 100 ppm HCPs and 100 pg DNA,
respectively [60].
Product-related contaminants result from product alterations during upstream and downstream
processing and include aggregated, misfolded, deformed, and disassembled particles or subunits.
VLP size and homogeneity are commonly assessed by electron microscopy and dynamic light-
scattering techniques. The quality of in vivo-assembled VLPs in recombinant systems depends
on several factors such as the host system, the cell environment, the expression of all required
viral structural proteins, and the virus subtype [61]. Since not all of the mentioned conditions
can be controlled sufficiently during in vivo VLP assembly, in vitro disassembly and reassembly
processes were developed and optimized for several VLPs [62, 63, 64, 65, 66]. VLP disassembly
and re-assembly enable the removal of encapsulated host cell impurities and have shown to in-
crease the homogeneity, stability, and reactivity of VLPs [67, 68]. New tools, such as molecular
dynamic simulations, have helped to improve understanding of the assembly mechanism and
to predict the quality of new designed VLP constructs [69, 70]. Further product-related con-
taminants are VLP aggregates formed during both upstream and downstream processing even
after VLP disassembly and re-assembly [71, 72, 73]. Hence, downstream processing of VLPs
should not only include the separation of process-related contaminants but also the reduction
and control of potential reactogenic product-related contaminants.
3 Downstream Process Unit Operations for Virus-
like Particles
Several purification steps are required to meet the desired purity criteria for recombinant VLPs.
These include unit operations for clarification, capturing, intermediate purification, and polish-
ing of the molecule of interest. Figure 1 gives an overview of downstream process unit operations
used for the purification of VLPs. Process-related contaminants should be separated particularly
at the beginning of the process while productrelated contaminants and residual process-related
impurities should be removed in the final polishing steps. In recent years, the rapidly grow-
ing field of large biomolecule products has enlarged the purification toolbox for VLPs. New
alternative and integrated downstream process unit operations are summarized in Figure 2.
3.1 Clarification of Cell Feedstocks
The first step in a VLP downstream process is the solidliquid separation of the cell culture
broth. VLPs in recombinant systems are either produced intra- or extracellularly depending on
host and viral proteins. If the VLPs are not secreted into the extracellular medium, a cell lysis
step is required before clarification. Large-scale lysis of cells for VLP recovery is commonly
done by high-pressure homogenization [59, 74, 75, 76]. The addition of protease inhibitors and
stabilizing agents is essential at this process stage. A popular, but expensive method for DNA
digestion can be carried out at such an early downstream process stage by the addition of nu-
cleases such as Benzonase R© endonuclease.
The actual clarification step, i.e. separation of cells, cell debris, and insoluble aggregates, is usu-
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Figure 1 Overview of downstream process scheme and state-of-the-art unit operations for the purification
of virus-like particles. The process scheme on the left shows the different steps of a downstream process
ranging from the initial product isolation out of cells to concentration, intermediate and polishing unit
operations. The methods of choice for these process stages are presented on the right side pointing out
several chromatography, filtration and integrating purification techniques. (Abbreviations: AC, affinity
chromatography; ATPS, aqueous two-phase system; DF, diafiltraton; EBA, expanded bed adsorption;
HIC, hydrophobic interaction chromatography; IEC, ion exchange chromatography; MM, mixed mode
chromatography; PEG, polyethylene glycol; SEC, size-exclusion chromatography; TFF, tangential flow
filtration; UF, ultrafiltration.)
ally performed by centrifugation and filtration steps [15]. Depending on the used host system
the final cell density and viability are critical factors affecting the performance of subsequent
purification steps [77]. Cell lysis during clarification increases the contaminant level and is
therefore especially critical for secreted VLPs. Centrifugation in batch or continuous mode
has been the method of choice for decades. However, the trend of incorporating cleaning- and
validation-free disposable technologies into manufacturing processes has forwarded the devel-
opment of new membrane formats. Membrane processes are easily scalable and offer an easier
control of shear stress during operation [15, 31]. High shear stress is not only critical for cells
but also for VLPs due to an increased risk of aggregation and particle deformation or disassem-
bly [78, 71]. Negrete et al. demonstrated the potential of tangential flow filtration (TFF) with
0.45 µm hollow fibers for the rapid clarification of shear-sensitive extracellular HIV gag-VLPs
derived from insect cells [31]. Hollow fiber microfiltration in diafiltration mode was also used
for the clarification of yeast cell lysates containing human papillomaVLPs with 0.45 µm or 0.65
µm pores [59, 75]. Peixoto et al. used disposable dead-end depth filters with 3 µm pores for
the clarification of insect cell lysate containing rota-virus-like particles [79]. An advantage of
using depth filters for clarification can be the adsorption of HCPs and DNA [80, 81]. Further
promising technologies for the initial clarification step are rotating or vibrating dynamic cross-
flow filter membranes [82] and the flocculation of cell debris with borax before centrifugation
[74].
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Figure 2 New technologies for the purification of virus-like particles. The majority of novel purification
tools for large biomoelcules can be devided into three groups: Aqueous two-phase extraction, chromatog-
raphy matrices and filtration designs. New chromatography materials entail either large pore sizes (e.g.
monoliths or membranes) accessible for bionano - particles or smaller pore sizes (e.g. core bead resins)
for the steric exclusion and flow through purification of viral particles.
3.2 Capturing and Concentration of Virus-like Particles
An efficient capture step should predominantly reduce the bulk volume and increase the con-
centration ratio of VLPs to host cell impurities. Appropriate methods, new techniques and
devices for this process step can be found in the fields of filtration, precipitation, chromatogra-
phy, and extraction. Ultra- and diafiltration (UF/DF) with large pore membranes is a common
platform unit operation for separating small host cell contaminants, digested DNA, and media
components from all kinds of VLPs. TFF with membranes or hollow fibers has been applied
for concentrating and purifying HIV gag-VLPs with 300 or 500 kDa cut-offs [78, 31], rota-VLPs
with 750 kDa cut-off [79, 83], cytomegalo-VLPs with 750 kDa cut-off [25] and enterovirus 71
VLPs with 1000 kDa cut-off [27]. Interestingly, the largest nominal molecular weight cut-off
(NMWC) was used successfully for capturing the smallest VLPs (entero-VLPs) with a diameter
of 25-30 nm. A general rule of thumb for the selection of NMWC is to choose a value of 0.2
to 0.3 of the product molecular weight [84]. However, NMWC values are typically determined
using protein or dextran markers and must be evaluated in small scale for each VLP. Typical
membrane materials used for UF/DF of VLPs are polysulfone and regenerated cellulose [84].
UF/DF is often needed as an essential preliminary step before chromatographic purifications.
An alternative method is the precipitation of the target component followed by a re-dissolution
in the desired buffer. Typical precipitants for large biomolecules are ammonium sulfate and
polyethylene glycol (PEG) [19]. PEGs with molecular weights ranging from 4,000 to 8,000 Da
have been used in the past for concentrating numerous viruses [85, 86, 87] and VLPs such as cow-
pea mosaic VLPs, noro-VLPs, and chikungunya-VLPs [88, 89, 90]. Tsoka et al. purified VLPs
derived from Saccharomyces cerevisiae by PEG-induced precipitation and scaled up the process
to pilot scale in a 100 L stirred tank [74]. They reported a purification factor of 1.6 for VLPs
with a product recovery of 90 %. Recently, precipitation with PEG has been revised for the pu-
rification of monoclonal antibodies and proved to be native and reversible [91], highly selective
[92, 93], scalable in combination with hollow fiber TFF [94] and ready to integrate into manu-
facturing processes [94, 95]. Several researchers have shown that the mechanism and efficiencies
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of PEG induced precipitation are predominantly linked to the hydrodynamic radius of PEG
and protein [85, 96, 97, 98]. This explains the high selectivity observed for large biomolecules.
However, drawbacks of the technique are the co-precipitation of other large biomolecules such
as baculoviruses, nucleic acids [99], batch variances due to varying feed-stream concentrations
and buffer compositions, and the risk of irreversible aggregation and product alterations [89].
Chromatography is undoubtedly the workhorse of downstream processes in the biopharmaceuti-
cal industry. Affinity, ion exchange, hydrophobic and mixed mode chromatography are powerful
interaction modes for capturing VLPs in bind-and-elute mode. A good accessibility of ligands
is an essential requirement for adsorptive interactions. Recently, chromatography suppliers
have developed numerous new matrices for large biomolecules such as monoliths [100], gigapore
resins [101], tentacle resins [102] or membrane adsorbers [103] with pore sizes in the microme-
ter region. The most popular purification method for biomolecules is affinity chromatography,
because it enables the separation of a large number of contaminants in a single process step
by taking advantage of highly selective interactions. However, affinity chromatography is only
an option for few VLPs. The method requires either a specific antibody, which can be fused
to a chromatography matrix, or a protein or peptide fusion tag on the VLP surface such as
glutathion-S-transferase, biotin or polyhistidine[104, 105, 106]. Drawbacks in both cases arise
due to high process costs, slow binding kinetics, low capacities, product alterations and in case
of protein tags the need for separating the tag as a process-related contaminant in subsequent
purification steps. A novel promising pseudo affinity interaction mode is cellufine sulfate (CS)
chromatography with sulphated cellulose as ligand. Ohtaki et al. captured West Nile-VLPs
from a mammalian cell culture supernatant using a CS column with a dynamic binding ca-
pacity of 3 mg/mL and a product recovery of 93% [107]. Using the heparin analogue suramin
as competitive eluent, they demonstrated that the binding mechanism can be attributed to
heparin groups on the VLP surface. Heparin chromatography has also been used for purify-
ing human papillomaVLPs and nervous necrosis VLPs derived from Saccharomyces Cerevisiae
[108, 109]. However, impurities such as HCPs and baculoviruses may also bind to CS and must
be separated either by optimizing the elution conditions or by using subsequent purification
steps [110].
Ion exchange chromatography (IEC) is the most prevalent chromatography method for bio-
molecules. IEC in bind-and-elute mode requires a low ionic strength and, therefore, mostly a
preliminary buffer exchange step to remove media or cell lysis buffer components. Almost all
large-scale downstream processes for VLPs include an IEC step at some point of the process.
Examples of VLPs captured by anion exchange chromatography (AEC) in bind-and-elute mode
are the purification of hepatitis B surface antigen (HBsAg) VLPs [111], Adenovirus type 3 do-
decahedric (Ad3) VLPs [112], rota-VLPs [83], noro-VLPs [113] and human B19 parvoVLPs [29].
Quaternary amine (Q), diethylamine (DEAE) and ethylenediamine (EDA) were used as ligands
with product recoveries ranging from 23% to 74%. Perfusion chromatography with sulfopropyl
cation-exchange ligands has been applied at Merck Research Laboratories for recovering up to
45% of human papillomaVLPs from clarified yeast cell lysate [59, 114]. A novel chromatogra-
phy technique incorporating the selectivity of PEG induced precipitation was developed by the
Gagnon group [115, 116, 117, 118]: This technique is referred to as steric exclusion chromatogra-
phy. Hydroxylated monoliths and starch-coated magnetic nanoparticles were used as stationary
phases for capturing bacteriophages, IgM, and IgG with very high capacities of up to 58 g IgG
per mL nanoparticles. The molecules of interest were retained in the stationary phase by steric
exclusion of PEG at high PEG concentrations and eluted by lowering the PEG concentration,
recovering about 70% product and separating more than 99% of HCPs and aggregates.
Other options for the initial purification step from clarified VLP feed streams are hydrophobic
interaction (HIC) and mixed-mode chromatography. An advantage of these techniques is the
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direct application of clarified cell culture feedstreams without preliminary buffer exchange steps
[119, 120].In a monolith case study on HBsAg-VLPs, Burden et al. determined higher recoveries
for binding and elution on weakly hydrophobic hydroxyl ligands than on stronger hydrophobic
butyl ligands. However, yeast cell lipids decreased the dynamic capacity drastically and induced
column fouling [120]. Thus, an additional lipid removal step is advisable when using HIC for
capturing VLPs from crude cell feedstocks.
3.3 Integrated Unit Operations for Process Intensification
Increasing the number of process steps in a downstream process triggers a decline of the overall
product recovery. Hence, the integration of several process steps into one unit operation is
an interesting feature of alternative separation technologies such as aqueous two-phase extrac-
tion (ATPE) and expanded bed adsorption. Aqueous two-phase systems (ATPSs) provide mild
conditions for the extraction of biomolecules and have been applied for small and large scale
purifications of numerous biopharmaceutical products [121, 122, 123, 124]. The number of new
biocompatible devices for multi-stage extractions such as mixer-settler-systems [125], packed
columns [126], centrifugal partition chromatography [127] and microfluidic platforms [128] is
steadily increasing. ATPE enables rapid capturing of biomolecules from crude cell feedstocks
incorporating clarification, concentration and purification with high selectivity [129, 130]. Proof
of concept has been shown for the purification of rota-VLPs [131], human B19 parvoVLPs [132]
and human papillomavirus protein L1 [133]. Nevertheless, low VLP capacities in the range
of 0.005 to 0.6 mg/mL, low separation efficiencies, and limited mechanistic understanding un-
derline the need of further research before getting a robust alternative unit operation for the
purification of VLPs.
Expanded-bed adsorption (EBA) chromatography [134] is another promising integrated method
for industrial-scale clarification, concentration, and purification of biomolecules. The interac-
tion modes can be selected from traditional chromatography by using affinity, ion exchange,
hydrophobic or mixed mode ligands. The fluidized bed allows the separation of cell debris in
the flow-through by capturing the molecule of interest in bind and elute mode. EBA has been
applied for the initial purification of hepatitis B core antigen (HBcAg) VLPs with DEAE and
immobilized metal affinity ligands from unclarified Escherichia coli homogenate. Obtained re-
coveries were about 50%, and purity factors of 3.6 similar to those found for density gradient
ultracentrifugation[135, 136]. Moreover, Cabrera et al. have developed and patented an EBA
method in collaboration with Medicago Inc. using DEAE ligands for capturing influenza VLPs
from plant cells [137].
3.4 Intermediate Purification of Virus-like Particles
Further purification after capturing is mostly achieved by a subsequent chromatographic sepa-
ration step such as IEC or HIC. Separation of residual HCPs or DNA is often done by anion
exchange chromatography (AEC) in flowthrough or bind-and-elute mode. A promising concept
for flow-through applications is the core bead technology comprising size exclusion and ion ex-
change chromatography. An industrial example is the purification of influenza VLPs derived
from insect cells at Novavax Inc [138]. Whereas VLPs were recovered at elevated ionic strength
in the flow-through, baculoviruses and DNA bound to Q ligands were found in the core bead
particles. Recoveries were ranging from 70% in the laboratory scale to 40% in the pilot scale
[139]. The same method was also used for intermediate purification of HIV gag-VLPs [31]. In
addition, there is also a tendency to use anion exchange membrane adsorbers for flow-through
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purification of large biomolecules [140, 141]. Flow-through chromatography is especially suit-
able for the purification of lipid-enveloped and less stable VLPs because the risk of product
alterations by binding and elution is reduced. However, a drawback is the need for processing
of large volumes necessitating several extra concentration steps.
A common two-step process reducing the bulk volume is the combination of precipitation with
PEG and AEC in bind-and-elute mode. Koho et al. purified noro- VLPs derived from insect
cells by precipitation with PEG 6000 and a step gradient elution on a Q AEC column with a
final purity of 95% [89]. A similar method was applied by the group for purifying Coxsackievirus
B3 VLPs using a monolithic Q column [24]. Although successful purification was achieved in
both case studies, no information was given on actual recovery values. More detailed perfor-
mance data for the two-step process was reported by Phelps et al.: only 22% of cowpea mosaic
VLPs could be purified from a plant cell feedstock. Precipitation with PEG 6000 and perfusion
chromatography media with a strong Q ligand yielded in a final purity of 95% [88]. In contrast,
Venkatachalam et al. recovered 55% of EnteroVLPs derived from insect cells by using a weak
DEAE ligand on a monolithic column after VLP precipitation with PEG 8000 [87]. Thus, a
weaker ion exchange ligand and larger pore sizes promoted higher VLP recoveries.
Kim et al. applied precipitation by ammonium sulphate for capturing and preparing human
papillomaVLPs for a subsequent chromatography step by CEC or heparin chromatography
[142]. The method separated HCPs in both chromatography processes with recoveries of 63and
demonstrated that the mechanism, elution profile, and selectivity of heparin chromatography
correlated well with a CEC step. VLPs captured by IEC at high ionic strength can be di-
rectly processed by HIC or ceramic hydroxyapatite (CHT) chromatography. Kim et al. purified
HBsAg-VLPs subsequent to AEC by bind-and-elute on a butyl HIC column with a recovery of
70% for the HIC step. Industrial intermediate purification of e.g., human papilloma-VLPs has
been performed with CHT chromatography subsequent to a CEC capture step [143, 114]. CHT
chromatography is a mixed mode chromatography method often used for large biomolecules
with typical pore sizes of 80 to 100 nm [144].
3.5 Polishing and Formulation of Virus-like Particles
In the final polishing steps of a downstream process, all product-related contaminants, resid-
ual and encapsulated process-related contaminants need to be removed. Final purification of
VLPs is mostly done by size-exclusion chromatography (SEC) [138], UF/DF [145], and ster-
ile filtration. VLPs are transferred into the final formulation buffer and concentrated to the
desired concentration for administration. Residual baculoviruses can be inactivated with e.g. β-
propiolactone [138]. As mentioned at the beginning, removal of encapsulated contaminants and
an increase in particle homogeneity can be accomplished by VLP disassembly and re-assembly.
Disassembly of capsids can be triggered by adding reducing agents such as β-mercaptoethanol
or dithiothreitol at elevated pH values [61, 146]. Thereafter, virus proteins can be further pu-
rified in the presence of reducing or chaotropic agents and are finally reassembled to VLPs by
diafiltration removing reducing agents [62, 147]. The homogeneity of the final VLP bulk can be
controlled by varying pH, ionic strength and adding divalent cations [72, 148]. For long-term
stability excipients such as sucrose, trehalose, sorbitol, glycine, chitosan glutamate or mannitol
can be added to the formulation buffer. A detailed review of formulation and stabilization of
VLP-based vaccines was recently published by Jain et al. summarizing excipients, adjuvants
and new routes of administration [149]. Prior to filling VLPs are sterile filtered with 0.22 µm
filter membranes.
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4 Challenges and Bottlenecks of Purification
Processes
The described examples of unit operations for VLPs illustrate the challenges and bottlenecks
associated with the processing of large biomolecules. Table 2 summarizes dynamic binding
capacities reported for VLPs captured from clarified feed streams by chromatographic meth-
ods. It is evident that capacities for VLPs are still far away from the capacity range of 50-200
mg/mL usually observed for proteins in affinity chromatography, IEC or HIC. In addition, the
reported VLP recoveries in bind-and-elute mode were mostly in the range of 30 to 60% due to
product alterations caused by interactions with stationary phases. While chromatography sep-
arations suffer from poor recoveries, filtration methods fail at removing larger process-related
contaminants such as baculoviruses and DNA. Another process challenge occurs at the final
sterile filtration step: VLPs are often retained in the filter by unspecific interactions or due to
large particle sizes approximating the mean filter pore size of 0.22 µm. Alternative downstream
unit operations such as ATPE, EBA, and precipitation are valuable purification tools for VLPs,
but require much time and effort for process development. Although ultracentrifugation pro-
cesses have been replaced in industrial-scale purifications, there is still a lack of straightforward
ready-to-use processes for material supply during early-stage development. Ultracentrifugation
remains the method of choice during preclinical studies [27, 152, 90, 29]. Moreover, process
development is often delayed by laborious offline analytical methods such as gel electrophore-
sis, Western blotting or electron microscopy. Rapid technologies are especially needed for the
control and characterization of product-related contaminants such as VLP aggregates.
5 Strategies and Tools for Future Downstream
Process Development
In the past, process development and optimization of downstream processes were mostly based
on empirical approaches conducting trial-and-error experiments. By virtue of a more global
industry and numerous new emerging technologies, the FDA has forwarded the implementation
of ’quality by design’ (QbD) and ’process analytical technology’ (PAT) for biopharmaceutical
products. The idea of these approaches is the development of a better knowledge and con-
trol of products and manufacturing processes by using PAT methods and rational development
strategies. PAT methods include, for instance, online high-performance liquid chromatography
(HPLC) systems or light-scattering techniques which enable process surveillance and control
of unit operations in realtime [153, 150]. New rational development strategies for biophar-
maceutical products involve the approaches of design of experiments (DoE), scale-down, high-
throughput experimentation, and process modeling. Promising concepts have already been
suggested for VLPs to obtain a more rational downstream process development. Vicente et al.
predicted the elution profile of rota-VLPs on a DEAE membrane adsorber by implementing
hydrodynamics and steric mass-action (SMA) model developed by Brooks and Cramer [154]
into a software package for process modeling [83]. Prediction of chromatography elution profiles
generates a profound process understanding and enables in silico optimization and estimation
of process fluctuations during chromatographic separations [155, 156]. A scale-down model of
chromatographic separations was implemented by Wenger et al. on a robotic liquid handling
station. Column chromatography was miniaturized 1000-fold from laboratory scale to micro-
pipette columns and allowed the establishment and assessment of a whole industrial HPV-VLP
vaccine downstream process at the microscale [114]. Such microscale processes enable rapid
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Table 2 Dynamic binding capacities and recoveries of chromatographic methods applied for the pu-
rification of VLPs. Ad3: adenovirus type 3 dodecahedric; CHT: ceramic hydroxyapatite; CS: cellufine
sulfate; DBC: dynamic binding capacity; DEAE: diethylamine; EBA: expanded bed adsorption; HBcAg:
hepatitis B core antigen; HBsAg: hepatitis B surface antigen; HPV: human papillomavirus; IDA: imin-
odiacetic acid; IEC: ion exchange chromatogaphy; NDV: newcastle disease virus; OH: hydroxyl; WNV:
west nile virus.





IEC (DEAE) Cross-linked agarose
gel
HBsAg 24.06 0.38 [150]
IEC (DEAE) Cross-linked agarose
gel with dextran sur-
face extenders
HBsAg 31.88 0.97 [150]
IEC (DEAE) Agarose coated giga-
porous polysterene
resin (120 nm pore
size)
HBsAg 43.18 1.87 [150]
IEC (DEAE) Agarose coated giga-
porous polysterene
resin (280 nm pore
size)
HBsAg 68.33 3.03 [150]
IEC-EBA (DEAE) Cross-linked agarose
with stainless steel
core material
HBcAg 52.43 0.5 [135]
IEC (Q) Methacrylate mono-
lith
Ad 3 52 1.38x1016
VLP/ mL
[112]
HIC (OH) Methacrylate mono-
lith
HBsAg 85 0.25 [120]
HIC (Butyl) Cross-linked agarose
gel
HBsAg 90 0.08 [120]
MM (CHT) Ceramic hydroxyap-
atite resin
HPV 82 2.9 [143]
AC (CS) sulfated cellulose
resin
WNV 93 3.0 [107]
AC -EBA (IDA) Cross-linked agarose
with stainless steel
core material
HBcAg 56 5.6 [136]
AC -EBA (IDA) Cross-linked agarose
with stainless steel
core material
NDV 9.6 2.94 [151]
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downstream process development for product subtypes as well as new constructs at early de-
velopment stages and improve the overall process and product understanding[157, 158, 159]. In
order to improve recoveries and dynamic capacities in chromatographic processes, the influences
of matrices, pore sizes, ligands, ligand densities, and stabilizers need to be further addressed for
VLPs. Inverse size exclusion chromatography, confocal laser scanning microscopy, miniaturized
bind-and-elute studies, and tracer experiments with dextrans are powerful tools for understand-
ing and designing chromatography processes. For instance, Wu et al. demonstrated by confocal
laser scanning microscopy that adsorption of HPV-VLPs is limited to a thin layer on the par-
ticle surface of perfusion resins due to steric exclusion from the particles’ micropores[160]. The
development of new PAT methods for the quantitative characterization of VLPs has been for-
warded in recent years with new technologies such as asymmetrical flow field-flow fractionation
(AF4), electrospray differential mobility analysis, native mass sprectroscopy, and in-line or at-
line light-scattering techniques [161, 150, 162, 163, 164]. Further rapid analytical techniques
have been applied for the characterization of viruses such as flow cytometry, tunable resistive
pulse sensing and nanoparticle tracking analysis [165, 166]. A tool for selective in-line quantifi-
cation of biomolecules has recently been described by our group using spectral data from diode
array detectors [167].
Concluding the findings of all described approaches for bind-and-elute chromatography, the au-
thors suggest to: (i) avoid the use of chromatography media with small pore sizes; (ii) avoid
the use of very strong ligands; and (iii) add stabilizers such as glycerol or PEG to the mobile
phase to counteract the risk of product alteration during adsorption and desorption processes
[112, 111]. The large size and complexity of VLPs are challenges to the downstream process-
ing. However, these characteristics can be utilized by size-dependent purification tools such
as filtration, flow-through or size-exclusion chromatography. A straightforward process scheme
possibly applicable to various VLPs could be designed as follows:
1. Clarification by TFF with 0.45 µm hollow fibers/ membranes;
2. UF/DF by TFF with 1000 kDa hollow fibers/ membranes for removal of small process-
related contaminants and media components;
3. IEC in flow-through mode for removal of large charged process-related contaminants;
4. UF/DF by TFF with 1000 kDa hollow fibers/ membranes for concentration and formu-
lation; and
5. Sterile filtration.
A possible option for avoiding the sterile filtration of very large VLPs is to design the whole
manufacturing process with aseptic single-use unit operations [25]. Such disposable technologies
are available for a variety of unit operations such as centrifugation, filtration, and chromatogra-
phy, and enable the design of flexible ready-to-use process solutions [168]. Another important
strategy for increasing the productivity while reducing overall costs is to switch manufactur-
ing from batch to continuous processing. Promising results were obtained in case studies for
the purification of influenza- and adenoviruses by simulated moving bed chromatography with
multiple SEC columns [169, 170].
6 Conclusion and Outlook
Responding faster to emerging pathogens, increasing the safety of vaccines, and accelerating
material supply during clinical phases are key issues affected by the downstream processing of
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VLPs. New technologies and strategies for VLP purification and process control have arisen in
recent years, representing the basis for future manufacturing processes. The reported methods
and case studies demonstrate the progressive replacement of ultracentrifugation steps in both
industry and science by scalable chromatography and filtration unit operations. Promising
new stationary phases have underlined their potential for VLP processing, and alternative
methods such as aqueous two-phase extraction, precipitation, and expanded-bed adsorption
chromatography are gaining increasing attention. Similar to monoclonal antibody processing,
the implementation of QbD and PAT in VLP processing will standardize downstream processes
used for future manufacturing and development phases. Downstream processes slowly move
towards a scalable platform process scheme with tangential flow filtration and anion exchange
matrices as the most prevalent unit operations. It is the turn of industry, process scientists, and
life science suppliers to take advantage of the size and complexity of VLPs for designing simple,
scalable, and efficient platform processes for all kinds of small and large VLPs. The foundation
of such generic processes has been laid in the case studies reviewed in here.
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Abstract
Protein drugs continue to grow both in medicinal importance as in scale of their production.
This fur- thers the interest in separation technologies that have the potential to replace chro-
matographic steps in a protein purification process. Two such unit operations that are employed
in large scale in the chemical industry are extraction and precipitation. Their usefulness for
the purification of proteins has been demonstrated, but the integration of such unit operations
in a way that generate an output stream of high protein concentration and low process related
impurities was missing. In this work, we employ centrifugal partition chromatography (CPC) in
combination with precipitation of the protein of interest to purify a cell culture supernatant of
a monoclonal antibody producing cell line. Centrifugal partition chromatography was used as
means of multi-step extraction using aqueous two-phase systems and was able to remove up to
88.2% of host cell protein (HCP). The following PEG driven precipitation and resolubilization
of the protein of interest was use to condition the CPC output stream to suit subsequent chro-
matographic steps, to increase mAb concentration, remove the phase forming polymer, further
improve HCP clearance, and integrate a low pH hold step for viral clearance. The entire process
reduced HCP content by 99.4% while recovering 93% of the protein of interest. High throughput
screening techniques were extensively employed during the development of the process.
Keywords: Aqueous two-phase partitioning, Centrifugal partition chromatography, Precip-
itation, Monoclonal antibody, Biopurification process design
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1 Introduction
Proteinaceous drugs are continually increasing in importance both economically and medically.
All protein drugs are produced in a process that can roughly be divided into three steps: fermen-
tation of the product (“upstream process”), purification of the product (“downstream process”)
and the creation of a commercial product by final formulation and filling. With a single molecule
class (monoclonal antibodies) gaining utmost importance over the recent decade the pharma-
ceutical industry has centered and matured around these molecules. While fermentation was
optimized to yield increasingly more product, the downstream process was standardized into
platform processes fitting most new molecules of this class. As fermentation titers increase an
inevitable need to scale or number up the purification unit operations arises as downstream pro-
cesses scale by mass rather than volume. Current plant footprints and chromatography skid sizes
are finite. Thus, two options to reduce processing cost and footprint have recently been come
into focus: alternative separations steps operating at high concentrations and (semi-)continuous
processing. Two alternative unit operations amenable to semi-continuous processing are precip-
itation and extraction [1, 2]. However, the application of these process steps to pharmaceutical
products is still very limited. There is hardly any experience with these process steps in large
scale, neither on their application than on the reaction of regulatory agencies to such non chro-
matographic purification steps. The preparative purification of proteins by precipitation or
aqueous two-phase extraction is widely acknowledged as simple and easily scalable process step.
Precipitation has been demonstrated to be applicable to monoclonal antibody (mAb) solutions
both at the very beginning and very end of a process. Matheus et. al [3] demonstrated the
use of precipitation by either PEG or salts for the purpose of creating highly concentrated
mAb solutions during drug formulation. Knevelman et. al [4] demonstrated the use of PEG
precipitation as initial process step in the recovery of IgG4 from cell culture supernatants. The
application of aqueous two-phase extraction to mAb purification has recently been extensively
studied by Aires-Barros and coworkers. They initially demonstrated the application of single
stage ATPS [5] to mAb-HCP separation. They continued in demonstrating the integration of
an ATPS step into a traditional chromatography based purification train by either loading the
salt rich bottom phase onto a HIC column [6] or the polymer rich top phase onto a cation
exchange resin [7]. Finally, multi-step cross-current extractions using a polymer-polymer ATPS
were evaluated by Rosa et. al [8]. Our group has contentiously worked on implementing small
scale screening methods for both ATPS [9, 10] and precipitation [11]. Building on the work of
Sutherland et. al [12, 13] and Ito et. al [14] we have recently combined the established high
throughput screenings for both ATPS and precipitation conditions in order to facilitate the
selection of conditions for centrifugal partition chromatography [15]. It was shown that such
multi-step extraction methods can readily be applied to protein separation, also in the context
of pharmaceutical production. The remaining major practical obstacle to the application of
precipitation and aqueous two-phase extraction is creating an output stream from these unit
operations that is high in protein concentration and low in conductivity and polymer content so
that the integration into a whole purification process can be readily achieved. In this work, we
demonstrate how aqueous two-phase extraction in the form of centrifugal partition chromatog-
raphy can be combined with precipitation and resolubilization of the target protein to yield a
highly pure and concentrated product stream. The resulting output stream can also be directly
applied to subsequent chromatographic purification steps thus resulting in a seamless process
integration of the investigated unit operations.
67
2 Materials & Methods
2.1 Disposables
For spectroscopic measurements Greiner Bio-One (Kremsmnster, Austria) 350 µL-UV-Star
plates were used. Precipitation studies were conducted in 350 µL-AcroPrep
TM
96 Filter Plates
(Pall Corporation, Port Washington, NY) containing a Bio-Inert R©(modified low protein-binding
Nylon) 0.2 µm membrane. ATPS were prepared in 1 mL-96 Deep Well plates (Nalgen Nunc In-
ternational, Rochester, NY, USA). For all other purposes Greiner Bio-One 350 µL-polypropylene
flat bottom MTPs were used.
2.2 Chemicals & Stock Solutions
PEG 400, PEG 600, and PEG 1000 were obtained from Merck KGaA (Darmstadt, Germany).
PEG 1450 and Trisodium citrate were purchased from Sigma-Aldrich (St. Louis, MO). Citric
acid was obtained from Merck KGaA (Darmstadt, Germany). Stock solutions were prepared
in dH2O as follows: 70% (w/w) PEG 400, 70% (w/w) PEG 600, 60% (w/w) PEG 1000, 60%
(w/w) PEG 1450, 40% (w/w) PEG 4000, 35% (w/w) citric acid, 35% (w/w) trisodium citrate.
Citrate stock solutions for ATPS were combined as follows: 96.43 g trisodium citrate solution
and 3.57 g citric acid solution to yield pH 6.0. All other chemicals were obtained from Merck
KGaA (Darmstadt, Germany).
2.3 Protein Solutions
Three monoclonal antibodies (‘mAb1’, ‘mAb2’, ‘mAb4’) and a corresponding HCP pool were
supplied by Boehringer Ingelheim Pharma GmbH & Co. KG (Ingelheim am Rhein, Germany).
All mAbs were derived from CHO cell culture and were of the same subtype IgG1. The mAbs
were supplied as active pharmaceutical ingredient (API). If needed, protein concentration in the
API solutions was increased by ultrafiltration using a 30 kDa MWCO membrane as described
earlier [10]. Protein stock solutions used for precipitation and ATPS ranged in concentration
from 4 to 25 mg/mL. The mAb free flow-through obtained from a Protein A chromatography
step of clarified cell culture fluid (CCF) of a mAb producing cell line was used as HCP pool.
This host cell protein (HCP) solution was concentrated by a factor of 10 to yield the HCP stock.
UV absorption gave a HCP concentration of 4.1 g/L for the 10x solution.
2.4 Liquid Handling Station
In this study, a Tecan Freedom Evo 200 system (Tecan, Crailsheim, Germany) was used as
liquid handling platform. Liquid handling calibration and set-up were described earlier [10].
Solid-liquid-separation by filtration was accomplished by using an integrated vacuum station
“Te-Vacs” (Tecan, Crailsheim, Germany).
2.5 Software
Excel 2007 (Microsoft, Redmond, WA) files were used as import format and for data storage.
All calculations, evaluation, and visualization of data were done using Matlab R2011a (The
Mathworks, Natick, ME) and OriginPro R©8.1G (OriginLab Corporation, Northampton). The
robotic workstation was controlled using Evoware 2.3 (Tecan, Crailsheim, Germany). The
spectrophotometer was controlled using Magellan 6.4 (Tecan, Crailsheim, Germany). The CPC
column was controlled by Armen glider CPC software (Armen Instrument, Vannes, France).
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2.6 High-throughput Screening Methods
2.6.1 Automated Precipitation Procedure
In order to find applicable precipitants for the separation of proteins as well as an explanation for
partitioning in ATPS, protein solubility curves provide important information. Hence, solubility
of 1 mg/mL mAb1, mAb2, mAb4 and 0.41 mg/mL HCP were analyzed separately for different
concentrations of PEG 400, PEG 600, PEG 1000, PEG 1450, PEG 4000 and Citrate pH 6.0.
Due to the high experimental demand a precipitation screening on the liquid handling station
was used. Each data point was measured at least in triplicates. First, systems of 300 µL total
volume were put together in filter plates: water and precipitant were dispensed and after an
intermediate mixing step on an orbital shaker (1000 rpm, 2 min) protein solution was added
followed by another mixing step (1000 rpm, 5 min). All liquids were pipetted using the system?s
fixed tips with the appropriate deposited calibration curves for the stock solutions. To ensure
equilibrium, systems were incubated for 30 minutes. At last, systems were filtrated (700 mbar
pressure difference, 15 min) to remove aggregates and 30 µL permeate samples were diluted with
270 µL dH2O before UV-measurement. Protein concentration was finally determined by UV280
absorption comparing samples to a reference with known concentration (external standard).
2.6.2 Automated Precipitation and Redissolving Procedure
Re-dissolution of precipitates in an appropriate buffer was accomplished by an extension of the
described precipitation screening. The method consisted basically upon three process steps,
each followed by filtration: precipitation, washing and re-dissolution. After precipitation the
protein precipitates were washed by dispensing 300 µL of a washing buffer containing the same
precipitant concentration as during the precipitation step. Washing was achieved by first mixing
precipitate and washing buffer (1000 rpm, 5 min) and second filtering the mixture (700 mbar,
15 min). The last process step was the re-dissolution of the protein precipitates in citrate buffer.
300 µL of either 20 mM Citrate pH 6 or 0.1 M Citrate pH 3 were dispensed and mixed with the
protein precipitates (1000 rpm, 30 min). Finally systems were again filtrated and the permeate
samples analyzed as in the precipitation procedure. All precipitate-re-dissolution screenings
were done with PEG 4000 in 50 mM Citrate pH 6 and each data point was measured at least
in triplicates.
2.6.3 Binodal and Tie Line Determination
Binodal curves and tie lines were measured to select reasonable screening ranges. Semi-automated
binodal determination was done using the ?cloud point method? as described previously [10].
Systems were put together and mixed in UV-plates on the liquid handling station and phase
separation was determined by visual inspection. While one-phase systems stay clear, two-phase
systems become opaque after mixing. In a series of increasing phase forming component con-
centration, one point on the binodal was identified as the mean of adjacent data points between
which phase separation was observed. Systems containing a dye known to partition exclusively
into the upper phase (methylviolet) were used to determine phase volumes as described before
[16]. Tie lines were then calculated by the lever arm rule. The average tieline slope was calcu-
lated based on five to ten different system compositions. Binodals and tie lines were determined
for four different ATPS. All ATPS were composed of PEG (molecular weights: 400, 600, 1000
and 1450 Da) and citrate buffer with a pH of 6.0. Binodal data was fitted to equation 1 as
described by Merchuk et al. [17].
[PEG] = a ∗ exp(b ∗ [Citrate]0.5 + c ∗ [Citrate]3) (1)
69
2.6.4 Automated ATPE Procedure
As binodals, tie lines and solubility curves of mAbs and HCP were determined, adequate data
points with a volume ratio of 1 were selected for analyzing protein partitioning. The method used
for ATPS screening was established and described earlier by our group [16, 10]. Distribution and
recovery of 1 mg/mL mAb1, mAb2, mAb4 and 0.41 mg/mL HCP were determined by UV280
absorption comparing samples to external standards. Based on the average tieline slope, five
total system compositions (termed ’systems points’ throughout this manuscript (SPs)) were
selected for each of the four PEG molecular weights for increasing tieline lengths (table 1).
Protein distribution and phase volumes were measured at least in triplicate, blank values at
least in duplicate. Mean values of protein distribution and recovery are reported throughout
this manuscript. Distribution coefficients were calculated as the ratio of protein concentration
in the upper phase to the concentration in the lower phase. Promising system points were
further investigated by increasing antibody concentration from 1 up to 8 mg/mL.
Table 1 The five total system compositions of PEG400-citrate systems used in this study. The term
’system point’ (’SP’) is used throughout this study to refer to the compositions given in this table.






2.7 Centrifugal Partition Chromatography
Centrifugal partition chromatography (’CPC’) experiments were performed on an Armen 500
mL CPC column (Armen Instrument, Vannes, France). It is equipped with one 500 mL rotor
containing 42 stacked discs with a total of 1008 bipartide chambers or 24 per disc. Each
chamber has a volume of 424 µL. An Armen Instruments HPLC pump delivered solvent flow to
the column. An Äkta prime (GE Healthcare) system was used for online UV and conductivity
signals as well as fraction collection.
CPC experiments were conducted with either the upper or lower phase of an ATPS as mobile
phase. Prior to each run ATPS (SP3: 21.02 w% PEG 400, 18.99 w% citrate) was prepared in 2.5
kg scale by dissolving 525.5 g PEG 400, 521.73 g trisodium citrate dihydrate and 18.55 g citric
acid monohydrate in dH2O. Thereafter the system was incubated for 30 min in a separating
funnel. For protein purification 40 mL CCF ATPS with the same composition as the 2.5 kg
ATPS were prepared in standard beaker glass. Stock solutions of phase forming components
and dH2O were combined as required and the systems mixed on a magnetic stirrer. After this
initial mixing step, protein stock solution was added as last component followed by another
mixing step. The obtained systems were then incubated in a separating funnel for 30 min.
Samples of both phases were taken, diluted 1:10 and analyzed for mAb and HCP content by
ProteinA-HPLC and ELISA.
A basic requirement for an efficient separation of two components in CPC is the stability of
the inserted two phase system, i.e. the retention of the stationary phase Sf. The CPC was
operated in Ascending Mode using the upper phase as mobile phase. Before adding proteins
the goal was to find ideal operating conditions yielding in a high retention of the stationary
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phase Sf. Hence, using a Design of Experiments approach five operating points with different
flow rates from 5 to 15 mL/min and rotational speeds from 1500 to 2500 rpm were selected
for describing ATPS behavior in CPC. For column equilibration with the stationary phase,
the column was operated at 500 rpm and 1.5 CV lower phase were pumped into the column
displacing distilled storage water with a flow rate of 50 mL/min. Successfull displacement of
water was checked by conductivity measurements. Fraction collection and UV and conductivity
measurement were started together with delivery of mobile phase to the column. Fraction size
was 10 mL. The elution was conducted for at least 90 minutes. Samples were analyzed for
stationary phase content using graduated fraction containers to determine column composition
and stability. The operating point inducing the highest retention of the stationary phase was
then used for a purification experiment with 5 mg/mL mAb2 and 0.41 mg/mL HCP. 10 mL
upper phase of the appropriate CCF-ATPS were injected in a sample loop of the CPC. 10
minutes after starting the elution with upper phase the sample was injected onto the column
by allowing the mobile phase to flow through the loop before entering the column. Protein
fractions were identified by UV signals and mAb and HCP contents were analyzed as described
below. For further optimization mAb2 was processed again at the same operating point, but in
Dual Mode, i.e. switching between upper and lower phase as mobile phase. Dual Mode [18, 19]
is a CPC operating mode that prevents continuous backmixing of components extracted by one
phase with those from the opposed phase. Thus, it was assumed to increase resolution and
simultaneously decrease product dilution. After 10 mL sample loading as described above 1.2
CV lower phase were pumped through the column in order to extract contaminants. Finally,
the purified sample was eluted with the upper phase as mobile phase.
2.8 Analytical Methods
2.8.1 Protein Quantification
In high throughput screenings, the protein content was measured by UV-absorption at 280
nm with appropriate blanks subtracted and by comparison to a reference sample with known
concentration (external standard). CPC fractions were analyzed by ProteinA-HPLC for mAb
concentration. HCP content in CPC fractions and after precipitation and re-dissolution were
measured using a proprietary ELISA-like assay. The assay relies on the binding of host cell
proteins by specific antibodies and the subsequent quantification of the host cell protein -
antibody complexes.
2.8.2 Fourier Transform Infrared Spectroscopy (FTIR)
Preservation of the native secondary protein structure is a major requirement in the devel-
opment of alternative purification techniques for therapeutic proteins. Thus, infrared spectra
of 2 mg/mL mAb solutions after precipitation and re-dissolution and reference samples were
recorded using a Confocheck FTIR-system (Bruker Optik GmbH, Ettlingen, Germany) equipped
with a BioATR II cell (Attenuated Total Reflectance). Prior to FTIR-analysis all samples were
diafiltered with Vivaspin-filters (30.000 MWCO PES, Sartorius Stedim Biotech, Gttingen, D)
into 20 mM citrate pH 6.0. 20 µL of each sample were measured with the BioATR-cell auto-
matically subtracting the signal of the buffer solution. Recorded infrared spectra were displayed
by Bruker Software Opus as vector-normalized second derivative amide I spectra.
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3 Results
3.1 Precipitation & Redissolving
Precipitations of the monoclonal antibodies used in this study and the appropriate HCP pool
were performed for two reasons. First, the selection of suitable ATPS conditions for centrifugal
partition chromatography at a preparative scale was done using the solubility guided process
development approach previously described [15]. Second, precipitation was evaluated as a pos-
sible alternative purification methods. Figure 1 shows selected results from these precipitation
experiments. In figure 1(a) the recovery of mAb2 and HCP is plotted against the weight percent
of PEG used for precipitation. A clear influence of the molecular weight of the PEG can be seen.
The antibody stayed in solution up to 36 % [w/w] of PEG 400. The last PEG concentration
at which full recovery was observed was reduced to 24 %[w/w] for PEG 600, 18 %[w/w] for
PEG 1000, 12 %[w/w] for PEG 1450, and 4%[w/w] for PEG 4000. The other two antibodies
investigated showed very similar results (data not shown). While the mAbs were prone to pre-
cipitation, HCP stayed in solution with an average recovery of 77 % at 42% [w/w] PEG. HCP
recovery was influenced less strongly by changes in the molecular weight of PEG and for easier
illustration of the data, the average recovery of HCP when precipitated with all but PEG 4000
is shown in figure 1(a). The data clearly indicated that HCP depletion through precipitation
of the antibody was likely. Figure 1(b) shows the recoveries of mAb1, mAb2, mAb4, and HCP
when precipitated with PEG 4000. It can be seen that all antibodies follow a similar trend
while showing slight differences in their susceptibility for precipitation. With HCP recoveries
of at least 75% in the permeate, a PEG 4000 concentration of 15% [w/w] was deemed most
promising, as no antibody was recoverable in the supernatant at this PEG concentration for all
three mAbs tested.























(a) Precipitation of mAb2





















(b) Precipitation with PEG 4000
Figure 1 Selected results from the precipitation screenings. Datapoints represent the mean value of
triplicates, lines are interpolations to guide the eye. (a): Precipitation of the most soluble mAb used
in this study with PEGs of different molecular weight. Precipitations were performed at 1 g/L mAb
concentration, 0.41 g/L HCP concentration and pH 6.0. Results shown for HCP represent the average
recovery of precipitations performed with PEG 400, 600, 1000, and 1450. (b): Precipitation of all
mAbs used in this study and an appropriate HCP pool with PEG4000. Precipitations were performed
at protein concentrations of 1 g/L for mAbs and 0.41 g/L for HCP at pH 6.0.
In order to use precipitation of the target protein as a process step, the precipitate needs to be
readily redissolvable and the protein needs to stay in its active conformation. Two conditions to
redissolve mAb precipitates were tested. The buffer in which the protein had initially been pre-
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cipitated and a citrate buffer at pH 3.0. The latter was chosen to incorporate into the process a
low pH hold viral inactivation step as the one incorporated into the standard mAb process after
ProteinA elution. Table 2 show the results of these experiments. Recoveries above 93% and
reductions of HCP by more than 89% were found under all conditions. With recoveries close to
100% and HCP depletions above 96.4% results were better when redissolving the precipitate at
pH 3.0 than at pH 6.0.
Table 2 HCP reduction and mAb recovery after precipitation of a mixture of 1 g/L mAb and 0.41 g/l
HCP in 50 mM citrate buffer at ph 6.0 with 15 %[w/w] PEG4000 and subsequent redissolving of the
precipitated protein in either 20 mM citrate buffer at ph 6.0 or 100 mM citrate buffer at pH 3.0.
Protein pH HCP-Reduction Recovery
[%] [%]
mAb1
pH 6 90.6 94.0
pH 3 96.4 100
mAb2
pH 6 89.1 96.2
pH 3 96.4 98.4
mAb4
pH 6 90.9 93.3
pH 3 97.6 99.3
FT-IR spectroscopy measurement of the mAbs before and after the precipitation and redissolv-
ing procedure were performed to check for significant structural changes. The raw absorption
spectrum and its second derivative of mAb2 are shown in figure 2(a) and 2(b). To illustrate
the difference in FT-IR spetra caused by denaturation, a heat treated sample of mAb2 was
added to the analysis. From figure 2 it can be seen that the specra and their second derivate
of mAb2 before and after precipitation and redissolving differ only insignificantly compared to
the heat treated sample. It should be noted that the results from mAb2 were chosen as an
illustration, as the observed spectral difference was largest for this protein. Additionally, the
redissolved protein was investigated for ProteinA binding by ProteinA-HPLC. No significant
change in ProteinA binding was observed.
3.2 Batch Partitioning in PEG400/Citrate-Systems
Prior to batch partitioning of proteins, binodal and tieline data of the PEG-citrate systems were
obtained. Figure 3 shows the resulting binodals and gives the average tieline slope determined
for PEG 400, 600, 1000, and 1450-citrate systems. Additionally, the three fit-factors for equation
1 are given. The binodals showed the expected trend of shifting towards the origin of the plot
with increasing PEG molecular weight. Average tieline slopes also showed the expected trend
of decreasing with increasing PEG molecular weight. For the further progress in the solubility
guided process development it is important to note that for all PEG molecular weights except
of PEG 400, the concentration of the non-dominating phase forming component was (Citrate in
the upper phase, PEG in the lower phase) significantly below 5% in both phases. Accordingly,
only in PEG400 systems the influence of the non-dominating phase forming component were
taken into account in the solubility measurements by adding 5% PEG400 to the precipitant.
Batch ATPS distribution experiments were performed for three monoclonal antibodies and a
corresponding HCP pool. The results for PEG 400-citrate systems are plotted in figure 4, with
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reference precipitated stressed (80°C)
(a) Original FT-IR spectra





















reference precipitated stressed (80°C)
(b) 2nd derivative of the FT-IR spectra
Figure 2 FT-IR spectra of mAb2 at 2 g/L and pH 6.0. ’Reference’: unprocessed mAb2, ’Precipitated’:
mAb2 precipitated by 15 % PEG4000 at 2 g/L, pH 6.0 and redissolved in 20 mM citrate buffer pH 6.0,
’stressed’: mAb2 at 2 g/L subjected to 80◦C for 10 minutes.


















Parameter values of the binodal fits TLS
PEG MW a b c
400 94.00 -0.316 -4.45E-5 -1.48
600 98.76 -0.385 -8.13E-5 -1.63
1000 98.26 -0.418 -1.35E-4 -1.79
1450 70.18 -0.330 -2.45E-4 -1.86
Figure 3 Binodals of PEG-Citrate aqueous two-phase systems measured by the automated turbidity
methods. Data was fitted to equation 1 as described by Merchuk et al. [17]. The parameter values of
the resulting fit are given in the table included in the graph. The column headed ’TLS’ in the table gives
the average tieline slope determined for the corresponding PEG MW using phase volume determination
and the lever arm rule.
figures 4(a) to 4(c) showing results of mAb1, mAb2, and mAb4 respectively, and figure 4(d)
the results of HCP. The concentration of the phase forming components is plotted on the axes.
Along the axes, bar plots show the recoveries that resulted of the precipitation experiments.
The binodal and the tielines of the systems used is plotted, with a dot plot representing the
protein recovery in each of the two phases. The distribution coefficient can be inferred from the
recoveries in the top and bottom phase. As can be seen from figure 4, the precipitation experi-
ments show a good qualitative correlation to the distribution of the proteins. mAbs showed a
strong distribution into the upper phase with distribution coefficients in the range of 60 to 200.
The HCP pool showed a significantly differed distribution with distribution coefficients of 1.6
to 2.0. While the mass balance for HCP was closed within the experimental certainty, recovery
of mAbs decreased with increasing tieline length. The effect was different for all mAbs with
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mAb4 showing the strongest (100% down to 11%) and mAb2 showing the weakest influence
(100% down to 90%).
































































































































































































Figure 4 Results of the batch ATPS screenings using PEG400-Citrate systems. Bar plots along the
axes show results of precipitation experiments with the phase forming components. Binodal and tielines
are shown. ’x’ corresponds to the total system composition. The recoveries in top and bottom phase are
shown as color coded dots at the composition of the respective top and bottom phase. The distributions
coefficient can be deduced from the shown recoveries. Protein concentrations were at 1.0 g/L for all
experiments with mAbs and at 0.41 g/L for all experiments with HCP.
The correlation between precipitation data and ATPS distribution of the mAbs suggested that
there was an influence of the total protein concentration in the system on the measured distri-
bution coefficient. In order to evaluate this influence and to determine the maximum capacity of
the system, the most soluble mAb, mAb2, was distributed in PEG 400 SP3 systems at different
total protein concentrations. Figure 5 shows the resulting mAb2 concentrations in the top and
bottom phase as a function of the total protein concentration in the systems. For all concen-
trations shown, the mass balance was closed within the experimental certainty. The top phase
concentration showed an approximate linear correlation to the total system concentration, the
bottom phase concentration increased only slightly with increasing total system concentration.
Total protein concentrations of 8 g/L, resulting in top phase concentrations of approximately 13
g/L, could be accommodated in the system without loss of product. As can be seen in 5 a slight
downwards curvature can be seen in the top phase concentrations. This could be a sign of a
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beginning capacitiy limitation of the top phase. As no significant loss of product was observed,
capacity limitation in the tested range seem negligible. Additionally, the decrease in top phase
concentration relative to the total system concentration might also be a result of slight changes
in the volume ratio of the phases in reaction to the changes in protein content. Higher mAb
concentrations were not tested due to limitations in the available stock solution concentration
and mAb mass.





















Upper Phase Lower Phase
Figure 5 Top and bottom phase concentration of mAb2 in batch PEG400 SP3 systems as a function of
total system concentration of mAb2.
3.3 Centrifugal Partition Chromatography
For the CPC experiments the combination of mAb2 and SP3 of the PEG 400 citrate systems
were chosen. This system point in combination with this protein had shown a high capacity
and the highest distribution coefficient. Additionally, SP3 is the longest tieline for which full
recovery in the top phase was observed. Longer tielines were considered more robust in terms
of the CPC process, as small changes in system composition carry less risk of shifting the
system into the single-phase region. The amount of stationary phase retained in the column
and the column back pressure generated under different operating conditions were evaluated
in a standard two level full factorial designed experiment. Figure 6 shows the results of these
experiments as contour plots. From figure 6(a) it can be seen that the stationary phase ratio Sf
was more strongly influenced by the flow-rate than by the rotational speed. Sf declined with
increasing flow-rate from 0.53 at 5 mL/min to 0.29 at 15 mL/min. Sf values were slightly higher
at higher rotational speed. Column back-pressure in contrast was influence strongly by both
parameters with higher flow-rates and lower rotational speed causing less back-pressure. At low
RPMs, the effect of flow-rate was less pronounced than at higher RPMs. Highest back-pressure,
4 MPa, was observed at 2500 RPM and 5 mL/min. Lowest back-pressure, 1.5 to 1.6 MPa,
was observed at 1500 RPMs and 5 to 15 mL/min respectively. Based on these observations,
operating conditions of 5 mL/min and 1500 RPM were chosen for the purification of mAb2.
Figure 7 shows resulting elution profiles of SP3 systems run in the CPC at 5 mL/min and 2500
RPM both in regular injection-elution mode as well as in dual mode as described in the methods
section. Figure 7(a) shows the elution profile of mAb2 and HCP from a 10 mL injection of an
SP3 top phase. While the antibody eluted in one comparably narrow peak between fractions






































































Figure 6 Evaluation of CPC operating conditions on the stationary phase ratio and column back-
pressure using a PEG400 SP3 system. Contour plot were generated using cubic interpolation. (a):
Stationary phase ratio Sf , (b): Column back-pressure
37 and 41, the HCP elution showed two distinct peaks. One of the HCP peaks co-eluted with
the antibody, while the second one stretched from fraction 42 to 47. It should be noted that
the mass balance for mAb2 was closed considering the single elution peak and that the mAb2
concentration was reduced fourfold by the process step. Mass balance for HCP was not closed
even when taking into account both elution peaks. 67.9 % of the injected HCP was not found
within the analyzed fractions. Figure 7(b) shows the online conductivity and UV280 traces
recorded in a dual mode run, using an SP3 system and a sample volume of 10 mL. Data shown
start directly after switching to the bottom phase as mobile phase. With the bottom phase
being the mobile phase, a steep increase in conductivity was observed. After approximately one
column volume, an increase in UV280 was observed. The fractions were tested and were found
to contain HCP but no mAb2. After elution with 620 mL bottom phase, the mobile phase was
switched back to the top phase. mAb2 co-eluted with the mobile phase after 850 mL. An HCP
reduction of 88.2% was reached. The dilution of the mAb2 after elution was 2.3 fold while the
mass balance for the mAb closed within the experimental certainty.
3.4 Combination of Process Steps
ATPS and CPC separation of mAb2 from HCP was combined with mAb2 precipitation and
re-dissolving in order to increase mAb2 concentration and reduce polymer concentration in the
solution. Table 3 shows both HCP reduction and mab2 recoveries of the combination of process
steps.
While a single batch ATPS step only yielded 27.4 % HCP reduction, switching from batch mode
to CPC increased the HCP reduction to 76.7% in regular mode and 88.2% in dual mode while
not changing the mAb2 recovery of 96.9%. A single precipitation step reduced HCP by 96.3%
with mAb2 recovery at 98.4%. Combining ATPS either in batch mode or in CPC mode with a
precipitation and re-dissolving step gave HCP clearances of 98.5% and 99.4% respectively while
reducing the mAb2 recovery slightly to 93.4 and 93.0%.
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Figure 7 (a): Elution profile of a CPC run performed with SP3 of PEG400. Operating conditions
were: 5 mL/min, 2500 RPM. Sample volume: 10 mL. Sample composition: top phase of an SP3 system
with total concentrations of 5 g/L mAb2 and 0.41 g/L HCP. (b): UV280 and conductivity trace of a
CPC run performed in dual mode using an SP3 system and 10 mL load. Elution of HCP after 500 mL
was clearly resolved from the elution of mAb after 850 mL.
Table 3 HCP reductions and mAb2 recoveries of different process steps and combinations thereof. Batch
ATPS was performed in PEG400-Citrate SP3 systems - results of batch-ATPS are given for the top phase.
Precipitation & re-dissolving was performed using 15% [w/w] PEG4000 at pH 6.0 to precipitate and 100
mM citric acid buffer at pH 3.0 to redissolve. Precipitation after CPC was done using 20% [w/w]
PEG4000. The mAb2 concentration in these experiments was 1 g/L.
Process step HCP-Reduction [%] mAb-Recovery [%]
Batch-ATPS 27.4 96.9
CPC (Ascending Mode) 76.7 96.9
CPC (Dual Mode) 88.2 96.9
Precipitation & Re-dissolving 96.4 98.4
Batch ATPS & Precipitation & Re-
dissolving
98.5 93.4




4.1 Precipitation & Resolubilization
Precipitations and re-dissolving of the process solutions were successfully implemented in a 96
well high-throughput screening scale. Using PEG as precipitant, the target protein was more
prone to precipitation as the impurities.Thus, purification by bringing the target protein out
of solution and subsequently redissolving it was evaluated and showed high HCP separation.
Precipitating the target protein rather than the impurities has certain advantages and disad-
vantages. Clear advantages are the possibility of increasing the target protein concentration,
the incorporation of a low-pH virus inactivation step and the high selectivity when precipitating
one certain protein rather than a pool of unknown proteins. Disadvantages might be the need
to show that the target protein is not adversely influenced by the procedure and the removal of
residual precipitant from the precipitate. In the case presented here, no adverse effect on the
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target protein was found. Both FT-IR and a functional assay (ProteinA-binding) showed no
effect of the procedure. While these assays cannot confirm the biological functionality of the
molecule, they are strong indicators, that no significant structural changes have occurred. The
remaining PEG 4000 in the precipitant could not be quantified. Re-dissolving of the mAbs was
successful both at pH 6.0 and at pH 3.0 with HCP depletion higher at the lower pH. This might
be a result of HCP proteins not re-dissolving at the lower pH. As the re-dissolved protein was
passed through a filter, HCP still in a precipitate would be removed by the filtration. While
the three mAbs tested in this study showed very similar behavior, and while it is likely that
other mAbs might also show this behavior, molecules other than mAbs will most likely show a
different behavior. For such molecules, this approach would have to be reevaluated. With the
current knowledge on the mechanism behind the precipitation of proteins by PEG [20, 21, 22],
it is likely that proteins of large molecular weight will react similar to the mAbs tested herein.
4.2 Batch Partitioning in PEG400/Citrate-Systems
Batch partitioning of monoclonal antibodies has been shown to be a promising approach for
HCP removal for both PEG-PO4 and PEG-Citrate systems. [23, 5]
High throughput screening processes to evaluate PEG-Citrate systems were successfully em-
ployed in this study. The phase selection theme, guided by solubility data, was performed as
previously described [15]. The entire work-flow, from precipitation data, to binodal and tieline
determination, to ATPS evaluation was performed in 96 well format as described in [16, 10].
The validity of the solubility guided phase selection scheme under preparative conditions was
again shown. The precipitation data suggested a significantly lower solubility of the mAbs in the
citrate rich bottom phase. Consequently, the bottom phase contained only minimal amounts
of mAb. In contrast, the PEG 400 concentrations in the upper phases of the shorter tielines
allowed for the mAb to stay in solution. With increasing tieline, the recovery of mAb decreased
in the case of mAb4, the target molecule that had shown the lowest solubility throughout the
study.
4.3 Centrifugal Partition Chromatography
The CPC setup as used in this study was also used by Sutherland et. al [13]. They showed that
by using a PEG1000-PO4 system in a CPC, two model proteins having partition coefficients
of 0.59 and 1.91 could be baseline separated over a CPC. While the separation power of this
process step was demonstrated, the shortcomings, dilution of the target molecules and low ca-
pacity, also became obvious. We have addressed these shortcomings in the present manuscript
by applying a different phase selection scheme and optimizing capacity both via phase selection
and operation in dual mode.
Multi-step extraction for HCP removal from antibody solutions has also been successfully im-
plemented both using an extraction column [24] or using mixer-settler batteries [25]. Including
a subsequent back-extraction step, the output stream was compatible with HIC. However, the
need for a back-extraction necessitated the use of high amount of NaCl in the initial ATPS,
thus severely limiting the capacity of the system.
4.4 Combination of Process Steps
Finally, combinations of batch ATPS, CPC, and precipitation were evaluated. It was shown,
that the combination of an extraction step with a subsequent precipitation of the protein of
interest can be highly advantageous. The precipitations step not only removed a significant
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amount of HCP, but also counteracted the dilution introduced by the CPC and made the in-
corporation of a virus inactivation step and polymer removal step possible. Additionally, it is
important to note that the combination of process steps yielded more than the simple sum of
HCP clarification of the two steps. Different populations of HCP are removed by the two steps
and as a result, they worked in a cooperative manner. The entire process would start with
a cell culture supernatant. Cells might be removed either by regular means (centrifugation,
depth filtration) or it might be left to the subsequent batch ATPS to remove cells. Second, a
batch ATPS would be created either to use it as single partitioning step, or to create a sample
for a CPC run. If a CPC run was performed, it would be run in dual mode, stripping HCP
from the mAb containing upper phase. After the extraction step (either batch or CPC), the
mAb would be precipitated by the addition of PEG4000. The precipitate would be washed and
re-dissolved in a standard citrate buffer at pH 3.0. A viral hold step might be included into
the process at this time. The final output stream of the entire procedure would end with a
higher concentration of the mAb than the input stream, a 2.2 log step clearance of HCP, and
an overall mAb recovery of 93%. This output stream could, after slight adjustments to pH and
conductivity be used directly as a feed stream to a following chromatographic separation. In a
review article Przybycien et. al [2] discussed the merits of various alternative separation steps.
ATPS was classified as having higher resolution but less industry maturity than precipitation.
In the investigation presented herein, we found precipitation to have a higher resolution than
ATPS. This might be due to the specific class of molecule investigated as explained above. One
of the most severe challenges impeding implementation of alternative separations for biophar-
maceuticals is their integration into a chromatography based process. This was also pointed
out by Przybycien et. al [2] who concluded that currently none of the alternative process steps
were easily integrable. The presented approach however yield a process stream that can be
readily combined with subsequent chromatographic steps. While the implementation of a CPC
in a GMP surrounding might yet be a challenging task, using batch extraction in combination
with precipitation could be implemented in a pharmaceutical process plant with little effort.
Process economics might necessitate the recycling of the polymer to reduce cost of goods and
cost of disposal. Several ways to recycle the polymer have been suggested [26, 27]. These in-
clude electrophoretic separation of proteins from the polymer solution with subsequent removal
of water by ultrafiltration, which would be the most appropriate approach under the given
circumstances.
5 Conclusion & Outlook
In this work, we have demonstrated how an alternative separation step in the form of aqueous
two-phase extraction in combination with precipitation and resolubilization can be developed
using high throughput screening techniques. The combination of these unit operations were
developed in small scale and the results shown to be transferable to larger scale systems. The
combination of these unit operations resulted in a high HCP clearance while providing and
output stream that is both high in target protein concentration and low in process related
impurities that might impede subsequent steps.
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aqueous two-phase extraction of human antibodies using a packed column., J. Chromatogr.
B 880 (1) (2012) 14856. doi:10.1016/j.jchromb.2011.11.034.
[25] M. R. Aires-Barros, Aqueous two-phase systems for antibodies purification: From macro
to micro-scale, in: Recovery of Biological Products XV, 2012.
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Abstract
The demand for vaccines against untreated diseases has enforced the research and development
of virus-like particle (VLP) based vaccine candidates in recent years. Significant progress has
been made in increasing VLP titres during upstream processing in bacteria, yeast and insect
cells. Considering downstream processing, the separation of host cell impurities is predomi-
nantly achieved by time-intensive ultracentrifugation processes or numerous chromatography
and filtration steps. In this work, we evaluate the potential of an alternative separation tech-
nology for VLPs: aqueous two-phase extraction (ATPE). The benefits of ATPE have been
demonstrated for various biomolecules, but capacity and separation efficiency were observed to
be low for large biomolecules such as VLPs or viruses. Both performance parameters were exam-
ined in detail in a case study on human B19 parvovirus-like particles derived from Spodoptera
frugiperda Sf9 insect cells. A solubility-guided approach enabled the design of polyethylene
(PEG) salt aqueous two-phase systems with a high capacity of up to 4.1 mg/mL VLPs. Unique
separation efficiencies were obtained by varying the molecular weight of PEG, the pH value and
by using neutral salt additives. Further improvement of the separation of host cell impurities
was achieved by multi-stage ATPE on a centrifugal partition chromatography (CPC) device
in 500 mL scale. While single-stage ATPE enabled a DNA clearance of 99.6%, multi-stage
ATPE improved the separation of host cell proteins (HCPs). The HPLC purity ranged from
16.8% (100% VLP recovery) for the single-stage ATPE to 69.1% (40.1% VLP recovery) for
the multi-stage ATPE. An alternative two-step downstream process is presented removing the
ATPS forming polymer, cell debris and 99.77% DNA with a HPLC purity of 90.6% and a VLP
recovery of 63.9%.
Keywords: VLP, Aqueous two-phase systems, Centrifugal Partition Chromatography, High-
throughput screening, DNA removal, Parvovirus
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1 Introduction
Virus-like particles (VLPs) represent a new class of bionanoparticles incorporating unique fea-
tures for medical applications. VLPs are composed of one or several viral structural proteins ca-
pable of spontaneously self-assembling into capsids. Thus, they can either mimic the pathogens
they derived from [1] or present antigen epitopes of foreign pathogens [2] or tumor cells [3].
Apart from diagnostic applications VLPs show increasing importance as vaccine candidates
against unsolved or emerging infectious diseases and as new ”designer vaccine platforms” [4, 5].
Currently, there are five VLP-based products licensed for vaccination: two cervical cancer vac-
cines (Gardasil R©, Merck & Co. and Cervarix R©, GlaxoSmithKline), two hepatitis B vaccines
(Recombivax HB R©, Merck & Co. and Engerix-B R©, GlaxoSmithKline) and a hepatitis E vaccine
(Hecolin R©, Xiamen Innovax Biotech Co., Ltd.). About 10 candidates entered clinical phases II
or III [6] for indications such as influenza, gastroenteritis and malaria. Further research studies
focus on using VLPs as vectors for targeted delivery of small molecules [7] or nucleic acids [8].
Hence, there is an increasing demand for pure clinical grade VLPs in both pharmaceutical
industry and research centres for infectious diseases. Purity guidelines for human VLP-based
vaccines are given by the U.S. Food and Drug Administration and the World Health Organi-
zation: DNA concentrations should be below 10 ng per dose and protein purities above 95%
[9, 10]. The production of VLPs has been optimized in recent years for a number of different
VLPs enabling the choice between varieties of recombinant systems such as bacteria, yeast, in-
sect, mammalian or plant cells [11]. In contrast, downstream processing of VLPs predominantly
relies on time-consuming and hardly scalable ultracentrifugation steps [2].
Vaccine manufacturers have recently focused on replacing ultracentrifugation by chromatog-
raphy or filtration steps [12, 13, 11]. Although this approach has significantly improved the
scalability of VLP processes, low binding capacities [14, 15], product loss due to irreversible in-
teractions and process-related product alterations [16, 17], long process times and high process
costs [18] remain major challenges. Making vaccines more available to the developing world,
responding faster to pandemics and accelerating research, development and clinical studies are
main issues to be solved. An alternative unit operation for biomolecules avoiding interactions
with solid phases is aqueous two-phase extraction (ATPE). ATPE has proven to be a rapid
[19], low-cost [20], scalable [21], selective [22] and integrated [23] bioprocess unit operation. A
high and steadily increasing number of publications has underlined the applicability of aqueous
two-phase systems (ATPSs) for the purification of antibiotics, enzymes, therapeutic proteins,
monoclonal antibodies and viruses [20, 22, 24, 25, 26, 19]. ATPSs have beneficial characteris-
tics, especially for capturing products from crude cell feedstocks [27]. Drawbacks arise due to
high experimental effort during process development, limited mechanistic understanding and
low capacities.
High-throughput screenings on liquid handling stations have proven to be a valuable tool for
rapid selection of adequate ATPSs for separation tasks and for improving the mechanistic un-
derstanding of protein partitioning [28, 29]. This study focuses on the effect of different ATPS
characteristics on the partitioning of human B19 parvo-VLPs derived from Spodoptera frugiperda
Sf 9 insect cells and the removal of host cell contaminants such as cell debris, host cell proteins
(HCPs) and DNA. Human B19 parvo-VLPs are currently investigated as prophylactic vaccine
candidates against diseases attributed to parvovirus infections [30, 31]. This virus infects human
erythroid precursor cells in the bone marrow and may cause aplastic anemia. An infection dur-
ing pregnancy can lead to fetal anemia, often resulting in fetal congestive heart failure (hydrops
fetalis) and miscarriage. Hence, there is a need for a vaccine, a diagnostic immunoreagent and a
scalable purification process with a high VLP recovery. Recent studies evaluating ATPSs for the
purification of VLPs have shown that such large biomolecules can be partitioned in a stable form
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in either polymer- or salt-rich phases. Benavides et al. [32] observed the partitioning of human
rota-VLPs derived from Sf 9 cells into the top phase of a PEG400-phosphate system achieving
an HPLC purity of 11%. Partitioning of human B19 parvo-VLPs in PEG1000-magnesium sul-
phate systems was investigated by Luechau et al. [33]. The outcome was either a partitioning
of VLPs and the majority of host cell proteins (HCPs) in the bottom phase or the interfacial
attachment of VLPs separating HCPs into top and bottom phase. Since one of the major advan-
tages of ATPSs is the incorporation of a solid-liquid separation step the latter result of Luechau
et al. using clarified cell lysate would not be a desired process design for an integrated capture
step. Moreover, Luechau et al. used low pH values throughout their study, which can entail
disassembly and aggregation of VLPs [34, 35]. While ATPSs might have unique advantages
for capturing products from crude cell lysates, separation efficiency depends predominantly on
the type of operation. Multi-stage ATPE provides mostly higher separation efficiencies than
single-stage ATPE due to improved concentration profiles and a higher number of theoretical
plates. A promising technique for multi-stage and large scale extraction of biopharmaceutical
products is centrifugal partition chromatography (CPC). CPC systems have been optimized to
achieve high stationary phase retentions for ATPSs and optimized mixing between stationary
and mobile phases [36]. CPC case studies with ATPSs have been performed in the past for
high-resolution separations of model proteins [37], and for the purification of monoclonal an-
tibodies [38]. In this work, we demonstrate how capacity, recovery and purity of VLPs can
be optimized in an integrated ATPE step. The resulting ATPS can be easily implemented as
single-step process in any laboratory scale with basic equipment or as a multi-stage process
with proper extraction devices. In addition, an alternative purification process for human B19
parvoVLPs is suggested.
2 Materials & Methods
2.1 Disposables
All solubility screenings on the liquid handling station were conducted in 96 well Half Area
polystyrene flat-bottom plates by Greiner Bio-One (Kremsmünster, Austria). ATPSs were
prepared in 1 mL-96 Deep Well polypropylene plates (Thermo Fisher Scientific Inc., Waltham,
Massachusetts, USA). All UV absorbance measurements were carried out in Greiner Bio-One
350 µL-polystyrene UV Star R©plates. All fluorescence measurements were conducted in black
Nunc R© MicroWell
TM
polystyrene plates (Sigma-Aldrich, St. Louis, MO, USA). For all other
purposes Greiner Bio-One 350 µL-polypropylene flat bottom MTPs were used. ATPS scale-up
was done in BD Falcon
TM
50 mL Conical Centrifuge Tubes (Becton, Dickinson and Company
(BD), Franklin Lakes, New Jersey, USA).
2.2 Chemicals & Stock Solutions
PEG 200 and PEG 1450 were purchased from Sigma-Aldrich (St. Louis, MO, USA). K2HPO4
and NaH2PO4 · H2O were obtained from VWR BDH Prolabo (Radnor, Pennsylvania, USA).
All other chemicals were purchased from Merck KGaA (Darmstadt, Germany). All buffer and
stock solutions were prepared with ultra pure water drawn from a water purification system
from Sartorius (Goettingen, Germany). Polymer and salt stock solutions were used as follows:
70% [w/w] PEG 400, 70% [w/w] PEG 600, 70% [w/w] PEG 1000, 60% [w/w] PEG 1450, 40%
[w/w] PEG 4000, 40% [w/w] NaH2PO4, 40% K2HPO4 [w/w], 35% [w/w] citric acid, 35% [w/w]
trisodium citrate, 40% [w/w] ammonium sulfate, 30% [w/w] sodium carbonate. Mono- and
dibasic phosphate and citrate stock solutions were combined to yield the desired pH-values: e.g.
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22.73 g NaH2PO4 solution and 77.27 g K2HPO4 solution yield pH 7.4. pH values of all other
stock solutions and buffer solutions were titrated with hydrochloric acid and sodium hydroxide
solutions.
2.3 Human B19 Parvovirus-like Particles
VLPs were derived from Spodoptera frugiperda Sf 9 insect cells. Recombinant production of
human B19 parvovirus-like particles and material supply was done by the industrial partner
Diarect AG (Freiburg, Germany). VLPs composed of the major capsid protein VP2 and the
minor capsid protein VP1 (VP1/VP2-VLP) and VLPs assembled by solely VP2 (VP2-VLP)
were used throughout this study. All experiments were performed with Sf 9 insect cell lysates
prepared according to the following procedure: Frozen (-80◦C) pellets containing 8 x 108 Sf 9
cells were resuspended in 20 mL lysis buffer (10 mM Tris pH 7.4, 15 mM MgCl2, 250 mM
NaCl, 0.5% [v/v] polysorbate 80, 10% [v/v] glycerol) by shaking the suspension for 30 min on
an overhead shaker. Thereafter, cells were lysed on ice by sonication with a Branson Sonicator
450D equipped with a 1/2 inch microtip horn (Branson Ultrasonics, Danbury, CT, USA): 8x 15
s sonication at 80%, with 59 s cooling steps in between. Protein degradation by proteases was
counteracted by adding EDTA-free SIGMAFAST
TM
protease inhibitor cocktail tablets (Sigma-
Aldrich, St. Louis, MO, USA) to the lysis buffer. Clarification of cell lysates was carried
out by centrifugation for 30 min at 10.000 g and filtration with 0.1 µm cellulose acetate filters
(Sartorius AG, Goettingen, Germany). Aliquoted cell lysates were stored frozen at -30◦C. VLPs
purified by several ultracentrifugation steps were supplied by the industrial partner and served
as reference material for analytics.
2.4 Liquid Handling Station
A Tecan Freedom EVO R©200 system (Tecan, Crailsheim, Germany) was used as liquid handling
platform. Liquid handling calibration, solid-liquid separation and set-up were described earlier
[26]. The robotic workstation was controlled using Evoware 2.3 (Tecan, Crailsheim, Germany).
Data import and output were done with Excel 2010 (Microsoft, Redmond, WA) files. Matlab
R2013a (The Mathworks, Natick, ME) was used for data calculations and visualizations.
2.4.1 Solubility Screening
A solubility guided approach was chosen to select suitable aqueous two-phase components for
VLPs. Solubility screenings for 0.5 mg/mL VP2-VLP were conducted with different concentra-
tions of PEG 200, PEG 400, PEG 600, PEG 1000, PEG 1450, PEG 4000 and phosphate at pH
7.4. Screenings were performed on the liquid handling station in 150 µL total volume with each
data point measured in triplicate. The automated procedure was described in detail earlier [38].
Briefly, stock solutions of polymers, salts and Sf 9 cell lysates containing VLPs were pipetted
into 96 well Half Area plates, incubated on an orbital shaker and centrifuged. Supernatant
samples were taken and analyzed for soluble VLP content. Solubility screenings were also used
to evaluate the performance of a VLP precipitation step with PEG 4000 after a single-stage
ATPE.
2.4.2 Automated ATPE Procedure
Binodals and tie lines for seventeen different ATPSs were determined according to automated
methods established and described by our group [29, 26]. Binodal data points were identified
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using the cloud point method [38] and fitted to Eq. (1) given by Merchuk et al. [39].
xPEG = a ∗ exp(b ∗ x0.5salt + c ∗ x3salt) (1)
Tie-lines were determined with the lever arm rule using volume ratios (Vr) calculated from mass
balances with a dye as described before [29, 26]. Automated ATPE experiments were conducted
according to Oelmeier et al. [26]. Subsequent to the solubility screenings promising ATPSs with
volume ratios near 1 were selected for investigating partitioning of VLPs. Parameters such as
molecular weight of PEG, salt type, pH, additive concentration and tie-line length were varied
to evaluate the effect on VLP separation from total protein and DNA. 650 µL ATPSs with a
concentration 0.5 mg/mL VP2-VLP were built by adding stock solutions of phase components,
cell lysates with known VP2-VLP concentrations and water into 96 Deep Well plates. ATPSs
were mixed, incubated and centrifuged for phase separation. Samples of top and bottom phases
were taken and analyzed for VLP, total protein and DNA content. Phase volumes, VLP, DNA
and total protein partitioning were measured at least in triplicate, blank values at least in
duplicate. Partitioning in top and bottom phases was determined by multiplying the measured
solute concentrations with the respective phase volumes. Mean values of recoveries of VLP,
total protein and DNA are reported throughout this manuscript. For a detailed analysis of the
pH effect, ratios of monobasic NaH2PO4 stock solution and dibasic K2HPO4 stock solution were
varied to yield the desired pH values in a range between pH 5.5 and 8.5. Prior to performing
pH screenings with VLP samples system compositions were tested in 10 mL scale for two-phase
separation. All actual system pH values of the bottom phases were checked and showed standard
deviations below 0.5% from the desired pH value.
2.5 Physical Characterization of ATPS
ATPSs with a promising performance for multi-stage extractions were further characterized
measuring viscosities and densities of top and bottom phases. ATPSs were built, mixed and
incubated in 50 mL scale. Phase separation was accelerated by centrifugation at 10.000 g for
10 min. Viscosity was determined using a cone-plate rheometer HAAKE RheoScope 1 (Thermo
Fisher Scientific, Waltham, Massachusetts, USA). The rheometer was controlled by HAAKE
RheoWin 4.30 (Thermo Fisher Scientific, Waltham, Massachusetts, USA). Viscosities of top
and bottom phases were measured with a C50/1◦ cone increasing shear stress from 0.1 to 10
Pa. Phase densities were measured with calibrated standard 5 mL Blaubrand R©pycnometers
(BRAND GMBH + CO KG, Wertheim, Germany) using an analytical balance (Sartorius AG,
Goettingen, Germany). Viscosity and density measurements were conducted at least in dupli-
cate with standard deviations below 5%.
2.6 Centrifugal Partition Chromatography
Multi-stage extractions were conducted by Centrifugal Partition Chromatography (CPC) on an
Armen 500 mL CPC column (Armen Instrument, Vannes, France). The CPC column consists
of 42 stacked discs with 24 twin chambers. Set-up including HPLC pump, ÄKTA prime (GE
Healthcare) for UV and conductivity detection as well as detailed proceeding of operation modes
were described earlier [38]. For each run a 3 kg ATPS was prepared by dissolving polymer and
salts in ultra pure water: e.g. 422.4 g PEG 400, 458.26 g K2HPO4, 34.67 g NaH2PO4 · H2O
and 225 g NaCl (system point (SP) 1*: 14.08 % [w/w] PEG400, 16.28 % [w/w] phosphate
pH 8.5, 7.5 % [w/w] NaCl). Phase settling was done in a separating funnel. CPC columns
can be run either in Ascending Mode using the top phase as mobile phase and the bottom as
stationary phase or in Descending Mode using bottom phase as mobile and the top as stationary
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phase. Ascending and Dual operation mode were tested for PEG 400- and PEG 600-phosphate
systems. In Ascending Mode the CPC column was at first filled with bottom phase at 50
mL/min and 500 rpm replacing residual distilled water present in the system. Complete filling
was assured by continuing bottom phase flow until the outlet conductivity signal remained
constant. Subsequently, the column was equilibrated by pumping the mobile phase at the
desired operating flow rate and rotational speed. Stationary phase retention was determined
by collecting the displaced bottom phase during the whole run. Column equilibration was
monitored by the change from high conductivity (salt phase) to a constant low conductivity
signal (polymer phase). Following the described procedure the stationary phase retention of
four PEG 400-phosphate systems and one PEG 600-phosphate system was studied at flow rates
from 3 to 10 mL/min and a rotational speed of 2500 rpm. System and operating points inducing
a stationary phase retention above 35% were utilized for purification experiments with a total
system concentration of 0.5 mg/mL VLP. Purification experiments were performed by injecting
10 mL top phase of a separately prepared ATPS containing crude Sf 9 cell lysate into the CPC
sample loop. Sample injection was done after column equilibration. Eluting proteins were
identified by UV measurements, fractionated and analyzed for VLP, HCP and DNA content as
described below.
2.7 Combination of ATPE & Precipitation
A combination of single-stage ATPE and precipitation was performed in 50 mL scale. ATPSs
were built by mixing 22.06% [w/w] PEG 400, 6.8% [w/w] phosphate pH 8.5, 7.5% [w/w] NaCl
and crude Sf 9 cell lysate containing human B19 parvoVLPs and cell debris. Purifications of
both VP2- and VP1/VP2-VLPs were tested for process evaluation. ATPSs were mixed for 30
min on a rotating shaker and centrifuged at 6.000 g for 15 min. The top phase was mixed in 50
mL scale with PEG 400 and NaCl stock solutions to attain a mixture of 13% [w/w] PEG 400
and 9% [w/w] NaCl. The mixture was incubated for 30 min and centrifuged at 6.000 g for 15
min. After a washing step with 13% [w/w] PEG 4000 in 50 mM Tris pH 9.0, 0.8 M arginine the
precipitate was redissolved in PBS at pH 7.4 on a rotating shaker for 2 h and filtrated with a 0.1
µm cellulose acetate filter (Sartorius AG, Goettingen, Germany). The process was conducted
in triplicate.
2.8 Analytical Methods
2.8.1 VP2 & HCP Quantification
Quantification of the major virus protein VP2 and HCPs was done by reversed-phase ultra-high-
performance-liquid chromatography (RP-UHPLC) using an UltiMate R©3000 RSLC x 2 Dual
system from Thermo Fisher Scientific (Waltham, Massachusetts, USA). Sample analysis was
performed on a Waters Acquity BEH300 C4 1.7 µm column (diameter x length = 2.1 mm x 50
mm) at a flow rate of 0.5 mL/min and a column temperature of 75◦C. Mobile phase buffers were
ultra pure water containing 0.5% [v/v] trifluoracetic acid (TFA) (solvent A) and acetonitrile
containing 0.4% [v/v] TFA (solvent B). Protein analysis was conducted as follows: Column was
equilibrated with 8% B for 1.4 min, followed by an increase to 45 % B in 0.35 min, held for 0.35
min, followed by a gradient of 45-50% over 2.15 min and an increase to 95% in 0.35 min, held for
0.7 min. Thus, the total analysis time was 5.4 min per sample. Prior to RP-UHPLC analysis
VLPs were disassembled. Disassembly was performed by diluting samples 1:4 with an adapted
dissociation buffer suggested by Yuan et al. [40]: 8 M guanidine-HCl/ 50 mM Tris pH 8.0, 60 mM
DTT and an incubation at 55◦C for 15 min. Due to the dissociation effect on VLPs and HCPs
the sample preparation method minimized the risk of column blockage by protein precipitation
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upon contact with acetonitrile and enabled the analysis of whole cell lysates. A calibration for
VP2 with purified reference samples with known VP2-VLP (and VP1/VP2-VLP) concentration
enabled the quantification of VP2 in cell lysates and ATPS samples. Samples of ATPS top and
bottom phases with lysis buffer instead of cell lysate were subtracted from chromatograms as
blank systems. A chromatogram of a Sf 9 cell lysate sample containing VP2-VLP is shown in
Fig.1 a. Fig. 1 b displays the RP chromatogram of the purified VP2-VLP standard.
VP2
(a) Sf 9 cell lysate (b) VP2-VLP standard
Figure 1 Selected chromatograms from Reversed Phase UHPLC runs. UV-signals at 226 nm are plottet
against the retention time. The major peak VP2 is marked in the chromatograms at a retention time
of 2.799 min. (a) Analysis of Spodoptera frugiperda Sf 9 insect cell lysate containing human B19 parvo-
VP2-VLPs. (b) Analysis of 5 µg human B19 parvo-VP2-VLPs (external standard)
For HCP measurements total peak areas of substances eluting at lower (HCP group 1) and
at higher (HCP group 2) acetonitrile concentrations than VP2 were integrated and summarized
into sub-HCP-populations for the evaluation of VLP purity. HPLC purity (P) was defined as






The electrophoresis was performed using XCell SureLock Mini-Cell (Invitrogen, Paisley, United
Kingdom) with NuPage 12% Bis-Tris gel and MES buffer according to the manufacturer’s
instructions. The VLP amount in each gel lane was kept constant for all analyzed samples at 5
µg VP2-VLP. Gels were stained applying a coomassie blue staining.
2.8.3 Total Protein Quantification
Total protein was quantified by UV measurements at 562 nm using a BCA assay kit (Thermo
Fisher Scientific Inc., Waltham, Massachusetts, USA) according to the manufacturer’s instruc-
tions. ATPS samples were diluted tenfold prior to analysis to minimize interference by polymers
and salts.
2.8.4 DNA Quantification
Determination of dsDNA concentrations was carried out using the PicoGreen R© dsDNA assay
kit (Invitrogen, Paisley, United Kingdom) in 96-well plates according to the manufacturer’s
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instructions. ATPS samples were diluted three hundredfold (two dilution steps) prior to analysis
to minimize interference by polymers and salts. All other samples were diluted tenfold. The
detection limit of the PicoGreen R© dsDNA assay kit is 25 pg/mL DNA.
2.8.5 Examination of VLP structure and Activity
The detection of virus proteins via RP-UHPLC or SDS-PAGE does not necessarily imply the
presence of assembled and active VLPs. Therefore, shape and structure of purified VLP samples
were monitored by transmission electron microscopy (TEM). Samples were applied on carbon-
coated grids at room temperature and dried for two minutes. Residual salt was washed off
with distilled water. Particles were stained with 2% [w/w] uranyl acetate and analyzed on
a Philips CM 200 FEG/ST transmission electron microscope at 200 kV. Activity of purified
VLP samples was examined by the industrial partner with human patient sera containing VP2-
binding antibodies.
3 Results
3.1 Solubility-guided Selection of ATPS Phase Components
The selection of ATPS phase components for VLPs was performed following the strategy of
a solubility-guided approach [28]: The solubility of 0.5 mg/mL VP2-VLPs was investigated at
increasing concentrations of different polyethylene glycols and phosphate at pH 7.4. In Fig. 2 the
recovery of VP2-VLPs is plotted against the precipitant concentration given in weight percent.
Fig. 2 shows a strong influence of the molecular weight of the polymer on the solubility of the
VLPs. While PEG 4000 induced precipitation of VLPs at low polymer concentrations, VLPs
remained in solution over a broader concentration range in the presence of smaller polymers
such as PEG 200. A decrease of the VLP concentration in the soluble fraction occurred at
a concentration of 39 % [w/w] PEG 200, 27 % [w/w] PEG 400, 16% [w/w] PEG 600, 12 %
[w/w] PEG 1000, 10% [w/w] PEG 1450, 3 % [w/w] PEG 4000 and 12 % [w/w] phosphate pH
7.4. These concentrations are important for the ATPS selection process, because higher phase
component concentrations may cause loss of product recovery [28, 38]. At a concentration
of 60 % [w/w] PEG 200 more than 0.35 mg/mL VP2-VLP were still present in the soluble
fraction. There were no VLPs detected in the supernatant at precipitant concentrations of 42%
[w/w], PEG 400, 26% [w/w] PEG 600, 24% [w/w] PEG 1000, 16% [w/w] PEG 1450, 7% [w/w]
PEG 4000 and 16% [w/w] phosphate pH 7.4. Moreover, the absolute value of the slope of the
solubility curves in the decreasing segment, defined as the precipitation efficiency ß by Sim et
al. [41], increases with the chain length of the polymer. The highest ß-values were obtained for
PEG 4000 and phosphate.
3.2 Single-stage ATPE: Partitioning of VLPs & Contaminants
3.2.1 ATPS Phase Diagrams
Prior to VLP partitioning studies, ATPSs were characterized on the liquid handling station.
Binodals and tie-lines of different PEG-phosphate systems at pH 7.4 were determined. Fig.
3 shows the binodals of PEG 200-, PEG 400-, PEG 600-, PEG 1000-, PEG 1450- and PEG
4000-phosphate systems at pH 7.4. The PEG concentration in weight percent is plotted against
the phosphate concentration in weight percent. All determined binodal plot coefficients and
average tie-line slopes are summarized in Table 1. In accordance to literature [24] binodals shift
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Figure 2 Solubility curves for human B19 parvo-VP2-VLPs determined in 96-well format by automated
solubility screenings. The recovery of 0.5 mg/mL VP2-VLP is plotted against the concentration of
different precipitants in weight percent. Screenings were conducted with Spodoptera frugiperda Sf 9 insect
cell lysate containing VP2-VLPs. Datapoints represent the mean value of triplicate measurements, lines
are interpolations to guide the eye.
the PEG molecular weight increased the absolute value of the tie-line slope for PEG-salt ATPSs.
The determined phase diagrams illustrate the difficulty of realizing salt concentrations below
12% [w/w] phosphate in the ATPS bottom phase. Such concentration ranges were required to
minimize the risk of VLP precipitation in the bottom phase.
























Figure 3 Binodals of PEG-phosphate aqueous two-phase systems at pH 7.4 measured by automated
turbidity methods. Data was fitted to equation 1 as described by Merchuk et al. [39]. The parameter
values of the resulting fit are given in Table 1.
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Table 1 Binodal coefficients and tie-line slopes (TLS) of PEG-salt aqueous two-phase systems determined
by automated turbidity and dye methods. Data was fitted to equation 1 as described by Merchuk et al.
[39].
Salt PEG MW [Da] pH a b c TLS
Phosphate
200 7.4 106.63 -0.386 -0.00002 -1.46
400 7.4 75.87 -0.333 -0.00009 -1.42
600 7.4 82.17 -0.419 -0.00012 -1.37
1000 7.4 76.37 -0.408 -0.00022 -1.70
1450 7.4 58.73 -0.337 -0.00035 -1.79
4000 7.4 76.6 -0.508 -0.00075 -2.17
400 8.5 73.70 -0.312 -0.00011 -1.50
600 8.5 79.83 -0.400 -0.00014 -1.74
1000 8.5 81.18 -0.434 -0.00025 -1.84
Phosphate & 7.5% [w/w] NaCl 400 8.5 44.71 -0.264 -0.00018 -1.26
Magnesium Sulphate
400 3 66.96 -0.288 -0.00013 -2.04
400 8.5 66.96 -0.288 -0.00013 -2.04
8000 3 72.06 -0.695 -0.00221 -2.53
8000 8.5 74.43 -0.725 -0.00201 -2.50
Ammonium Sulphate 400 7 93.86 -0.32 -0.00006 -1.74
Carbonate 400 11 71.27 -0.386 -0.00043 -2.63
Citrate 400 7.4 93.83 -0.320 -0.00004 -1.65
3.2.2 PEG 200- & PEG 4000-phosphate ATPSs
The VLP solubility screenings have demonstrated that VP2-VLPs were soluble over a broad
concentration range for low PEG molecular weights. Hence, initial batch ATPS partitioning
studies aimed at inducing top phase VLP partitioning by using the smallest PEG tested in
the solubility screenings. On the other hand the largest PEG was investigated for evaluating
the potential of bottom phase VLP partitioning. Fig. 4 shows the results obtained for these
experiments with 0.5 mg/mL VP2-VLPs. Concentrations of phase forming components are
marked on the axes. Binodals and tie-lines of the systems are plotted, with a coloured dot
plot representing the VLP recovery in each of the two phases. In all ATPS experiments with
VLP or total protein loss a thick interphase layer was observed between top and bottom phase.
Hence, if the mass balance for VLPs or other components was not closed for top and bottom
phases within the experimental uncertainty, interfacial partitioning due to precipitation was
assumed to be the causation. A trend of top phase partitioning of VLPs for PEG 200 ATPS
and bottom phase partitioning for the PEG 4000 ATPS was observed. The plots point out
that high VLP recoveries above 90 % were obtained for all tested PEG 200 top phases with
minimal loss of recovery for increasing tie-line lengths. There were no VLP nor total protein
trace amounts detected in the lower ATPS phase of the PEG 200 phosphate systems. In PEG
4000-phosphate systems the highest VLP recovery obtained in the bottom phase was 74.5% for
the shortest tie-line. Increasing the tie-line length resulted in a strongly decreasing recovery of
VP2-VLPs, indicating precipitation. No separation of DNA was achieved for neither PEG 200-
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(a) VLP Partitioning in PEG 200-phosphate
ATPS at pH 7.4









































(b) VLP Partitioning in PEG 4000-phosphate
ATPS at pH 7.4
Figure 4 Selected results from the aqueous two phase single-stage extraction screenings. Binodals and
tie-lines are shown. Colour coded dots at the composition of the respective top and bottom phases illus-
trate the recoveries of human B19 parvoVLPs. ’x’ corresponds to the system compositions of the ATPSs
containing 0.5 mg/mL VP2-VLP. Each data point represents the mean value of triplicate partitioning
experiments. Experiments were conducted with Spodoptera frugiperda Sf 9 insect cell lysate containing
VP2-VLPs.
nor PEG 4000-phosphate systems. A major drawback of PEG 4000-phosphate ATPS was the
settling of cell debris in the bottom phases (data not shown). This characteristics would further
complicate the design of an integrated ATPS capture step in comparison with a system with
interfacial cell debris partitioning such as a PEG 200 ATPS. High product recoveries and an
integrated removal of cells or cell debris as with the PEG 200 ATPS are important requirements
for developing a VLP capture step from complex feedstocks. Therefore, further optimization
studies with ATPSs built of small PEG molecules focused on improving the separation of HCPs
and DNA and identifying promising ATPSs for multistage ATPE. For process optimizations the
effect of pH, molecular weight of PEG, salt type and additives on top phase recovery of VLPs,
total protein and DNA were investigated.
3.2.3 The Effect of System pH
System pH was varied between pH 5.5 and 8.5 for a defined PEG 400-phosphate system point
(15.3% [w/w] PEG 400, 16.9% [w/w] phosphate). PEG 400 was preferred to PEG 200 in
order to increase the separation of HCPs or DNA by lowering phosphate concentrations in
the bottom phases. Although binodals and tie-lines change slightly for different pH values, all
system compositions were found to lie in the two-phase region. Detailed information on binodal
and tie-line drifts caused by pH or ionic strength changes can be found in Table 1: increasing
pH values and sodium chloride concentrations lead to a shift of the two-phase region to lower
PEG and salt concentrations. Fig. 5 shows the effect of the system pH on the partitioning of
VLPs, total proteins and DNA. The recoveries for a VP2-VLP concentration of 0.5 mg/mL are
plotted against the pH value. It is evident that high pH values induced high VLP-, but also
high total protein and DNA recoveries in the top phase. While total protein content remained
above 50% in the top phase over the entire pH range, VLPs precipitated and partitioned to the
interphase below pH 7.0. A decrease in VLP yield was observed from 79% at pH 7.0 to 15% at
pH 6.7. By decreasing the system pH towards the acidic region the partitioning of DNA can
be switched from top phase towards bottom phase partitioning. DNA recovery in the bottom
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Figure 5 Effect of the ATPS pH value on the top phase partitioning of VLP feedstock components
for a PEG 400 phosphate system (15.3% [w/w] PEG 400, 16.9% [w/w] phosphate). Experiments were
conducted with Spodoptera frugiperda Sf 9 insect cell lysate containing human B19 parvo-VP2-VLPs. A
concentration of 0.5 mg/mL VP2-VLP was set in each ATPS. Each data point represents the mean value
of triplicate partitioning experiments.
phase increased from 17% at pH 6.4 to 78% at pH 5.5. The highest VLP recovery of 92.9% in
the PEG-rich top phase was achieved at pH 8.5 coming along with a total protein reduction of
21.1%, a DNA removal of 9.5% and an HPLC purity of 15.9%.
3.2.4 The Effect of PEG Molecular Weight and Salt Type
In the next step the influence of molecular weight of PEG and salt types was studied for im-
proving the separation of host cell contaminants by top phase VLP partitioning. Four different
PEG-phosphate systems at pH 8.5 (PEG 200, PEG 400, PEG 600 and PEG 1000) each with
five different tie-line lengths were screened for VLP, total protein and DNA recovery. Binodal
and tie-line data is appended in Table 1. While the performance of the PEG 200 ATPS showed
the same trend for pH 8.5 and 7.4, VLPs were hardly soluble in PEG 1000 ATPSs (data not
shown). In Fig. 6 a and 6 b VLP recoveries are plotted again as coloured dot plots in the phase
diagrams of a PEG 400- and PEG 600-phosphate system at pH 8.5. It can be seen that VLPs
partitioned exclusively to the top phases and an increase of the tie-line length lead to a loss
of VLP recovery for both PEG 400- and PEG 600-phosphate systems. The highest recovery
in the PEG 600 phosphate systems was 78% VLP at a concentration of 0.5 mg/mL VP2-VLP
for the shortest evaluated tie-line and an HPLC purity of 18.9%. There was no decrease of
VLP recovery observed for the PEG 400 system points on the two shortest tested tie-lines. It
was noticed that larger PEG molecules lead to an increased partitioning of total protein to the
bottom phases, but at the same time VLP solubility in the top phase was reduced and lead to
precipitation.
For further optimizations of the PEG 400 system, ATPS salt screenings were performed. Apart
from phosphate a number of salts such as citrate, sulphate or carbonate can be used for creating
ATPSs. In all studies performed with PEG 400-magnesium sulphate (pH 3.0, pH 7.4, pH 8.5
tested) and PEG 400-ammonium sulphate (pH 7.0) systems, precipitation and interfacial par-
titioning was observed for both VP2- and VP1/VP2-VLPs (data not shown). More promising
results were obtained with PEG 400-citrate and PEG 400-carbonate ATPSs and are illustrated
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in Fig. 6 c and 6 d. The highest top phase VLP recovery achieved with a PEG 400-citrate
system was 57.5% for the shortest tie-line and 58 % with a PEG 400-carbonate system. The cor-
responding HPLC purities in the PEG 400-citrate and PEG 400-carbonate ATPSs were 17.7%
and 22.3% respectively.










































(a) PEG 400-phosphate ATPS at pH 8.5










































(b) PEG 600-phosphate ATPS at pH 8.5












































(c) PEG 400-citrate ATPS at pH 7.4












































(d) PEG 400-carbonate ATPS at pH 11
Figure 6 Selected results from the aqueous two-phase single-stage extraction screenings. Binodals and
tie-lines are shown. Colour coded dots at the composition of the respective top and bottom phases illus-
trate the recoveries of human B19 parvoVLPs. ’x’ corresponds to the system compositions of the ATPSs
containing 0.5 mg/mL VP2-VLP. Each data point represents the mean value of triplicate partitioning
experiments. Experiments were conducted with Spodoptera frugiperda Sf 9 insect cell lysate containing
VP2-VLPs.
3.2.5 The Effect of Sodium Chloride
Another way of changing partitioning in two-phase systems is to add a neutral salt as modifier.
Sodium and potassium chloride were tested as additives for the PEG 400-phosphate system
with the highest VLP recovery and capacity (SP1). In Fig. 7 a and 7 b the VLP, total protein
and DNA recoveries for top and bottom phases are plotted against the concentration of sodium
chloride given in weight percent. A drastic change in partitioning can be observed for DNA
from top phase to bottom phase partitioning upon addition of sodium chloride. Since VLPs
were recovered in the top phases at all tested sodium chloride concentrations, a separation of
up to 99% of DNA was achieved in one step. Furthermore, it is noticeable that upon addition
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(a) Top phase recovery of VLP feedstock com-
ponents at varying NaCl concentrations
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(b) Bottom phase recovery of VLP feedstock
components at varying NaCl concentrations
Figure 7 Effect of sodium chloride on the partitioning of VLP feedstock components for a PEG 400-
phosphate system (14.08% [w/w] PEG 400, 16.28% [w/w] phosphate pH 8.5). Experiments were con-
ducted with Spodoptera frugiperda Sf 9insect cell lysate containing human B19 parvo-VP2-VLPs. A
concentration of 0.5 mg/mL VP2-VLP was set in each ATPS. Each data point represents the mean value
of triplicate partitioning experiments.
of sodium chloride about 20% of the VP2-VLPs precipitate and partition to the interphase.
Nevertheless, the VLP recovery does not decrease further for increasing sodium chloride con-
centrations. The same partitioning trends for VLPs, total protein and DNA were achieved by
adding potassium chloride instead of sodium chloride to the PEG 400-phosphate ATPS (data
not shown).
3.3 Multi-stage ATPE: Centrifugal Partition Chromatography
CPC experiments were conducted with three PEG 400-phosphate ATPSs, one PEG 400-phosphate
ATPS with 7.5% [w/w] NaCl and one PEG 600-phosphate ATPS at pH 8.5. Detailed informa-
tion on the exact system composition, viscosities and densities of top and bottom phases are
summarized in Table 2. Regarding the physical characteristics it can be seen that increasing
the tie-line length for the PEG 400-phosphate system increased both the viscosity ratio between
top and bottom phase from 3.12 to 4.05 and the density difference from 0.095 to 0.15 g/mL.
The highest density difference of 0.161 g/mL was obtained by addition of 7.5% [w/w] sodium
chloride to the PEG 400-phosphate system (SP1). Top and bottom phases of the tested PEG
600-phosphate system showed the lowest density difference of 0.063 g/mL and the lowest viscos-
ity ratio of 2.22. In the CPC the ATPSs were at first tested for stationary phase retention (Sf)
and stability against column bleeding (loss of stationary phase during the run). Rotor speed
was set at 2500 rpm as suggested by Oelmeier et al. [28] and flow rate was varied from 5 to 10
mL/min. The PEG 600 system with the lowest density difference proved to be unsuitable for
CPC extractions. The Sf-value was only 9% at 5 mL/min and column bleeding was observed.
The amount of stationary phase retained in the column for the PEG 400 phosphate system
was evaluated in a standard two-level full factorial designed experiment varying flow rate and
tie-line length. Fig. 8 shows the result of the experiments. Sf-values increased from 26% for
tie-line 1 (TL1) at 10 mL/min to 67% for TL5 at 5 mL/min.
Based on these observations, operating conditions of 3 and 5 mL/min and 2500 rpm were cho-
sen for the purification of VP2-VLPs. Purification runs were performed in duplicate with three
PEG 400-phosphate ATPSs: SP1 (TL1), SP5 (TL5), SP1* (with 7.5% [w/w] NaCl). Promising
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Table 2 Physical properties of ATPS phases tested in CPC stability experiments: Viscosities (η) and
densities (ρ) are summarized for PEG 400-phosphate ATPS for varying tie-line lengths, for a PEG
600-phosphate system and for a PEG 400-phosphate system with additional NaCl.
PEG PO4 TL ηTP ηBP ηr ρTP ρBP ∆ρ
% [w/w] % [w/w] [-] [mPas] [mPas] [-] [g/mL] [g/mL] [g/mL]
14.08a 16.28 1 5.994 1.920 3.12 1.11 1.205 0.095
16.13a 16.25 3 6.560 1.858 3.53 1.099 1.225 0.125
17.83a 16.45 5 7.086 1.751 4.05 1.098 1.291 0.15
14.08a,b 16.28b 1b 7.322 2.848 2.57 1.131 1.292 0.161
14.58c 13.1 1 5.647 2.548 2.22 1.102 1.165 0.063
a PEG 400.








































Figure 8 Evaluation of operating and system conditions on the stationary phase retention (Sf) in
CPC for PEG 400-phosphate systems. The rotor speed was set to 2500 rpm. Additional information
regarding the evaluated tie-lines (TL) is summarized in Table 2. Contour plot was generated using cubic
interpolation. Each data point represents the mean value of duplicate CPC experiments.
separations were limited to the PEG 400-phosphate ATPS with sodium chloride (SP1*). The
results from the 3 mL/min run with an Sf-value of 70% are shown in Fig. 9. In Fig. 9 a the
UV absorption at 280 nm in mAU is plotted against the process time in minutes. The chro-
matogram shows three sections: (I.) column loading with bottom phase replacing CPC storage
solution at 50 mL/min, (II.) column equilibration with mobile top phase displacing bottom
phase and (III.) injection and elution of VLP feedstock components at 3 mL/min. Components
with a high affinity to the mobile top phase elute at an earlier point than components which in-
teract with the stationary bottom phase. The chromatogram in section III. shows two partially
overlapping main peaks. The first peak is narrower and higher than the second peak. Fig. 9
b displays the results from the analyzed CPC fractions. The VP2-VLP concentration and RP
chromatogram areas of HCP-group 1 and HCP-group 2 are plotted against the volume. The
first UV main peak in Fig. 9 a contains mainly HCPs. VLPs elute at a higher retention volume
than host cell impurities, mainly in the second UV peak of the chromatogramm in Fig. 9 a.
Total VLP recoveries in the CPC runs were 98.2% for SP1, 79.3% for SP5 and 64.4 % for SP1*.
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Figure 9 CPC purification run performed with Spodoptera frugiperda Sf 9 insect cell lysate containing
human B19 parvo-VP2-VLPs. Operating conditions were: 3 mL/min, 2500 rpm. Sample volume: 10
mL. Sample composition: top phase of a PEG 400 SP1* system (14.08% [w/w] PEG 400, 16.28%
[w/w] phosphate pH 8.5, 7.5% [w/w] NaCl) with a total concentration of 0.5 mg/mL VP2-VLP. (a)
Chromatogramm of a CPC purifiction run with human B19 parvoVLPs: I. Bottom Phase Loading; II.
Equilibration; III. Sample Injection & Elution. (b) CPC Elution profile of VLP feedstock components.
3.4 Evaluation of Process Performance
The evaluation of single- and multi-stage ATPE methods was done by addressing several cri-
teria: VLP recovery, HPLC purity, DNA removal, DNA concentration, VLP structure and
antigen reactivity. The data is summarized in Table 3. One of the major challenges hindering
implementation of ATPE into manufacturing processes for biopharmaceuticals is the presence
of high polymer and salt concentrations. One strategy for removing ATPS components is pre-
cipitating the molecule of interest. A common and mild precipitant for large biomolecules is
PEG 4000 [42, 43, 44]. Hence, Table 3 includes also process performance data on a combina-
tion of a single-stage ATPE (SP1*,Vr=0.2), a subsequent precipitation (13 % [w/w] PEG 4000,
9% [w/w] NaCl) followed by re-dissolution in PBS and a sterile filtration. While a high DNA
removal of 99% was achieved with a single-stage ATPE, HPLC purities above 69% could only
be realized with a subsequent multi-stage ATPE or a precipitation step. The most promising
ATPS for an integrated one step purification incorporating solid-liquid-separation (removal of
cells & cell debris), VLP concentration up to 3.4 mg/mL VP2-VLPs, separation of 99.6% DNA
and 16.8% HPLC purity consisted of 22.05% [w/w] PEG 400, 6.8 % [w/w] phosphate pH 8.5
and 7.5 % [w/w] NaCl. Fig. 10 illustrates the characteristics of the used ATPS in a phase
diagram with the binodal curve and system compositions for varying volume ratios (Fig. 10 a),
and in a photograph visualizing the interfacial partitioning of cells & cell debris in the ATPS.
Antigen binding of purified VP2-VLPs was confirmed for ATPS and precipitation samples by
the industrial partner. TEM images of purified samples and the corresponding SDS-gel lanes
are summarized in Fig.11. The TEM image of the filtrated Sf 9 cell lysate reveals the presence
of baculoviruses and other particulates apart from VLPs. There were no baculoviruses discov-
ered in the TEM images of neither CPC fractions nor of the process combination sample. An
icosahedral structure and an average particles size of 28 nm was observed in all TEM images.
Fig. 11 c demonstrates the homogeneity of human B19 parvo-VP2-VLPs produced in Sf 9 cells
and purified by the alternative two-step downstream process combining ATPE and precipitation.
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Table 3 Process performance data of alternative purification methods for human B19 parvoVLPs.











Filtrated Cell Lysate 100.0% 5.3% 0.0% 10.668 -
Batch-ATPEa 98.5% 15.9% 9.1% 9.693 4.1
Batch-ATPE with NaClb 74.7% 16.3% 98.9% 0.1163 3.4
Batch-ATPE with NaClc 102.1% 16.8% 99.6% 0.0395 3.4
CPC 64.4% 31.4% 100.0% 0 -
CPCd 40.1% 69.1% 100.0% 0 -
Batch ATPEc & Precipitation 63.9% 90.6% 99.8% 0.0246 -
a PEG 400-phosphate system (14.08% [w/w] PEG 400, 16.28%[w/w] phosphate pH 8.5)
b PEG 400-phosphate system (14.08% [w/w] PEG 400, 16.28%[w/w] phosphate pH 8.5, 7.5%
[w/w] NaCl)
c PEG 400-phosphate system with Vr=0.2 (22.06% [w/w] PEG 400, 6.8%[w/w] phosphate pH
8.5) and crude Sf 9 cell lysate as starting material.
d Data for pooled CPC fractions of VLPs eluting after 194.4 min.




















(a) Phase diagram (b) Solid-liquid
separation
Figure 10 PEG 400-phosphate APTS at pH 8.5 with 7.5% NaCl. (a) Phase diagram with binodal
curve and system compositions in red for volume ratios from 1 to 0.1. (b) ATPS conducted with crude
Spodoptera frugiperda Sf 9 insect cell lysate containing 0.5 mg/mL human B19 parvo-VP2-VLPs at a
phase volume ratio near one (14.08% (w/w) PEG 400, 16.28% (w/w) phosphate pH 8.5, 7.5% (w/w)
NaCl). Cell debris and precipitate partitioned to the interphase after centrifugation.
4 Discussion
4.1 Batch Partitioning in PEG Salt ATPSs
Solubility curves for VLPs, ATPS phase diagrams and ATPS partitioning trends were success-
fully determined in 96-well high-throughput screening scale. Screenings pointed out that the
solubility of human B19 parvoVLPs in PEG solutions is predominantly a function of the PEG
molecular weight. The low solubility of VLPs in PEG and salt solutions is the main issue im-




(a) Filtrated Sf 9 Cell Lysate
60 kDa
(b) CPC Fraction (194.44 min)
60 kDa
(c) Batch ATPE & Precipitation
Figure 11 TEM images and SDS-PAGE gels of human B19 parvo-VP2-VLPs derived from Spodoptera
frugiperda Sf 9 insect cells at different process steps.
peding the development of a robust and selective ATPE step. Larger PEG molecules cause VLP
precipitation at lower PEG concentrations. Sim et al. [41] have demonstrated that protein pre-
cipitation by polymers is mainly a function of the hydrodynamic radius of protein and polymer,
which explains the high precipitation efficiency obtained for PEG 4000 as this declines from
high to low PEG molecular weights. Similar to previous studies [28, 38] solubility curves for
biomolecules could again be correlated with good accordance to the partitioning behaviour in
ATPSs. This was for instance shown for the PEG 200- and PEG 4000-phosphate ATPSs: VLPs
partitioned according to the solubility curve in the PEG-rich or salt-rich phase. A stepwise op-
timization strategy was performed to separate host cell impurities. Low PEG molecular weights
were chosen for top phase partitioning and removal of cell debris. High pH values increased
the recoveries of VLPs in ATPS top phases and a PEG molecular weight of 400 Da improved
the separation of HCPs in the bottom phase compared to a PEG 200 ATPS. DNA removal
was achieved by adding sodium chloride to the PEG 400-phosphate ATPS. The DNA depletion
from top to bottom phase was accompanied by a loss of a constant VLP fraction which may
be attributed to the separation of VLP-DNA complexes in the interphase. Virus proteins are
known to bind DNA [45, 46]. Such VLP-DNA-complexes might have a higher tendency for
interfacial partitioning if they vary in size, surface charge and hydrophobicity from a single unit
VLP. The constant percentage of VLP recovery loss for a broad sodium chloride concentration
range and for higher VLP feed concentrations underline the assumption of an inhomogeneous
VLP particle size distribution in the Sf 9 cell lysate. Further characterization by Asymmetrical
Flow Field Flow Fractionation (AFFFF) would help determining the structure and homogene-
ity of human B19 parvoVLPs produced by the Baculovirus/Sf 9 cell system [47]. Remarkably,
if the ATPS was built with crude cell lysate, the recovery for VLPs was improved to 102%
(compared to a clarified cell lysate). An explanation for this is the top phase recovery of VLPs
attached to cell debris or cells. These VLPs get lost in a clarification process by centrifugation
or filtration. Furthermore, the batch partitioning studies showed that the performance could
not be optimized, but rather deteriorated when changing the dominant salt from phosphate to
citrate, carbonate or sulphate.
In summary, the partitioning of human B19 parvoVLPs in PEG salt ATPSs could be con-
trolled or switched solely by modifying two parameters: (I) the PEG molecular weight and
(II) the system pH. Short PEG molecules induced top phase partitioning, long PEG molecules
induced bottom phase partitioning. System pH values above the isoelectric point of the product
strengthened top phase partitioning and recovery. For improving the separation efficiency of a
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single-stage ATPE the PEG molecular weight could be varied stepwise or a neutral salt could
be added. Sodium chloride drastically changed the partitioning of DNA. This finding paves new
ways for ATPS applications in bioprocesses and could be ascribed to a change in electrostatic
properties of the two phases. Andrews et al. [48] suggested that higher concentrations of NaCl
result in a more negative PEG-rich phase due to an increase in the concentration of chloride
ions. Negatively charged components such as DNA might be excluded from the top phase to
the bottom phase by a change in electrostatic interactions.
4.2 Centrifugal Partition Chromatography
Chromatograms and stationary phase retentions for different ATPSs have once again proven
the applicability of CPC for biomolecule purification by multi-stage ATPE. High stationary
phase retention was always linked to a high density difference between top and bottom phase.
Since the density difference is predominantly a function of the salt concentration in the bot-
tom phase, system compositions of longer tie-lines lead to higher Sf-values. Nevertheless, the
results demonstrated that high stationary phase retention did not imply a good separation of
components. For a good chromatographic resolution the components’ partitioning coefficients
(k) should not assume extreme values (k >> 1 or k << 1) [37, 49], which is difficult to realize
for large biomolecules due to the solubility issues mentioned above. Hence, past multi-stage
extractions for biomolecules have focused on using extractor devices for stripping impurities
by washing steps using counter current extraction [50] or CPC Dual Mode [38]. In case of the
tested PEG 400-phosphate ATPSs this procedure hardly optimized the performance for the
VLP purification. An important finding was the effect of sodium chloride on the stationary
phase retention and on the separation of HCPs and VLPs. In the ATPS batch experiments
there were no changes measured in the partitioning coefficients of neither HCPs nor VLPs upon
addition of sodium chloride. Hence, the explanation for the observed separation must be a
change in physical properties of the ATPS. Adding sodium chloride increased the density dif-
ferences between top and bottom phase strongly and decreased the viscosity ratio between the
two phases. A higher Sf-value and a lower viscosity ratio improve the mass transfer between
mobile and stationary phase [51, 52]. A prolonged retention of VLPs could occur due to an
increase in electrostatic repulsion or in interfacial tension upon addition of NaCl. As suggested
by Luechau et al. [53] and demonstrated in this work for cell debris and precipitate, the ad-
sorption of particles on the ATPS interphase depends on the interfacial tension of the system
and the particle size. Interfacial tensions are usually low for PEG-salt ATPSs with short PEG
molecules and can mostly be neglected for very small particles below 50 nm [53, 54]. However,
the big interfacial areas generated in the CPC at high centrifugal speed and at a low viscosity
ratio probably intensified the interaction of VLPs with the interphase. Since all HCPs were
smaller in size than the VLPs, the separation mechanism was probably related to the size of
the molecules. Further studies correlating interfacial tension, interfacial area and particle size
with the CPC retention time are needed to get a better understanding of the separation mech-
anism observed inhere for VLPs. The findings can strike a new path in the development of an
alternative platform technology for size-dependent particle fractionation.
4.3 Evaluation of ATPE for the Purification of VLPs
The obtained results demonstrate the benefits of ATPE for the downstream processing of human
B19 parvoVLPs. The single-stage ATPE allowed the removal of cell debris, the clearance of
above 99% DNA and a decrease in HCP content. High VLP recoveries above 60% were obtained
for all evaluated purification methods and VLP capacities between 3.4 and 4.1 mg/mL in the
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ATPS top phases could be used for concentrating feedstreams with low product concentrations
by varying the volume ratio of the ATPS. Two methods were investigated for the separation of
HCPs from the top phase of a single-stage ATPS. A separation of HCPs by CPC was shown
to be possible and should be evaluated with other CPC devices for an optimization of peak
resolution. Drawbacks observed for the purification method were the strong dilution of the
biomolecules and the recovery loss of 35% VLPs. The decrease in recovery might be attributed
to long process times increasing the risk of product aggregation. The other method suggested
inhere was the precipitation of VLPs with PEG 4000 in the presence of NaCl. Since NaCl
counteracted the co-precipitation of HCPs by shielding electrostatic attraction, the method was
highly selective for the purification of VLPs. In addition, the VLP concentration of the output
stream could be set by adapting the volume of the re-dissolution buffer. Antigen reactivity
and particle morphology were preserved for both multi-stage ATPE and the redissolved VLP
precipitates. VLP preparations were shown to be uniform in size with particles around 28 nm.
DNA trace amounts after purification with the suggested alternative downstream processes lay
below acceptable threshold values (10 ng per dose [9]) for doses below 400 µg VLP.
5 Conclusion & Outlook
In this work, we have shown the potential of ATPE for the purification of VLPs. PEG-salt
systems were optimized on a high-throughput screening platform for the isolation of human B19
parvoVLPs from crude Sf 9 insect cell lysate. A new alternative VLP downstream process was
developed integrating a product concentration, solid-liquid separation and DNA removal step
into one unit separation. Intact VLPs were concentrated in the top phase with a high capacity
separating cell debris and almost all DNA in the inter- and bottom phase. Further purification
of the top phase was demonstrated by multi-stage ATPE using CPC and by precipitation
with PEG. A proof of concept of multi-stage ATPE was shown for the first time for such large
biomolecules as VLPs. Unique selectivities were obtained for both single- and multi-stage ATPE
by the addition of sodium chloride. The combination of ATPE and precipitation resulted in
a high HPLC purity, icosahedral and reactive VLPs, the removal of ATPS phase components
and an adjustable concentration of the product of interest. The proposed two-step downstream
process is rapid, easily scalable [55, 56], requires only a very basic laboratory equipment and
can be a valuable addition to the VLP purification toolbox.
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Abstract
Recombinant protein-based virus-like particles (VLPs) are steadily gaining in importance as in-
novative vaccines against cancer and infectious diseases. VLPs carry no replicative viral genetic
information and are produced as large protein assemblies in recombinant expression systems.
Multiple VLPs are currently evaluated in clinical phases requiring a straightforward and ratio-
nal process design. To date, there is no generic platform process available for the purification of
VLPs. Numerous process steps are needed to separate undesired host cell impurities. In order
to accelerate and simplify VLP downstream processing, there is a demand for novel development
approaches, technologies, and purification tools. Membrane adsorbers have been identified as
promising stationary phases for the processing of bionanoparticles due to their large pore sizes.
In this work, we present the potential of two strategies for designing VLP processes following the
basic tenet of ’quality by design’: High-throughput experimentation and process modeling of an
anion-exchange membrane capture step. Automated membrane screenings allowed the identi-
fication of optimal VLP binding conditions yielding a dynamic binding capacity of 5.7 mg/mL
for human B19 parvovirus-like particles derived from Spodoptera frugiperda Sf 9 insect cells. A
mechanistic approach was implemented for radial ion-exchange membrane chromatography us-
ing the lumped-rate model and steric mass action model for the in silico optimization of a VLP
capture step. For the first time, process modeling enabled the in silico design of a selective,
robust and scalable process with minimal experimental effort for a complex VLP feedstock.
The optimized anion-exchange membrane chromatography process resulted in a protein purity
of 81.5%, a DNA clearance of 99.2%, and a VLP recovery of 59%.
Keywords: Quality by design, Membrane chromatography, Predictive modeling, Downstream
processing, Virus-like particle vaccine, High-throughput process development
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1 Introduction
Virus-like particles (VLPs) are highly ordered protein assemblies mimicking the structure of
viruses. Recent progress in the development of VLP-based vaccines against highly pathogenic
viruses and organisms such as Ebola [1], Malaria [2] or Influenza [3] highlights the importance
of this novel molecule class for the global health system. Ensuring a fast and economic avail-
ability of VLP vaccines requires a rapid and robust manufacturing process. VLPs are currently
produced in recombinant systems such as bacteria, yeast, insect or plant cells necessitating
subsequent downstream process steps for the separation of host-cell impurities to minimize the
risk of side effects [4]. The most prevalent unit operation for the purification of biopharmaceu-
tical products is ion-exchange chromatography. Traditional chromatography media are based
on adsorber particles with pore sizes in the nanometer region causing mass transfer limitations
and low binding capacities for bionanoparticles such as viruses or VLPs [5, 4]. Among others,
membrane adsorbers have been developed and constantly advanced for the purification of large
biomolecules in bind-and-elute mode [6, 7, 8, 9, 10, 11]. Membrane adsorbers are composed of
multiple flat sheets of functionalized membranes with pore sizes in the range of micrometers.
An increase in the specific surface in such flat sheets can be achieved by grafting hydrogels on
membranes to embed ligands [12]. According to Nestola et al. hydrogel-grafted membranes lead
to higher recoveries for virus purifications than directly grafted membranes [13]. The geometries
of membrane adsorbers are usually either stacked flat sheet or spiral wound modules with axial
or radial flow. Regarding separation performance parameters such as resolution, peak width,
and dynamic binding capacity, there are no outstanding differences between axial and radial
flow geometries [14, 15]. However, radial flow geometries are especially suited for large-scale
applications by virtue of lower pressure drops as demonstrated by Besselink et al. [15]: Wide,
short axial flow columns can be similarly replaced with low-pressure narrow, tall radial-flow
columns without a significant change in performance. The combination of both radial flow ge-
ometry and convection-driven mass transport in membrane adsorbers allows high throughputs
and productivities for biopharmaceutical products [16, 17].
In recent years, the process development for biologics has been relying predominantly on empir-
ical studies. Minimizing the risks of manufacturing failures and lot-to-lot variations of biological
products has been the key motivation for the FDA to forward the approaches ’quality by design’
(QbD) and ’process analytical technology’ (PAT) [18]. One major contribution to and impor-
tant tool for process control and design is mechanistic modeling. Multiple thermodynamic and
hydrodynamic models have been developed and steadily extended for chromatographic sep-
arations of proteins [19, 20, 21, 22, 23, 24, 25]. Recently, novel hydrodynamic models were
established for membrane adsorbers including axial and radial flow and validated in various
protein case studies [26, 12]. In contrast, there have been only few publications on modeling
and simulation of VLP processes. Vicente et al. demonstrated the applicability of the steric
mass action model [27] for purified rotavirus-like particles with a mean diameter of 80 nm on
stacked flat sheet anion-exchange (AEX) membrane adsorbers [7]. However, the measured and
simulated chromatograms for the complex VLP feedstock differed significantly and up to now
there has not been any case study reporting on the in silico optimization of a VLP separation.
The difficulty for in silico simulations and optimizations of complex biological feedstocks lies in
modeling the mass transfer of components of unknown size and concentration. An approach to
dealing with this was previously reported by Hahn et al. [28] and Baumann et al. [29]. In both
case studies, UV absorption-based modeling was implemented to simulate the elution profile of
complex biological feedstock components using UV peak areas instead of molar concentrations.
In this work, we present a case study for the purification of human B19 parvo-VLPs derived
from Spotoptera frugiperda Sf 9 insect cells applying both high-throughput experimentation and
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UV absorption-based chromatography modeling. Human B19 parvo-VLPs have a size of 25 to
30 nm and can be assembled in insect cells by expressing the major capsid protein VP2. The
particles are currently evaluated in clinical phase studies as vaccine candidates against diseases
attributed to parvovirus infections such as fifth disease in children, anaemia, and hydrops fetalis
[30, 31]. The developed membrane process allowed the separation of major contaminants such
as host cell proteins and DNA in one step and can be predicted and controlled by in silico
process simulations.
2 Materials & Methods
2.1 Disposables
For screening purposes on a liquid handling station, 1 mL-96 deep well polypropylene plates
(Thermo Fisher Scientific Inc., Waltham, Massachusetts, USA) and 96-well half area polystyrene
flat-bottom plates by Greiner Bio-One (Kremsmünster, Austria) were used. Fraction collection
on a FPLC system was done with 2 mL-96 deep well polypropylene plates (Nalge Nunc In-
ternational, Rochester, USA). Sterile filtration of buffer solutions was conducted with 0.2 µm
cellulose acetate filters (Sartorius AG, Goettingen, Germany). Buffer exchange was performed
with PD-10 desalting columns (GE Healthcare, Uppsala, Sweden).
2.2 Chemicals & Buffers
Bis-Tris, Bis-Tris propane and dextran T2000 were purchased from Sigma-Aldrich (St. Louis,
USA). Guanidine hydrochloride from AppliChem GmbH (Darmstadt, Germany) and dithio-
threitol from Amresco (Solon, USA) were used for the preparation of UHPLC samples. All
other chemicals were purchased from Merck KGaA (Darmstadt, Germany). For automated
batch membrane chromatography experiments, a low and high pH multicomponent buffer with
a buffer capacity of 10 mM, composed of Bis-Tris, Bis-Tris propane and Tris was used to obtain
a linear pH gradient between pH 7.5 and pH 9.0. The buffer recipe was calculated according
to Kröner and Hubbuch [32]. 10% (v/v) glycerol and 0.5% (v/v) polysorbate 80 were added to
all ion-exchange buffers to prevent aggregation and secondary interactions of VLPs [33]. FPLC
runs were performed with 20 mM Tris pH 8.5, 0.5% (v/v) polysorbate 80 and 10% (v/v) glycerol
(buffer A) and 20 mM Tris pH 8.5, 1 M NaCl, 0.5% (v/v) polysorbate 80 and 10% (v/v) glycerol
(buffer B). Membranes were regenerated with 1 M NaOH and 3 M guanidine hydrochloride and
stored in 20% (v/v) ethanol in 20 mM Tris pH 8.5.
2.3 Human B19 Parvovirus-like Particles
Human B19 parvo-VLPs composed of the major viral capsid protein VP2 were derived from
Sf 9 insect cells. Insect cell pellets were provided by Diarect AG (Freiburg, Germany) and lysed
and clarified as described previously by sonication, centrifugation, and filtration [34]. Prior to
membrane experiments, buffer exchange was performed using PD-10 desalting columns (GE
Healthcare, Uppsala, Sweden).
2.4 Anion-Exchange Membrane Chromatography
All AEX chromatography experiments were performed with Sartobind R© Q membranes from
Sartorius AG (Goettingen, Germany). Binding studies for VLPs were conducted in 96-well
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membrane plates on a robotic liquid handling system. Membrane characterization and salt elu-
tion studies with clarified VLP feedstocks were done with 3 mL Sartobind R© nano Q membrane
capsules. Experiments with membrane capsules were performed on an ÄKTA-purifier 10 fast
protein liquid chromatography (FPLC) equipped with a pump module P-900 (up to 10 mL/min),
UV (10 mm path length) monitor (UV-900), a conductivity monitor, and a fraction collector
Frac-950 (GE Healthcare, Uppsala, Sweden). The instrument was controlled using the software
UNICORN 5.31 (GE Healthcare, Uppsala, Sweden).
2.4.1 Hydrodynamic & Thermodynamic Models
FPLC experiments were conducted with radial spiral-wound membrane adsorbers as displayed
in Fig. 1. A general rate model for radial flow chromatography has been developed by Gu et
al. [35] considering radial dispersion, convection, and pore diffusion of a component i in radial
direction x using differential mass balances. The continuity equation for the component i with














− (1 − εpores)
εpores
keff,i (ci − cp,i) i = 1, . . . , N (1)
The algebraic sign of the convective transport term u(x) is positive for inward flow which was
the case for the membrane capsules used in this work. In Eq.(1), the first term describes the
convective transport, the second term the hydrodynamic dispersion, and the last term refers
to the transport of component i between bulk and membrane pore volume ci − cp,i for the
membrane porosity εpores. Danckwerts’ boundary conditions [36, 37] can be used to describe
the effect of diffusion-dispersion phenomena on the concentration at the column inlet x = ra
(outer radius)(Eq.(2)). In contrast, the outlet concentration at x = ri (inner radius) for inward
flow is unaffected by these phenomena (Eq.(3)).
x = ra :
∂ci
∂x
(t, x = ra) =
u(x = ra)
Dax
(ci(t, x = ra) − cin,i(t)) (2)
x = ri :
∂ci
∂x
(t, x = ri) = 0 (3)
As described previously by Van Beijeren et al. [12], the frontal area Afront for a spiral wound
geometry depends on the radial position x and the membrane height H (Eq.(4)):
Afront = 2πxH (4)
Thus, for inward flow with the volumetric flow rate F, the linear interstitial velocity u increases





Most membrane adsorbers include a grafted hydrogel layer with embedded ligands to obtain a
higher specific surface area [9]. Such hydrogels may exclude large molecules such as dextran
T2000 and viruses [9, 10]. The hydrogel mass transfer can be modeled by incorporating a hydro-
gel porositiy εhydrogel. Hence, the mass balance for the stationary phase considers accumulation











i = 1, . . . , N (6)
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The mass transport of component i in the liquid phase is described by the film transfer coefficient
keff,i, the pore concentration cp,i, the hydrogel porosity εHydrogel, and the concentration bound
to the stationary phase qi. The adsorption term can be described for ion-exchange (IEX)
chromatography with the steric mass action (SMA) model developed by Brooks and Cramer
[27]. The semi-mechanistic isotherm considers several effects for IEX adsorption and desorption
processes:
• Concentration of available binding sites given by the total ionic capacity Λ
• Shielding of ligands by large macromolecules i described by the shielding factor σi
• Number of macromolecules’ binding sites described by the characteristic charge νi




• Changing salt concentrations cp,salt in the pore volume
The rate of change of the concentration in the stationary phase qi can be modeled with the














cp,i − cνip,saltqi i = 1, . . . , N (7)
Eq. (8) describes the competition of salt ions and other components for binding sites in the
stationary phase:




For estimating SMA and hydrodynamic parameters of complex feedstocks with multiple com-
ponents of unknown concentration, the absorption coefficient ai is used. The factor scales the
molar concentrations required for modeling mass transport in the stationary phase to absorbance
















cp,i − cνip,saltqi i = 1, . . . , N (9)
According to Baumann et al. [29], the total ionic capacity predominates, and occupied ligands
can be neglected in the case of small sample loadings which do not approach the maximum
binding capacity of the stationary phase. This makes it feasible to estimate most SMA and
hydrodynamic parameters directly from chromatograms by UV absorption-based modeling as
demonstrated previously [29, 25, 28].
Parameter estimation was performed as described previously by chromatogram fitting using a
genetic algorithm [38]. Both, parameter estimation and in silico optimization of a VLP capture
process, were conducted with the chromatography software ChromX [39].
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2.4.2 Automated Batch Binding Screenings
Optimal binding conditions for VLPs on the AEX membranes were determined by miniatur-
ized and automated microbatch experiments on a Tecan Freedom EVO R© 200 system (Tecan,
Crailsheim, Germany) using Sartobind R© Q 96-well plates with a membrane area of 0.7 cm2.
The high-throughput screening procedure followed the same routine for adsorption isotherms
and binding screenings: Equilibration, centrifugation, sample preparation, incubation, loading,
centrifugation and preparation of analytical samples. Membranes were equilibrated with 2 mL
buffer per well at the desired pH and ionic strength. Centrifugation was performed at 1000 rpm
for 10 min. Sample preparation was conducted by mixing stock solutions of buffers and VLP
feedstocks at different dilutions in 96-DeepWell plates. Systems were incubated for 10 min on
an orbital shaker at 1000 rpm. Subsequently, 300 µL sample volume was added to each well
of the 96-well membrane plate. Thereafter, samples were centrifuged and VLPs in the flow-
through were tracked by RP-UHPLC as described below. The adsorption isotherm screening
was performed under buffer conditions similar to the initial cell lysis step at 50mM Tris pH 7.4,
50 mM NaCl, 10% (v/v) glycerol and 0.5% (v/v) polysorbate 80. Data was fitted to the Lang-
muir isotherm. Eq. (10) [40, 41] describes the correlation for the equilibrium concentration in
the mobile phase ceq,i and the concentration in the stationary phase qi assuming a saturation





Subsequent to the determination of VLP adsorption isotherms, the goal was to find optimal
buffer conditions for the binding step due to possible displacement effects by other components
in the VLP feedstock. Four stock solutions with and without VLP feedstock were prepared
at pH 7.5 and pH 9 with 15 and 120 mM NaCl using the multicomponent buffer described
under Section 1.1. Buffers were mixed in the appropriate volume ratio to obtain a Design
of Experiments (DoE) set-up with four pH values and eight ionic strengths with triplicate
determinations. Method and analysis were the same as for the isotherm determination. To
obtain optimal binding conditions, the starting VLP concentration in each well was chosen
from the non-linear region of the adsorption isotherm.
2.4.3 System & Membrane Characterization
Modeling of hydrodynamic and thermodynamic mass transfer in the membrane capsule and
FPLC system requires knowledge of several membrane and system characteristics. The deter-
mination of system dead volumes Vd, membrane porosity εpores and hydrogel porosity εhydogel
was done by injecting small and large tracer molecules: 1% v/v acetone, 1 M NaCl, and 10
mg/mL dextran T2000. 100 µL of the tracer substances were injected via an ÄKTA sample
loop with a twofold loop overfill and tracked using UV and conductivity detectors. Acetone and
NaCl were used to determine the system dead volume from sample loop to UV and conductivity
detector, respectively. Dextran T2000 served as large tracer component for the determination
of the interstitial volume Vint, the membrane porosity εpores and the hydrogel porosity εhydogel.
The ionic capacity of the anion-exchange membrane was obtained by performing a titration
with 0.5 M NaOH and 0.01 M HCl according to standard protocols [42, 38] (Eq. (11) :
Λ =
cHClVHCl
VM (1 − εt)
(11)
All tracer runs and acid-base titrations were performed in at least five copies. Membrane char-
acteristics such as membrane thickness L, membrane height H, outer radius ra, and inner radius
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Figure 1 Schematic illustration of a spiral wound membrane adsorber with inward radial flow F , mem-
brane thickness L, membrane height H, outer radius ra and inner radius ri.
An overview of all system & membrane parameters is given in Table 1 providing corresponding
equations for the calculated values. Chromatograms of dextran T2000 and NaCl pulse exper-
iments were used to estimate the hydrodynamic parameters, i.e. the axial dispersion Dax and
the film transfer coefficient keff,NaCl by chromatogram fitting. All calculated membrane pa-
rameters are specified in Table 2.
Table 1 Measured membrane parameters
Parameter Symbol Value Proceeding
Membrane volume VM 3 mL From manufacturer
Membrane thickness L 8 mm From manufacturer
Outer radius ra 11.25 mm From manufacturer
Inner radius ri 3.25 mm From manufacturer
Membrane height H 8 mm From manufacturer
Total porosity εt 0.798 From manufacturer
Flow rate F 3 mL/min Manually controlled
System dead volume Vd 0.25 mL Acetone injection without membrane
Retention volume acetone VRetAc 3.7 mL Acetone injection with membrane
Retention volume dextran VRetDex 2.86 mL Dextran injection with membrane
Retention volume NaCl VNaCl 3.42 mL NaCl injection with membrane
Volume of HCl VHCl 12.8 mL Acid-base titration
Molarity of HCl cHCl 0.01 M Manually controlled
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2.4.4 Determination of Dynamic Binding Capacity
An important parameter for selecting and evaluating chromatography media is the dynamic
binding capacity (DBC). The DBC of the AEX membrane adsorbers was determined for
VLPs by overloading the membrane with 10 mL VLP feedstock at a VLP concentration cV LP,0
of 2.7 mg/mL, and optimum buffer conditions, derived from the batch binding studies (20 mM
Tris pH 8.5, 15 mM NaCl, 0.5% (v/v) polysorbate 80, 10% (v/v) glycerol). The breakthrough
experiment was conducted at a flow rate of 3 mL/min on the ÄKTApurifier 10 FPLC. Frac-
tions were collected and analysed by reversed-phase (RP)-UHPLC. The DBC was calculated
determining the applied volume at 10% breakthrough V10% from the fitted breakthrough curve
(Eq. (12)):




2.4.5 Calibration of Steric Mass Action Model
For the simulation and in silico optimization of an AEX membrane chromatography step, a
component-specific calibration of the SMA model was required. Experiments were performed
with 3 mL Sartobind R© Q membrane adsorbers on the ÄKTApurifier 10 FPLC. The composition
of buffer A was 20 mM Tris pH 8.5, 0.5% (v/v) polysorbate 80, 10% (v/v) glycerol. For elution,
buffer A was supplemented with 1 M NaCl to create buffer B. Regeneration buffer was 1 M
NaOH and storage buffer 20% EtOH in 20 mM Tris pH 8.5. Membranes were equilibrated with
5 CV of 1.5% B prior to sample injection. 1 mL VLP feedstock was injected in each run and
fractions were collected during the whole run to track the VLP elution. Three salt gradients
with gradient slopes of 10 CV, 20 CV and 30 CV from 1.5% to 100% B were performed to gen-
erate chromatograms for the SMA parameter estimation. Applying the peak integration tool
of the ÄKTA software UNICORN 5.31, the VLP feedstock was divided into multiple subcom-
ponents. Each UV peak was integrated for the 30 CV gradient run and the ratio of peak area
and load volume was set as concentration for the UV-based modeling [25] of each component.
Estimation of the SMA parameters keq,i, νi and the film transfer coefficients keff,i was done by
chromatogram fitting using a genetic algorithm.
2.4.6 Optimization of VLP Purification
Given a defined set of hydrodynamic and thermodynamic parameters, it is possible to simulate
chromatograms of a multicomponent system and to optimize the separation of a target compo-
nent in silico. In this work, this was attempted by varying the salt concentrations of a three-step
elution process and simulating the effect on purity (P ) and yield (Y ). Salt concentrations of
the first and second salt step were varied between 0.2 and 0.5 M NaCl, while the third salt step
elution was at 1 M NaCl. The least-square optimization was performed for an objective fraction
volume of 3 CV. The solution of the optimization problem popt is defined as (Eq. (13)):
popt = arg min
p

(1 − P (p))︸ ︷︷ ︸
impurity




The proposed optimal salt concentrations for the step elution process were evaluated for a
loading of 1 and 6.5 mL and flow rates of 1 CV/min, 2 CV/min, and 3 CV/min.
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2.5 Size-Exclusion Chromatography
Polishing of VLPs captured by an optimized salt step elution by AEX membrane chromatog-
raphy was performed on a Superose R© 6 Increase 10/300 column (GE Healthcare, Uppsala,
Sweden). 500 µL of a 2 mg/mL VLP solution was injected at a flow rate of 0.5 mL/min using
PBS pH 7.4 as mobile phase buffer. Fractions were analyzed by RP-UHPLC and capillary gel
electrophoresis to evaluate the final purity of the samples.
2.6 Analytical Methods
2.6.1 VLP Quantification
Quantification of VP2-VLPs was conducted as described previously by RP-UHPLC [34]. In
brief, a Waters Acquity BEH C4 column was run in acetonitrile gradient elution mode on an
UltiMate R© 3000 RSLC x 2 Dual system (Thermo Fisher Scientific, Waltham, Massachusetts,
USA). Samples were pre-denatured with a denaturing buffer containing 8 M guanidine hy-
drochloride and 60 mM DTT to avoid column blocking by aggregation and carryover. Final
concentrations were determined by comparing peak areas with external VLP reference standards
of known concentration.
2.6.2 Capillary Gel Electrophoresis
The final protein purity of processed VLPs was assessed by a LabChip R© GX II capillary gel
electrophoresis device separating proteins by size. Sample and chip preparation procedures
were performed as described in the manufacturer’s protocol for the HT Protein Express Assay
[43]. Product quantification was based on peak-baseline integration and the protein purity (P )







DNA quantification was performed using the PicoGreen R© dsDNA assay kit (Invitrogen, Paisley,
United Kingdom) in 96-well plates according to the manufacturer’s instructions.
2.6.4 Transmission Electron Microscopy
FPLC fractions and purified VLP samples were further analyzed by transmission electron mi-
croscopy to evaluate polydispersity and morphology of VLPs. As described previously [34],
samples were applied on carbon grids, washed with ultrapure water, and stained with uranyl
acetate prior to analysis on a Philips CM 200 FEG/ST transmission electron microscope at
200 kV.
3 Results & Discussion
3.1 Optimization of VLP Binding by High-Throughput Exper-
imentation
Optimal binding conditions for human B19 parvo-VLPs on AEX membranes were determined by
varying pH and ionic strength of the binding buffer in automated high-throughput microbatch
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screenings. In a first step, the binding at pH 7.4 and 50 mM NaCl was investigated for increasing
VLP concentrations. In Fig. 2 a, the VLP concentration in the stationary phase Q is plotted
against the concentration in the mobile phase cV LP with standard deviations illustrated by
error bars. The values were fitted using the Langmuir isotherm obtaining a saturation capacity
qS of 5.6 mg VLP per mL membrane volume. The curve shows a similar pattern as usual one-
component adsorption isotherms with a linear region for low concentrations and a saturation
region for high VLP concentrations. Nevertheless, there is a strong decrease in capacity for
higher VLP concentrations such as 1.15 mg/mL. It must be taken into account that the VLP
feedstock used for the experiments is a complex multicomponent mixture containing multiple
host cell proteins (HCPs), baculoviruses, and nucleic acids (DNA). AEX ligands strongly bind
DNA at pH-values higher than pH 4.0, potentially causing the displacement of bound VLPs at
high loadings [44]. Besides multicomponent displacement effects, the binding of biomolecules
on IEX stationary phases is also influenced by secondary interactions such as hydrophobic
adsorption and desorption processes [45, 46]. Therefore, both pH and NaCl concentration were
varied using a DoE approach to identify optimum binding conditions for VLPs. For a bind-and-
elute procedure, the pH working range was chosen beyond the predicted isoelectric point of the
major capsid protein VP2 at pH 6.5 [47]. Moreover, to minimize the risk of VLP disassembly
during the IEX process, the pH working range did not exceed a pH of 9.0 [47].







































(b) Binding capacity at varying buffer conditions
Figure 2 Batch adsorption of human B19 parvo-VLPs on Sartobind R© Q membranes. Experiments were
performed with Spodoptera frugiperda Sf 9 insect cell lysate containing VLPs composed of the major
capsid protein VP2. The VLP concentration in the stationary phase Q at 50 mM Tris pH 7.4, 50 mM
NaCl is fitted using the Langmuir isotherm(solid line). The binding screening for varying pH values and
NaCl concentrations was conducted with a multicomponent buffer system at a VLP concentration of
1 mg/mL. Each data point represents the mean value of triplicate binding experiments.
Fig 2 b displays the correlation of the VLP concentration in the stationary phase Q1 (1 mg/mL
VLP in the mobile phase) with both NaCl concentrations and pH. It can be seen that the affinity
for VLPs initially increases with pH and the maximum loading concentration is obtained at
pH 8.5 and 15 mM NaCl. The bound amount of VLPs at pH 7.5 and 120 mM NaCl is almost
40% lower than at the optimum condition. Interestingly, the highest pH does not come along
with the highest Q1-value. At pH 9 and 15 mM NaCl, the loading mass is 19% lower than at
pH 8.5. However, Q1 at pH 9.0 hardly decreases with increasing salt concentrations in contrast
to pH 7.5, 8 and pH 8.5.
In general, there is a clear trend of decreased binding at increasing NaCl concentrations. Low
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NaCl concentrations below 15 mM lead to precipitation of VLPs, and datapoints below 15 mM
NaCl are therefore not included in Fig. 2 b. The stabilizing effect of NaCl has been reported
before for various VLPs [48, 47]. The optimal binding buffer at pH 8.5 and 15 mM NaCl
probably incorporates a negative VLP net charge, a low surface hydrophobicity, and a stable
VLP conformation [47]. A slight pH increase to pH 9.0 implies a more negative net charge of
the capsid protein VP2, but might coincide with conformational changes or even disassembly
of VLPs as reported recently for hepatitis B surface antigen VLPs by Yang et al. [49].
3.2 Calibration of Hydrodynamic & Steric Mass Action Model
Subsequent to setting the buffer conditions for the AEX binding step by the DoE approach,
elution conditions were optimized by process modeling and simulation. For modeling of the
hydrodynamics in the membrane capsule, a dextran pulse was used to determine the axial dis-
persion coefficient Dax by chromatogram fitting. In Fig. 3a, the UV absorption at a wave length
of 215 nm is plotted against the mobile phase volume for a 10 mg/mL dextran T2000 pulse
injection on a 3 mL Sartobind R© Q membrane adsorber. The chromatogram shows an overlay
of measured (dotted line) and simulated (solid line) UV signal. The simulation was possible by
estimating the axial dispersion coefficient under consideration of the system and capsule dead
volume. All calculated membrane-specific parameters are summarized in Table 2.
Table 2 Calculated membrane parameters
Parameter Symbol Value Proceeding
Fluid volume Vf 3.4 mL VRetAc − Vd
Void volume capsule VvoidC 1.006 mL Vf − εtVM
Interstitial volume Vint 2.56 mL VRetDex−Vd−VvoidC
Membrane porosity εpores 0.518
Vint
VM
Hydrogel porosity εhydrogel 0.581
εt−εpores
1−εpores








Ionic capacity Λ 0.211 M cHClVHClVM (1−εt)
Volume applied at
10% breakthrough




DBC 5.7 mg/mL cV LP,0
V10%−VRetDex
VM
An axial dispersion coefficient Dax of 0.0374 mm
2/s was estimated which is quite low in com-
parison to the dispersion in agarose-based chromatography columns [38]. Thus, the determined
Dax-value already implies a small peak-broadening effect by axial dispersion. In order to model
the ion-exchange on the membrane surface, the film diffusion coefficient of NaCl was estimated
by chromatogram fitting of a 1 M NaCl pulse injection. In Fig. 3b, the conductivity signal
is plotted against the mobile phase volume. In contrast to the dextran peak, the measured
NaCl peak (dotted line) shows a noticeable tailing and a longer retention volume. The NaCl
peak was simulated (solid line) using the obtained Dax value from the dextran chromatogram
fitting and an estimated film transfer coefficient keff,NaCl of 0.1829 mm/s. The differences in
the retention volume of dextran T2000 and NaCl confirm the exclusion effect of large molecules
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from hydrogel pores reported by Vicente et al. [10] and Tatarova et al. [9]. Both dispersion
and film diffusion could be modeled using the continuity equation for radial flow with a lumped
diffusion coefficient and standard tracer molecules for chromatographic stationary phases.
























(a) Simulation of axial dispersion of dextran
T2000
























(b) Simulation of film diffusion of NaCl
Figure 3 Comparison of measured (dotted lines) and simulated chromatograms (solid lines) for pulse
experiments on a 3 mL Sartobind R© Q membrane capsule with 100 µL of the tracer molecules dextran
T 2000 (10 mg/mL) and NaCl (1 M). System and capsule void volumes are subtracted from each
chromatogram.
The SMA model was calibrated by determining the ionic capacity of the membrane (Table 2) and
estimating component-specific SMA parameters by chromatogram fitting. In a first step, the
dynamic binding of the AEX membrane for VLPs was determined by performing a breakthrough
curve with the VLP feedstock. Knowledge of the dynamic binding capacity is essential to assess
whether the requirements for UV absorption-based modeling are fulfilled in subsequent calibra-
tion runs (see Section 2.4.1). Fig. 4a shows the chromatogram of a breakthrough experiment:
The UV absorption at 280 nm is plotted (black solid line) against the mobile-phase volume.
The ratio of mobile-phase VLP concentration c to initial VLP concentration c0 is illustrated
by green bars with standard deviations for the analytics represented by grey error bars. The
VLP breakthrough starts at 8.9 mL mobile-phase volume and the determined dynamic binding
capacity at 10% breakthrough is 5.7 mg VLP per mL membrane adsorber (Table 2). The UV
signal shows a first increase at about 3.7 min and a saddle point at approximately 9.2 mL fol-
lowed by the same sharp increase as for the VLP concentration in the analyzed fractions. The
sharp breakthrough of VLPs indicates a low dispersion of VLPs through the membrane pores
as observed in the dextran T2000 pulse experiments for another large molecule. The achieved
DBC of 5.7 mg/mL outperforms to the best of our knowledge all so far reported capacities of
chromatographic matrices for VLPs [4]. VLP concentrations exceeding the starting concentra-
tion c0 suggest a displacement effect of bound VLPs by other feedstock components with higher
ligand affinities. Without the knowledge of the exact feedstock composition, modeling of the
breakthrough of each component is not possible [28]. Therefore, model calibration and process
simulation was only performed for low loadings with a total volume of 1 mL and a VLP mass of
2 mg corresponding to approximately 11% of the DBC. Figs.4b-d show the obtained UV 280
chromatograms for three different salt gradient lengths of 10, 20 and 30 CV from 0.015 M to 1 M
NaCl. UV signal and VLP concentrations are again plotted by black solid lines and green bars,
respectively. The conductivity is displayed by a dotted grey line. The chromatograms indicate
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(a) VLP breakthrough curve





















































(b) 10 CV salt gradient

























































(c) 20 CV salt gradient




















































(d) 30 CV salt gradient
Figure 4 UV chromatograms of bind-and-elute experiments with a clarified human B19 parvo-VLP
feedstock on a 3 mL Sartobind R© Q membrane capsule. The experiments were conducted at a VLP
concentration of 2.7 mg/mL (breakthrough experiment) and 2 mg/mL, respectively. The solid lines
display the UV absorption signal at 280 nm, the dotted lines show the conductivity signals, and the
green bars represent the VLP concentration in all fractions. The sample volumes were 10 mL for the
breakthrough experiment and 1 mL for the salt gradient runs. Three different salt gradient slopes were
applied with 10, 20 and 30 CV gradients from 15 mM to 1 M NaCl.
the separation of multiple components by the salt gradient elution with increasing resolution
for longer gradients. The most outstanding peak with the highest UV absorption at 280 nm
elutes at a salt concentration between 0.3 and 0.5 M NaCl in between two other main peak
groups. The fraction analysis of all gradient runs demonstrates that VLPs elute exclusively
in the region of this major peak. As expected, VLPs get more diluted for lower salt gradient
slopes. Although VLPs successfully bind and elute on the anion exchange membrane, the total
recovery was only 61±3% for all experiments. The remaining amount of VLPs can only be
washed out of the membrane with 1 M NaOH. Such product loss in an IEX bind-and-elute
mode of up to 70% [50, 51] is often observed for VLPs and requires development and evaluation
of novel chromatographic matrices and ligands. Conformational changes during adsorption and
desorption processes might also elicit the product loss [49]. However, since the VLP recovery
was nearly the same for both salt gradient and step elution runs in the evaluated calibration
and optimization dataset, all chromatograms could be used for model calibration and process
simulation. As described in Section 2.4.5, the UV chromatogram peaks were divided into 17
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subgroups and used for SMA parameter estimation by chromatogram fitting. Figs. 5a-c il-
lustrate chromatograms of measured (dotted line) and simulated (solid line) elution of VLP
feestock components for the 10, 20 and 30 CV salt gradients. The simulated VLP elution is
displayed by a red line, while contaminant peaks are shown as turquoise lines. Estimated SMA
parameters, measurement factors, and film diffusion coefficients are provided in Table 3. The
simulated chromatograms describe the measured elution with good accordance regarding peak
shapes, areas, heights and retention volumes. An even higher accordance of measured and sim-
ulated chromatograms might of course be obtained by increasing the number of components for
the complex feedstock. On the other side, the number of components strongly affects the mod-
eling effort, provides few information without an extra feedstock characterization procedure,
and should thus not be too high.




































(a) Simulation of 10 CV salt gradient elution profile




































(b) Simulation of 20 CV salt gradient elution profile


































(c) Simulation of 30 CV salt gradient elution profile
Figure 5 Comparison of measured (dotted lines) and simulated UV chromatograms (solid lines) for the
complex VLP feedstock on the AEX membrane capsule. The feedstock was divided into 16 contaminant
species (turquoise lines) and the target component (red lines). All component-specific lumped rate and
SMA model parameters are provided as supplementary material along with the electronic version of this
article. System and capsule void volumes are subtracted in each chromatogram.
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Table 3 UV peak areas and converged SMA parameters for a Spodoptera frugiperda Sf 9 insect cell lysate
containing human B19 parvovirus-like particles
Component Area280nm[mAU ∗mL] keff keq ν
Contaminant 1 527 0.430 0.300 0.790
Contaminant 2 202 0.662 0.161 2.112
Contaminant 3 606 0.390 0.647 2.245
Contaminant 4 687 0.652 1.827 2.667
Contaminant 5 1260 0.202 4.999 2.742
Contaminant 6 695 0.150 21 7.817
Contaminant 7 339 0.980 90 7.955
Contaminant 8 343 0.820 318 9.000
Target 1111 0.162 6.21E+13 34.320
Contaminant 9 426 0.216 2.65E+04 12.571
Contaminant 10 427 0.161 8.00E+03 8.600
Contaminant 11 722 0.337 4.80E+06 13.548
Contaminant 12 396 0.990 2.80E+07 13,690
Contaminant 13 40 0.280 1.20E+10 18.548
Contaminant 14 228 0.990 2.23E+15 28.260
Contaminant 15 328 0.199 5.43E+15 28.050
Contaminant 16 655 0.140 1.35E+05 7.060
3.3 In silico Optimization
Knowledge of hydrodynamic and SMA parameters finally allowed the identification of opti-
mal elution conditions for the investigated separation problem. Using the simulation software
ChromX, the salt concentrations of a three-salt step elution process were varied to evaluate the
effect on purity and yield. Figs. 6a and 6b illustrate by 3D plots the correlation of VLP purity




















(a) Prediction of model-based VLP purity for
























(b) Prediction of combined model-based VLP
purity and yield for varying salt step elutions
Figure 6 In silico designed correlations of the model-based VLP purity and yield with regards to salt
concentrations in a three-salt step elution process with a Sartobind R© Q membrane adsorber. The calcu-
lations are solely based on the modeled contaminant groups and component-specific SMA parameters.
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The first salt step elution is applied to separate impurities with a lower ligand affinity, while
the second step elutes both VLPs and impurities with a similar net charge. Thus, purities
and yields are only calculated for VLPs eluting in the second salt step for a fraction volume
of 3 CV. Fig 6a shows that the purity increases for higher salt concentrations in the first salt
step and lower salt concentrations in the second salt step elution. This correlation can be ex-
pected since there are sweet spots for the elution of both VLPs and contaminants. The highest
and lowest simulated purities obtained were 91% and 30%, respectively. However, the VLP
yield shows an opposite trend and increases with lower salt concentrations of salt step 1 and
higher salt concentrations of salt step 2, which must be considered for the process design. Fig
6b demonstrates that a high purity and yield can only be reached in a narrow region of salt
concentrations. A high salt concentration of salt step 1 causes VLP elution in the first salt step
while a lower salt concentration of salt step 2 leads to VLP elution in the third salt step. The
sweet spot for an optimized capturing of VLPs is 0.3±0.02 M in salt step 1 and 0.38±0.02 M
in salt step 2. It should be noted that given purities are UV-based and calculated exclusively
for those contaminant groups included in the model calibration dataset. Moreover, the model-
based VLP yield is determined for the eluting fraction and does not account for the product
loss caused by irreversible binding or conformational change as described above. The obtained
correlations represent a design space for the AEX membrane processing of VLPs that can be
used to optimize a capture step, to scale the separation as well as to understand and forecast
the effect of process fluctuations following the basic tenet of ’quality by design’ (QbD).
To evaluate the feasibility of the proposed salt step process, simulated and measured data were
compared and are shown in Fig. 7a-d. The salt concentrations are 0.301 M NaCl (salt step
1), 0.384 M NaCl (salt step 2), and 1 M NaCl (salt step 3) predicting a VLP purity of 88.6%
in the second salt step. Fig.7a and Fig. 7c display the measured (dotted lines) and simulated
(solid black lines) UV signals of the purification process for a loading of 1 mL and a loading of
6.5 mL with VLPs peaks in red and contaminant peaks in turquoise. Fig. 7b and Fig. 7d show
the measured UV absorption (solid black lines) and the VLP concentrations (green bars) in all
collected fractions. For both loadings, VLPs eluted exclusively in the second salt step. The
total yield of 59±2% was almost the same as in the calibration salt gradient runs indicating
that no VLPs were lost by elution in the first or third salt step. The obtained protein purity for
the pooled VLP fractions of the second salt step was 81.5±2% as determined by capillary gel
electrophoresis (Fig. 9c). The chromatograms illustrate that most contaminants elute in the
first and third salt step, although two contaminant groups have similar elution characteristics as
the target component and can hardly be separated. Even with longer salt gradients or other salt
concentration profiles, a separation of these contaminants cannot be achieved without changing
stationary and/ or mobile phase (data not shown). The chromatogram in Fig. 7c shows the
same peak elution profile as in Fig. 7a, but with higher peak areas and heights. It must be
taken into account that the UV detection limit lies close to 2700 mAU which leads to different
peak heights at high loadings for measured and simulated chromatograms. Interestingly, the
chromatogram and VLP concentrations in the second salt step demonstrate that the proposed
in silico optimization procedure can also be used to depict the separation for higher loadings
( 76% of DBC) than applied in the model calibration dataset. This suggests a quite steep SMA
isotherm indicating that in this case, non-linear effects could be neglected for simulating higher
loadings of complex feedstocks.
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(a) Optimized step elution (1 mL sample vol-
ume)




















































(b) Measurement and fraction analysis of opti-
mized step elution (1 mL sample volume)






































(c) Optimized step elution (6.5 mL sample vol-
ume)
























































(d) Measurement and fraction analysis of opti-
mized step elution (6.5 mL sample volume)
Figure 7 Comparison of measured (dotted lines) and simulated UV chromatograms (solid lines) for
the optimized VLP capture process on the AEX membrane capsule at varying load volumes (1 mL and
6.5 mL VLP feedstock). The salt concentrations were 0.301 M NaCl for step 1, 0.384 M NaCl for step 2,
and 1 M NaCl for the high-salt step. The upper limit of the UV detector is reached at values between
2500 and 3000 mAU. Product tracking by fraction analysis is shown in figures (b) and (d) displaying
VLP concentrations as green bars.
3.4 Impact of Flow Rate
A major advantage of membranes in comparison to conventional chromatography resins is the
rapid mass transport lacking intraparticle diffusion limitations [17]. In order to investigate the
impact of flow rate on the bind-and-elute VLP process the optimized salt step elution was run
at a flow rate of 2 CV/min and 3 CV/min. Fig. 8a and Fig. 8b show the obtained UV chro-
matograms and tracked VLP concentrations. In contrast to the operation at 1 CV/min, VLPs
were not only detected in the second salt elution step, but also in fractions of salt step 1 and for
3 CV/min even in fractions of the flow-through. This demonstrates that an increase in flow rate
drastically changes the performance and capacity of the AEX membrane process. The observed
variations might be ascribed to kinetic and diffusive limitations of large biomolecules at higher
flow rates. Similar phenomena have been reported by Rao [52] for the protein thyroglobulin
applied on IEX membranes showing decreased DBC at higher flow rates. The findings point
out that hydrogel and ligand design on membranes require further optimization by industry
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(a) Step elution at 6 mL/min
























































(b) Step elution at 9 mL/min
Figure 8 Effect of the flow rate on the performance of the optimized salt step elution procedure of the
VLP feedstock for a 3 mL Sartobind R© Q membrane adsorber and a loading of 6.5 mL VLP feedstock.
The solid lines display the UV absorption signal at 280 nm, the dotted lines show the conductivity
signals, and the green bars represent the VLP concentration in all fractions.
and academia to obtain higher binding capacities and faster downstream processes for large
biomolecules.
3.5 Polishing & Process Evaluation
The designed AEX membrane process yielded a protein purity of 81.5±2 %, a DNA concentra-
tion of 8±1 ng DNA per 100µg VLP (99.2% clearance), and a VLP recovery of 59±2%. Particle
morphology and homogeneity were assessed by TEM analysis (Fig. 9).
(a) TEM micrograph of bac-
ulovirus
(b) TEM micrograph of puri-
fied VLPs



























(c) Capillary gel electrophero-
gram
Figure 9 Analysis of process samples by transmission electron microscopy (TEM) and capillary gel
electrophoresis. Electropherograms of process samples were normed to the target peak area.
Fig. 9a shows the micrograph of an FPLC fraction collected at a retention volume of 28 mL.
A rod-shaped particle is visible with a size of 50 x 300 nm. Comparing the particles with
TEM micrographs from Vicente et al. [8] and Yang et al. [53], both size and morphology
indicate the presence of baculoviruses in the first salt step of the optimized elution process.
In contrast, there were not any baculoviruses observed on the micrographs of the pooled VLP
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fractions. Fig. 9b displays a high number of homogeneous icosahedral particles with a diameter
of 25 nm characteristic of human B19 parvo-VLPs [54, 47, 30]. This demonstrates that the
VLP structure was not affected by the bind-and-elute membrane process. To further increase
the purity of the processed VLPs, pooled fractions from the membrane step were applied on an
SEC column. The UV chromatogram of the SEC step is depicted in Fig. 10. The protein purity
after the SEC step was 97.9±1 % with a step yield of 84±2 % separating VLP aggregates and
smaller biomolecules. Fig. 9c shows the electropherogram of the VLP feedstock (black dotted
line), the membrane-processed VLPs (blue line), and the polished VLPs (red dotted line). The
electropherogram underlines that the majority of contaminants is removed by the optimized
AEX membrane process with only three residual protein impurity peaks left. Using the AEX
membrane capture step and the SEC polishing procedure, all major protein impurities were
successfully separated from the target component. The final DNA concentration of the purified
VLPs was 0.5 ng DNA per 100 µg VLP (99.9% clearance).
































Figure 10 UV chromatogram of a size-exclusion chromatography run with human B19 parvovirus-like
particles captured from Spotoptera frugiperda Sf 9 insect cells by anion-exchange membrane chromatog-
raphy. 500 µL of a 2 mg/mL VP2-VLP solution were injected on a Superose R© 6 Increase 10/300 column
at a flow rate of 0.5 mL/min. PBS pH 7.4 was used as mobile phase buffer. The solid black line shows
the UV absorption at 280 nm while the green bars represent the VLP concentration in the collected
fractions.
4 Conclusion & Outlook
The aim of this study was to design a bind-and-elute membrane process for VLPs derived from
Sf 9 insect cells using rational development tools. For the first time, a proof of concept for
simulating and optimizing the chromatographic separation of VLPs with a radial lumped rate
model and the SMA isotherm was demonstrated. Automated high-throughput screenings in 96-
well format allowed the identification of suitable binding conditions yielding a dynamic binding
capacity of 5.7 mg VLP per mL Q membrane. In silico process modeling, simulation, and
optimization were performed for a radial AEX membrane capsule to control and forecast the
elution of VLPs and impurities. Using UV absorption-based modeling, the complex feedstock
was divided into 17 subcomponents, and a design space for the elution conditions of the target
component was established. An in silico optimized process with three salt steps enabled the
separation of VLPs from the majority of baculoviruses, HCPs and DNA. The simulated and ex-
perimental purities were 88.6% and 81.5±2%, respectively. Residual contaminants were cleared
by a subsequent SEC polishing procedure. A downside of the developed process was, however,
the product loss (60% recovery) and the decrease in performance at increased flow rates. Both
effects require a better understanding of the mass transport phenomena on the membrane for
a more generic process model incorporating potential conformational VLP changes. Further
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membrane optimizations should focus on customizing ligand and stationary phase design for
large biomolecules to increase the productivity of membrane-based VLP processes. Both high-
through experimentation and chromatography modeling have proven to be valuable rational
design tools for process development of VLPs.
Nomenclature
ai Absorption coefficient
Dax Axial dispersion coefficient
εPores Membrane porosity
εHydrogel Stationary phase porosity
εt Total porosity
H Membrane height
keff Effective film/pore transfer coefficient
keq Adsorption equilibrium coefficient
keq,L Adsorption equilibrium coeff. for Langmuir isotherm
L Membrane thickness
Λ Stationary phase ionic capacity
ν Characteristic charge for SMA isotherm
q Stationary phase concentration of protein
qs Single-component saturation conc. for Langmuir isotherm
qsalt Stationary phase concentration of salt
ra Outer radius of spiral wound membrane
ri Inner radius of spiral wound membrane
σ Steric shielding coefficient for SMA isotherm
t Time dimension
u Interstitial mobile phase velocity
x Space dimension
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Abstract
The production of safe vaccines against untreatable or new diseases has pushed the research
in the field of virus-like particles (VLPs). Currently, a large number of commercial VLP-
based human vaccines and vaccine candidates are available or under development. A promising
VLP production route is the controlled in vitro assembly of virus proteins into capsids. In
the study reported here, a high-throughput screening (HTS) procedure was implemented for
the upstream process development of a VLP platform in bacterial cell systems. Miniaturized
cultivations were carried out in 48-well format in the BioLector system (m2p-Labs, Germany)
using an Escherichia coli strain with a tac promoter producing the murine polyomavirus capsid
protein (VP1). The screening procedure incorporated micro-scale cultivations, HTS cell disrup-
tion by sonication and HTS-compatible analytics by capillary gel electrophoresis. Cultivation
temperatures, shaking speeds, induction and medium conditions were varied to optimize the
product expression in E. coli. The most efficient system was selected based on an evaluation
of soluble and insoluble product concentrations as well as on the percentage of product in the
total soluble protein fraction. The optimized system was scaled up to cultivation 2.5 L shaker
flask scale and purified using an anion exchange chromatography membrane adsorber, followed
by a size exclusion chromatography polishing procedure. For proof of concept, purified VP1
capsomeres were assembled under defined buffer conditions into empty capsids and character-
ized using transmission electron microscopy (TEM). The presented HTS procedure allowed for
a fast development of an efficient production process of VLPs in E. coli. Under optimized cul-
tivation conditions, the VP1 product totalled up to 43% of the total soluble protein fraction,
yielding 1.63 mg VP1 per mL of applied cultivation medium. The developed production process
strongly promotes the murine polyoma-VLP platform, moving towards an industrially feasible
technology for new chimeric vaccines.
Keywords: Virus-like Particles, Escherichia coli, High-throughput Screening, Micro-scale Cul-
tivation, BioLector R©
3 PUBLICATIONS & MANUSCRIPTS
138
1 Introduction
Virus-like particles (VLPs) represent novel molecular means for the containment of infectious
diseases and the immunotherapeutic treatment of cancer, Alzheimer’s disease, and autoimmune
diseases [1, 2, 3, 4]. A steadily increasing number of VLP-based vaccines is currently undergoing
clinical phase studies and several recombinant VLPs have been licensed for prophylactic vacci-
nation against cervical cancer (Gardasil R©, Cervarix R©), hepatitis B (Recombivax R©, Engerix R©),
and hepatitis E (Hecolin R©) [5, 6]. Protein-based VLPs are produced by recombinant expres-
sion of virus proteins in yeast, insect, or bacteria cells [7]. For the production of homogeneous
particles, currently licensed VLP-based vaccines are assembled in vitro under defined and con-
trollable buffer conditions. Separate disassembly process steps are needed for in vivo assembled
VLPs. A promising approach to the rapid and scalable production of VLPs is the expression
of virus proteins in Escherichia coli. E. coli is the recombinant system of choice for multiple
biopharmaceutical products, such as human insulin [8], human growth hormones [9], antibody
fragments [10], or hepatitis vaccines [11], providing high product titers and total soluble protein
values of up to 50% [12].
In recent years, several microbial VLP production systems were developed and tailored to
epitope presentations in vaccine formulations, such as the bacteriophage Qβ system [4, 13],
the human hepatitis B core protein [14, 15, 16], the woodchuck hepadnavirus core protein
(WHcAg) [17] or the papaya mosaic virus (PapMV) system [18]. Another well-characterized
VLP-based nanocarrier is the murine polyoma virus protein VP1 that is capable of sponta-
neously self-assembling into capsids and lacking the risk of human pre-existing carrier-specific
immunity. E. coli -derived VP1 builds pentamer structures that allow processing small protein
complexes instead of whole particles and, thus, do not require any additional disassembly steps.
Chimeric murine polyoma-VLPs were used in the past for the presentation of influenza antigen
epitopes (H190, M2e) [19, 20, 21], group A streptococcus epitopes (J8i) [22, 23], tumor cell
epitopes [24, 25], and packaging of small molecules and DNA [26, 27]. However, the current
state-of-the-art platform for E. coli -derived VP1 is limited by the expression and processing of
glutathion-S-transferase (GST)-VP1 fusion tag complexes [28]. These protein tags are widely
used for enhancing the solubility of proteins, increasing product titers, and facilitating lab-
scale purification by using affinity chromatography for capturing the product of interest with
a high selectivity [29, 30, 19]. Major drawbacks of protein tags arise due to multimerization
effects, slow and high-priced affinity chromatography media, and the demand for additional
downstream procedures for the removal of the fusion tags [28, 31]. Boosting the productivity
of the murine polyoma-VLP platform requires an optimization, acceleration, and simplification
of both upstream and downstream processing.
An optimization of protein expression in E. coli often is time-intensive when performing shaker
flask cultivations. Rapid process development can be performed in silico using molecular dy-
namics simulations of the product of interest [32] or by high-throughput experimentation with
multiple recently developed tools for miniaturized automated cultivations [33, 34, 35]. However,
miniaturization may result in a reduction of accessible process information, leading to difficul-
ties in process control and scale-up [33]. To overcome these shortcomings, more sophisticated
systems were developed, e.g. the Advanced Micro-scale Bioreactors (ambr R©) technology (Sar-
torius Stedim Biotech, Germany) mimicking lab-scale fermenters on a robotic workstation [36]
and the BioLector system (m2p-Labs, Germany) used in this study [37, 38]. For the BioLector
system, special 48-well cultivation plates with flower-shaped wells exist for improving mixing
and oxygen uptake into the medium [39]. Successful scale-up from the micro-scale to lab-scale
can be implemented to gain a large pool of cell broth for subsequent downstream process de-
velopment [40, 41].
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In this paper, we present a high-throughput approach to the design of the upstream process of
murine polyoma-VLPs. For proof of concept, we suggest an alternative membrane-based down-
stream process enabling the rapid large-scale production of future chimeric murine polyoma-
VLP-based vaccine candidates.
2 Material & Methods
2.1 Material
2.1.1 Disposables
Cell transformation was carried out in 1 mm polycarbonate electroporation cuvettes (Biozym
Scientific GmbH, Germany). Micro-scale cultivation experiments were performed in 48-well
FlowerPlates R© covered with adhesive sterile sealing foil (m2p-Labs, Germany). All pre-cultures
were cultivated in 250 mL baffled flasks (Schott, Germany). For scale-up, 2.5 L baffled TUNAIR
TM
shake flasks (Sigma Aldrich, Germany) were used. Cell lysis and centrifugation procedures were
carried out in 300 µL polypropylene 96-well plates with a conical bottom (VWR, Germany).
Sterile filtration of cell lysates prior to chromatography runs was conducted with 0.45 µm and
0.1 µm cellulose acetate filters (Sartorius AG, Germany). 3 mL Slide-A-Lyzer
TM
G2 dialysis
cassettes with 10 K MWCO cellulose membranes (Life Technologies, USA) were used for the in
vitro VLP assembly. For gel electrophoresis (GX) experiments, Novex R© NuPAGE R© 4-12% Bis-
Tris (1.0 mm, 12 wells) protein gels were purchased from Life Technologies, Sweden. Capillary
gel electrophoresis (GX II) was carried out in an HT Protein Express & Pico LabChip R© (Perkin
Elmer, USA). GX II sample preparation was conducted in skirted 96-well twin.tec R© PCR plates
(Eppendorf, Germany). For western blotting, XCell
TM
blot sponge pads, filter papers, and a
nitrocellulose transfer membrane were purchased from Life Technologies, USA.
2.1.2 Chemicals & Buffers
For the electroporation experiments, super optimal broth (SOB) medium composed of 20 g/L
wheat peptone for microbiology (Fluka, Germany), 5 g/L bacteriological yeast extract (Am-
resco, USA), 10 mM sodium chloride, 2.5 mM potassium chloride (VWR, Germany), and super
optimal broth with catabolite repression (SOC) medium, including the ingredients of SOB with
additional 10 mM magnesium chloride, 10 mM magnesium sulfate (Merck kGaA, Germany),
and 20 mM glucose (VWR, Germany) were used.
For cultivations, a terrific broth (TB) medium was applied, composed of 12 g/L wheat peptone,
24 g/L bacteriological yeast extract, 5 g/L glycerol bidistilled 99.5% (VWR, Germany), and
89 mM potassium dihydrogen phosphate (VWR, Germany). For the selection of transformed
cells, antibiotics were added to a final concentration of 100 µg/mL carbenicillin and 34 µg/mL
chloramphenicol (AppliChem GmbH, Germany). The TB medium was adjusted to pH 6 or
pH 7 using potassium hydroxide and for experiments including magnesium, magnesium sulfate
heptahydrate (Merck kGaA, Germany) was added to a final concentration of 2 mM. The in-
duction procedure of the pTac promoter was realized with isopropyl-β-D-thiogalactopyranosid
(IPTG) from a 1 M stock solution (VWR, Germany).
As a lysis buffer for native protein release (compatible with the GX II system), a 20 mM
Tris buffer (Merck KGaA, Germany) adjusted to pH 8 with hydrochloric acid (Merck KGaA,
Germany), including 1X SigmaFAST
TM
protease inhibitor and 5 mM dithiothreitol (DTT)
(Sigma Aldrich, Germany), was used. The lysis buffer for purification experiments consisted of
20 mM Tris-HCl (VWR, Germany), 1 mM EDTA disodium dihydrate (Fluka Chemie GmbH,
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Switzerland), 5% (v/v) glycerol, 1X SigmaFAST
TM
protease inhibitor, and 5 mM DTT (Sigma
Aldrich, Germany). Total protein extraction under denaturing conditions was carried out using
trichloroacetic acid (TCA) BioChemica (AppliChem, Germany) and acetone for liquid chro-
matography (Merck kGaA, Germany).
The compositions of the binding and elution buffer for anion-exchange chromatography were
20 mM Tris (pH 8), 5 mM DTT, 1 mM EDTA, and 5% (v/v) glycerol, with an additional 1 M
NaCl (Merck KGaA, Germany) in the elution buffer. 20 mM Tris (pH 8), 5 mM DTT, 1 mM
EDTA, 5% (v/v) glycerol, and 250 mM NaCl were used as running buffer for purification by
size-exclusion chromatography. The VLP assembly buffer developed by Middelberg et al. [19]
was used, which consists of 0.5 M ammonium sulfate, 20 mM Tris (pH 7.4), 5% (v/v) glycerol,
and 1 mM calcium chloride (VWR, Germany).
Gel electrophoresis (GX) was carried out using 20X Bolt R© MES SDS running buffer, NuPAGE R©
4X LDS sample buffer, and the Novex R© Sharp unstained protein standard (Life Technologies,
Sweden). DTT was prepared as a 1 M stock solution. For protein staining, a ’blue silver’
staining solution, consisting of 10% (v/v) phosphoric acid of 85% purity (Roth, Germany),
100 g/L ammonium sulfate BioChemica (AppliChem, Germany), 1.2 g/L Coomassie Brilliant
Blue G-250 (Merck, Germany), and 20% (v/v) methanol (Sigma Aldrich, Germany), was used.
For capillary gel electrophoresis (GX II) experiments, an HT protein express reagent kit was
purchased from Perkin Elmer, USA. A 1 mg/mL lysozyme solution (Hampton research, USA)
served as an internal concentration standard.
The transfer buffer for western blotting was composed of 192 mM glycine, 20% (v/v) methanol
(Sigma Aldrich, Germany), and 25 mM Tris(hydroxymethyl)-aminomethane (Merck KGaA,
Germany) and was adjusted to pH 8.3. As further buffers, Tris-buffered saline (TBS), including
500 mM chloride and 20 mM Tris adjusted to pH 7.5, and TBS-T with additional 0.05% (v/v)
of Tween 20 were applied. The solution for color development (AP color development reagent
kit) was purchased from BioRad Laboratories, USA.
2.1.3 Instrumentation
Transformations were conducted using a MicroPulser
TM
Electroporator (Bio-Rad Laboratories,
USA). High-throughput micro-scale cultivation experiments were carried out in a BioLector R©
MB micro-scale fermentation system (m2p-Labs, Germany). Shake flask cultivations were con-
ducted in a MaxQ
TM
6000 incubator (Thermo Fisher Scientific, USA). A 5810 R centrifuge (Ep-
pendorf, Germany) was used for liquid-solid separation procedures, including cell harvest. Re-
lease of the intracellular product was realized using a Model 120 Sonic Dismembrator equipped
with an eight-tip horn positioner (Thermo Fisher Scientific, USA) for high-throughput micro-
scale cell disruption and with a Digital Sonifier R© 450 (Branson Ultrasonic Corporation, USA)
for the scale-up cell lysis procedure. Product purification experiments were carried out in an
ÄKTA
TM
Purifier system (GE Healthcare Life Sciences, Sweden), equipped with a pump P-900,
mixer M-925, UV detector UV-900, motor valve INV-907, pH and conductivity monitoring unit
pH/C-900, and a fraction collector Frac-950 unit. For pH adjustment of all buffers, an HI-
3220 pH meter (Hanna Instruments, USA) was used. Gel electrophoresis was carried out in an
Xcell SureLock
TM
Novex R© MiniCell gel chamber equipped with a PowerEase R© 500 power sup-
ply (Life Technologies, USA). Capillary gel electrophoresis (GX II) was carried out in a Caliper
LabChip R© GX II (Perkin Elmer, USA). Sample denaturation for both the GX and GX II system
was realized in a MUR 13 thermo-shaker with additional lid heating (HLC BioTech, Germany).
Assembled virus-like particles were inspected by transmission electron microscopy (TEM) on a
CM 200 FEG/ST electron microscope (Philips, Netherlands).
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2.2 Upstream Process Development
2.2.1 Plasmid Construction & Host Strain
The plasmid pALVP1TAC [42] was generously provided by Prof. Robert Garcea (University
of Colorado, USA) and sequenced by JenaGen GmbH, Germany. The plasmid pTacVP1 was
constructed by inserting the nucleic acid sequence of murine polyoma virus capsid protein VP1
(sequence M34958) with optimized codon usage (Fig. 1) between the NdeI and HindIII sites of
a pTac-MAT-Tag-1 expression vector (Sigma-Aldrich, USA). A stop codon was inserted in front
of HindIII to prevent the translation of the N-terminal metal affinity tag. The plasmid was
designed and synthesized by Centic Biotec, Germany. E. coli Rosetta(DE3)pLysS cells (Merck
KGaA, Germany) were prepared for electroporation by the standard procedure: Growth in
SOB medium (250 mL shaker flasks, 37◦C, 180 rpm), harvest at an OD600 nm-value of 0.3 by
centrifugation (4◦C, 18,000 x g), followed by several cooling and washing steps with sterile bi-
distilled water. Transformation was carried out in a MicroPulser
TM
Electroporator at 1.8 kV
with 100 µL cells and 100 ng DNA. Transformed cells containing pTacVP1 with the ampicillin
resistance gene were selected on carbenicillin agar plates.
2.2.2 Micro-scale Cultivations
The pre-cultures for the micro-scale cultivations were prepared as 80 mL cultures in TB medium
using E. coli Rosetta pTacVP1 from a cryo culture in the MaxQ
TM
6000 incubator (180 rpm
- 37 ◦C). 4 different pre-cultures were employed, applying TB medium of variable composition
(pH 6 - w or w/o 2 mM magnesium sulfate and pH 7 - w or w/o 2 mM magnesium sulfate).
After 16 h (late exponential phase), the cells were diluted to a final OD600 nm of 0.1 AU using
the different TB media (equally treated pre-culture for all experiments). The working volume
of the 48-well FlowerPlate R© was set to 1 mL for all cultivation experiments. The cultivation
plate was sealed with an adhesive gas-permeable sterile membrane.
The micro-scale cultivation experiments were performed at shaking speeds of 600 rpm or
1200 rpm, covering a temperature set of 27, 32, and 37 ◦C. According to the FlowerPlate R© prod-
uct sheet [43], 600 rpm shaking speed at 1 mL filling volume represents oxygen limited conditions
(KLa = 85.9 1/h) whereas 1200 rpm shaking speed at 1 mL filling volume (KLa = 371.6 1/h) is
in a range of a bench scale stirred tank reactor [44]. Per 48-well FlowerPlate R©, each cultivation
experiment was performed in triplicate, allowing for a total of 16 conditions to be screened
(combined with all shaking speeds and temperatures, this adds up to 16·6 = 96 conditions).
These 16 conditions covered 2 different pH values (pH 6 and pH 7), 2 different additive se-
tups (w and w/o 2 mM magnesium sulfate), 2 different induction times (OD600 nm of 0.5 AU
and 4 AU), as well as 2 different inducer concentrations (0.1 mM and 0.5 mM of IPTG) as
a full factorial experimental design. The respective induction times, being in scattered light
units in the BioLector R© system, were calculated using scattered light - OD600 nm correlation
functions (600 rpm: Scattered light = 11.69 · OD600 nm + 17.59; 1200 rpm: Scattered light
= 11.36 · OD600 nm + 16.14). After 20 h, the cultivation procedure was stopped. 50 µL of
each well of the FlowerPlate R© were transferred to 300 µL polypropylene 96-well plates with
a conical bottom for TCA total protein extraction under denaturing conditions. Additionally,
150 µL of cell broth were transferred to another 300 µL polypropylene 96-well plate for native
cell disruption by sonication. All plates for protein release were centrifuged at 3200 x g and
10 ◦C for 30 min and the supernatant was discarded.
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2.2.3 High-throughput Cell Disruption
For total protein extraction under denaturing conditions using a TCA protocol, the cell pellets
were resuspended in 200 µL of ultrapure water. Then, 10 µL of 100% (w/v) TCA solution
were added to each well and the plate was shaken for 20 s and subsequently stored on ice for
10 min. The plate was then centrifuged at 3200 x g and 4 ◦C for 10 min and the supernatant was
discarded. The pellet was washed twice with 200 µL of cold pure acetone, followed by another
centrifugation cycle after each washing step. In a final step the supernatant was removed, the
pellet was dried for 3-4 h and stored at -20 ◦C until analysis.
For HTS sonication experiments using the Model 120 Sonic Dismembrator (Fisher Scientific),
the cell pellets were resuspended in 150 µL of lysis buffer for native protein release (compatible
with the GX II system). The sonication device was operated with an amplitude of 70%, applying
6 cycles of 20 s pulse duration. Between the pulses, 30 s chilling on ice followed. After the final
sonication cycle, the plates were centrifuged twice at 4 ◦C and 3200 x g for 30 min. The
supernatant was transferred to another 96-well plate and stored at -20 ◦C until analysis in the
GX II system.
2.2.4 Scale-up Culture
A scale-up culture from the 1 mL micro-scale cultivation yielding highest VP1 titers to a 2.5 L
shake flask culture was realized by keeping the oxygen transfer rate constant, as shown by
Hermann et al. [45]. The corresponding shaking frequency for scale-up (180 rpm) was taken
from Baumann et al. [41]. The TB medium at pH 6 included 2 mM magnesium sulfate and the
induction was carried out at OD600 nm of 0.5 AU with 0.5 mM IPTG. 20 h after inoculation, the
cells were centrifuged at 3200 x g and 4 ◦C for 30 min. Product release under native conditions
was performed by sonication using a Digital Sonifier R© 450 equipped with a 1/2” extension
cylindrical sonication probe. The cell pellets from 400 mL culture were suspended in 20 mL
native lysis buffer for purification experiments. The sonication procedure was carried out at an
amplitude of 70% applying 8 cycles of 15 s pulse duration (each cycle followed by 30 s chilling
on ice). The lysates were centrifuged twice at 10 ◦C and 18,000 x g for 30 min, followed by a
0.45 µm filtration step using PES filters by Sartorius, Germany.
2.3 Downstream Process Development
VP1 expressed in E. coli Rosetta cells was purified by anion-exchange (AEX) membrane chro-
matography and size-exclusion chromatography (SEC). A clarified E. coli lysate (1 mL) was
loaded onto a 3 mL Sartobind R© Q Nano Membrane Capsule (Sartorius Stedim Biotech GmbH,
Goettingen, Germany) at 3 mL/min and purified by applying a salt step elution with NaCl.
Pooled VP1 fractions of the AEX eluate were further processed on a Superose 6 R© Increase
10/300 GL column (Ge Healthcare, Uppsala, Sweden) at a flow rate of 0.5 mL/min. Purified
VP1 was finally assembled into VLPs by dialysis into the assembly buffer, followed by dialysis
against PBS for 16 h prior to analysis by transmission electron microscopy (TEM).
2.4 Analytical Methods
2.4.1 SDS-PAGE & Western Blot
For gel electrophoresis, the TCA pellet from the total protein extraction protocol was dis-
solved in 1X NuPAGE R© LDS sample buffer, including 12.5 mM DTT for gel electrophoresis
(OD600nm · 200 µL), for 2 h in an overhead shaker. For native samples in solution, the sample
preparation was performed according to the Novex R© NuPAGE R© 4-12% Bis-Tris protein gel
143
manual [46]. Purified VP1 derived from the GST-tag process developed by Middelberg et al.
[19] served as reference standard. All samples were denatured at 100 ◦C and 300 rpm for 15 min
on a plate shaker with lid heating. All following steps were carried out as described in the user
manual. For each set of samples, two distinct gels were created, one for western blotting without
staining and another stained with ’blue silver’ staining solution.
Proteins were transferred from SDS-PAGE gels to a nitrocellulose membrane at 30 kV for 1 h
using the XCell II
TM
blot module from Life Technologies, USA. Washing, blocking with 5%
BSA, and incubation with primary and secondary antibodies were performed according to the
user manual [47]. Rabbit-derived anti-VP1 antibody was a gift of Prof. Robert Garcea [42] and
was used as primary antibody. Alkaline phosphatase affinity-purified donkey anti-rabbit IgG
(Jackson ImmunoResearch Laboratories, USA) served as secondary antibody. Product detec-
tion was carried out using alkaline phosphatase color reagents (BioRad Laboratories, USA). All
gels and membranes were analyzed in a Bio-5000 gel scanner.
2.4.2 Capillary Gel Electrophoresis
For quantitative determination of purities and VP1 concentrations, all samples were analyzed in
a LabChip R© GX II capillary gel electrophoresis device as duplicates with an HT Protein Express
LabChip R© kit. Purified VP1 derived from the GST-VP1 process developed by Middelberg et
al. [19] served as reference standard. The sample and chip preparation procedures for liquid
samples were performed as described in the manufacturer’s protocol for the HT Protein Express
Assay [48]. In contrast to this, the dried samples from the TCA extraction were dissolved in
100 µL HT Protein Express sample buffer, including 34 mM of DTT. All further steps followed
the above-mentioned protocol for liquid samples. Sample analysis was carried out using the
HT Protein Express 200 assay in the LabChip R© GX 3.1 software. Product quantification was
based on peak-baseline integration of the product peak and comparison to a lysozyme standard
of 1 mg/mL.
2.4.3 DNA Quantification
PicoGreen R© dsDNA assay kit (Invitrogen, Paisley, United Kingdom) was used to quantify DNA
according to the manufacturer’s instructions. Samples were diluted ten fold with TE buffer prior
to measurement.
2.4.4 Transmission Electron Microscopy
Visualization and characterization of assembled virus-like particles were carried out by transmis-
sion electron microscopy (TEM) on a CM 200 FEG/ST electron microscope. Sample preparation
was performed as described previously by Ladd Effio et al. [49].
3 Results & Discussion
3.1 Codon Optimization & Product Detection
The expression of virus proteins in E. coli depends on various parameters, such as strain and
vector design, promoter, cultivation and induction conditions, as well as on codon usage. First
cultures with E. coli Rosetta(DE3)pLysS cells and the pALVP1TAC [42] plasmid showed very
poor yields below 1% of total soluble protein (TSP) (data not shown) following cultivation pro-
tocols by Chuan et al. [30]. Chuan et al. [30] demonstrated the presence of several rare codons
in the pALVP1TAC-derived insert of pGexVP1. Hence, we sequenced pALVP1TAC and looked
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for under-represented codons in the E. coli genome. According to Henaut et al. [50], Chen et
al. [51], and Nakamura et al. [52], codons which are considered rare in E. coli are AGG, AGA,
CGG, and CGA encoding for arginine, GGA encoding for glycine, ATA encoding for isoleucine,
CTA encoding for leucine, and CCC encoding for proline. As shown in Fig. 1, seven of these
rare codons are represented in the insert of the VP1 sequence.
Aiming at a higher protein expression, the sequence was codon-optimized for E. coli by
Centic Biotec (Heidelberg, Germany), obtaining a modified insert sequence than Chuan et al.
[30] (85% identity). Subsequently, the codon-optimized DNA sequence was inserted into a vec-
tor with a tac promoter and transformed into E. coli Rosetta cells (see section 2.2.1). For
the proof of concept, expression of the product of interest on the shaker flask scale was evalu-
ated by several analytical methods: SDS-PAGE, western blot, capillary gel electrophoresis, and
reversed-phase ultra-high-performance liquid chromatography (data not shown). Fig. 2 shows
an overview of the different procedures for the detection of VP1 in E. coli cell lysates with and
without the constructed pTacVP1 plasmid. A protein ladder and a VP1 standard are included
in each of the analytical technologies. Fig. 2A illustrates the VP1 identification using capillary
gel electrophoresis, showing virtual gels with VP1 highlighted as a red box. The VP1 standard
(red) was detected at 49 kDa (aligned time of 21.7 s inside the capillary). Accordingly, the
transformed E. coli Rosetta pTacVP1 strain (black) revealed a pronounced peak at the same
molecular weight as the VP1 standard, whereas the E. coli Rosetta wild type (blue) shows low
fluorescence at 49 kDa only. In Fig. 2B the product-specific western blot is illustrated with
VP1 highlighted as a red box. Lane 1 represents the VP1 standard, lane 2 and 3 include the
total protein extracts of E. coli Rosetta pTacVP1 and the Rosetta wild type respectively. The
VP1 standard (lane 1) revealed an identical band pattern in the western plot as as the total
protein extract of E. coli Rosetta pTacVP1 (lane 2). The gel bands of the total protein extract
of the E. coli Rosetta wild type (lane 3), by contrast, were insensitive to the product-specific
antibody.
Different orthogonal analytical methodologies, namely, capillary gel electrophoresis, SDS-PAGE,
western blot, as well as reversed-phase chromatography (data not shown), indicated the pres-
ence of VP1 in the codon-optimized E. coli Rosetta pTacVP1 strain. As shown in the E. coli
Rosetta wild type lysate, a minor amount of impurities was detected with the same molecular
weight as VP1. The weak bands of the E. coli Rosetta wild type lysate (Fig. 2B, lane 3) is
explained by cross reactivity of the proteins to the primary antibody for VP1, as reported by
Leavitt et al. [42].
3.2 High-throughput Cultivations
3.2.1 Growth Curves
The high-throughput cultivation experiments covered shaking speeds of 600 rpm and 1200 rpm,
temperatures of 27, 32, and 37 ◦C, two medium pH values of pH 6 and pH 7, two additive setups
(w and w/o 2 mM magnesium sulfate), two induction times of OD600 nm = 0.5 AU and 4 AU,
as well as two inducer concentrations of 0.1 mM and 0.5 mM IPTG. The growth curves for
all conditions investigated are illustrated in Fig. 3 with separated plots for the different combi-
nations of temperature and shaking speeds. In each individual plot, cultivations performed at
pH 6 are marked in red and at pH 7 in blue (dark colored conditions include 2 mM magnesium
sulfate). Conditions induced at an OD600 nm of 0.5 AU are illustrated as lines (dashed lines for
induction using 0.1 mM IPTG, solid lines for 0.5 mM IPTG), whereas inductions at OD600 nm
of 4 AU are shown as markers (asterisk for induction using 0.1 mM IPTG, circles for 0.5 mM
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Figure 1 Codon optimization of the VP1 sequence for recombinant protein expression in E. coli. The
original DNA sequence of VP1 is illustrated above the sequence after codon optimization (VP1∗) with
rare codons highlighted in red. Unchanged sequences in the VP1 genetic code are indicated by lines.














Figure 2 Product (VP1) identification out of a crude feedstock of transformed E. coli Rosetta pTacVP1.
A: Capillary gel electrophoresis of a purified VP1 standard, an E. coli Rosetta pTacVP1 lysate, and an
E. coli Rosetta wild type lysate. VP1 is detected at 49 kDa in the virtual gel. B: Western blot of a
purified VP1 standard (lane 1), an E. coli Rosetta pTacVP1 lysate (lane 2), and an E. coli Rosetta wild
type lysate (lane 3). The relevant product-related bands are highlighted in red at a molecular weight of
45 kDa.
IPTG).
The lag phase of the E. coli Rosetta pTacVP1 cells decreases steadily from 27 ◦C (6 to 7 h) up to
37 ◦C (3 h), shifting the induction times (downward triangles) closer to the time of inoculation
(0 h). All other factors show negligible impact on the lag phase, with the medium pH being the
only exception. In all setups the lag phase of cells cultivated at pH 6 is elongated compared
to those grown at pH 7, most pronounced for the cells cultivated at 27 ◦C. The increased time
until starting the exponential phase for cultivations at lower temperatures is intuitive due to
the decrease in metabolic activity of E. coli cells at a temperature other than the optimum of
37 ◦C. The negative effect of acidic pH on the lag phase is due to E. coli having its pH optimum
in the neutral region.
The shape of the exponential growth shows highest variations when comparing conditions of
different shaking speeds. All cells cultivated at 1200 rpm (right graphs, Fig. 3) display an ideal
exponential growth until the stationary phase. In contrast to this, all cultivations performed at
600 rpm result in multiple varying slopes of the exponential growth separated by intermediate
plateaus. This effect is pronounced for cells cultivated at pH 7. Such behavior was also de-
scribed by Funke et al. [53] for E. coli when accumulating acidic metabolites under fermenting
conditions. Lower shaking frequencies (600 rpm - KLa = 85.9 1/h) result in poor mixing and
low oxygen uptake into the medium inducing such fermenting conditions. Cultivations per-
formed at pH 6 are less influenced as cells grow under ’pseudo-fermenting’ conditions starting
from inoculation due to the acidic environment.
The final plateaus of the stationary phase are elevated for all conditions at a shaking speed of
1200 rpm compared to those at 600 rpm, yielding a maximal scattered light plateau of 285 SU at
27 ◦C. In comparison, the maximal scattered light signal for the same temperature at 600 rpm
is about 40% lower (180 SU). With an increase in temperature up to 37 ◦C, this effect is
less pronounced. Whereas the stationary phase plateaus vary significantly for different shaker
speeds and temperatures, all other cultivation factors investigated are negligible. As discussed
above, higher shaking speeds result in a better oxygen uptake into the medium (1200 rpm -
KLa = 371.6 1/h) and, thus, enhance growth under aerobic conditions.
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= 0.5 AU (0.1 mM IPTG)
Ind. OD
600 nm
= 0.5 AU (0.5 mM IPTG)
Ind. OD
600 nm
= 4 AU (0.1 mM IPTG)
Ind. OD
600 nm
= 4 AU (0.5 mM IPTG)
pH 6 (- Mg)
pH 6 (+ Mg)
pH 7 (- Mg)
pH 7 (+ Mg)
Induction time
Figure 3 BioLector R© growth curves of E. coli Rosetta pTacVP1 under different cultivation conditions:
Temperatures of 27, 32, and 37 ◦C and two shaking speeds of 600 and 1200 rpm were investigated. For
each setup, four distinct media compositions were examined, being two pH values of pH 6 (red curves)
and pH 7 (blue curves) with (dark colored) and without (light colored) addition of 2 mM magnesium
sulfate. As a final factor, four different induction setups were investigated, being the induction times
OD600 nm of 0.5 (lines) and 4 (markers) using 0.1 mM (dashed line/ asterisk) or 0.5 mM IPTG (solid
line/ circle), respectively.
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3.2.2 Soluble VP1 Fraction
The soluble protein fraction of cells after sonication and lysate clarification for all conditions
investigated is shown in Fig. 4 as 3D bar plots. Again, plots are separated for different combina-
tions of shaking speeds and temperatures. All VP1 concentrations cV P1 are normalized to the
maximal concentration attained under all conditions cV P1,max of 1.63 mg/mL ± 0.13 mg/mL
(37 ◦C, 600 rpm, pH 6, including 2 mM magnesium sulfate, induced at OD600 nm of 0.5 AU
using 0.5 mM IPTG).
All cultivations performed at 1200 rpm (right) resulted in lower VP1 titers compared to those
at shaker speeds of 600 rpm (left), with the highest value 38.8% ± 4.5% at 27 ◦C and 1200
rpm compared to the overall maximum cV P1,max. A decrease in temperature is beneficial for
the formation of soluble VP1 at 1200 rpm, shifting cV P1/cV P1,max from up to 16.4% ± 1.9% at
37 ◦C to 38.8% ± 4.5% at 27 ◦C. Nevertheless, the maximal VP1 concentration investigated at
1200 rpm was below that of most conditions examined for 600 rpm shaking speed, ranging from
cV P1/cV P1,max of 30.8% ± 4.2% to 100% ± 8.2%. For experiments performed at 600 rpm, the
VP1 concentration in the soluble protein fraction follows an inverse trend towards cultivation
temperature, shifting cV P1/cV P1,max from up to 49.2% ± 4.9% at 27 ◦C to 100% ± 8.2% at
37 ◦C. For 32 ◦C and 37 ◦C, additional pH effects become apparent, showing a positive effect for
cells cultivated under acidic conditions (pH 6) compared to experiments performed in a medium
of pH 7. The addition of 2 mM magnesium sulfate did not show pronounced effects in all setups
investigated. Also the induction time and inducer concentration were determined to be factors
of minor importance.
These findings of high native protein production under fermenting conditions with low oxygen
supply and increased temperature agree with the findings of Baumann et al. [41] for glutathione-
S-transferase and Losen et al. [54] for benzoylformate decarboxylase. However, they contradict
the experiments of Chuan et al. [30], who found an optimal production of 0.18 mg/mL VP1
at a decreased temperature of 26 ◦C. Note that the maximal VP1 concentration in this study
of 1.63 mg/mL ± 0.13 mg/mL corresponds to an increase of approximately a factor of 10 com-
pared to Chuan et al. [30]. Nevertheless, both Chuan et al. [30] and Liew et al. [55] conclude
that growth limiting cultivation conditions lead to increased product titers of VP1 or GST-
VP1, respectively. Finally, the pH of the cultivation medium was found to be an important
factor for enhancing native VP1 production. The effect of increased soluble protein production
under acidic conditions was also reported by Kopetzki et al.[56] for α-glucosidase produced in
E. coli. As fermenting conditions with acidic by-products have a positive impact on soluble VP1
formation, the decreased pH after inoculation can enhance this effect. Whereas the negligible
influence of the inducer concentration on the product formation agrees with Baumann et al.
[41], the low impact of the induction time investigated in this study is in contradiction, as was
also reported by Galloway et al. [57].
When comparing the trends of the growth curves to the soluble VP1 titers, there is a clear
correlation of increased productivity of E. coli cells under non-optimal growth conditions. All
experiments performed at high shaker speed (1200 rpm) resulted in unlimited growth (Fig. 2,
right) and, consequently, yielded low titers on soluble VP1 (Fig. 3, right). Fermenting condi-
tions at 600 rpm shaker speed, by contrast, resulted in varying slopes of the exponential growth
separated by intermediate plateaus and were found beneficial for soluble VP1 formation with
product concentrations of up to 1.63 mg/mL ± 0.13 mg/mL (Fig. 3, left). Note that excess
stress on cell growth, as shown for fermenting conditions (600 rpm) and low cultivation temper-







































































































































































































































Figure 4 Soluble protein fraction of lysed cells shown in 3D bar plots. Separated plots are shown
for different combinations of shaking speeds (600 rpm and 1200 rpm) and temperatures (27, 32, and
37 ◦C). Results for different media compositions (pH and magnesium sulfate concentrations), induc-
tion times, and inducer concentrations are shown for each individual sub-plot. All VP1 concentra-
tions cV P1 are normalized to the maximal concentration attained under all conditions cV P1,max being
1.63 mg/mL ± 0.13 mg/mL.
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3.2.3 Ratio of VP1 to Total Soluble Protein
Besides the overall product titer of soluble VP1, also the initial purity of the sample (ratio
of VP1 to total soluble protein) is an important factor for subsequent purification processes.
A comparison of soluble VP1 titers and total soluble protein (TSP) is shown in Fig. 5A. The
different combinations of temperature and shaker speeds are indicated as different markers,
whereas different media compositions are highlighted as colors. All data points were fitted with
a linear regression function yielding a coefficient of determination R2 of 85.6%, indicating that
the purity of the samples increased linearly with the amount of produced soluble VP1. All cell
lysates derived from cultivations at 1200 rpm are found in the bottom left corner of Fig. 5A
(circles, upward triangles, diamonds). 600 rpm cultures, by contrast, are found at higher soluble
VP1 and TSP values in Fig. 5A (asterisks, downward triangles, hexagrams) with the overall
best result found for the 37 ◦C cultivations (hexagrams), as was discussed earlier. The linear
increase of TSP with soluble VP1 indicates a product enrichment without causing additional
upward regulation of impurity levels. Fig. 5B illustrates this effect of shaker speed and tem-
perature on the VP1 titer and the TSP for lysates from cultivations equivalent to the optimal
system point (1.63 mg/mL ± 0.13 mg/mL VP1) by capillary gel electrophoresis runs. In the
electropherograms the VP1 peak is highlighted at an aligned time of 21.7 s (49 kDa). Green
lines illustrate analyzed lysates from cultivations performed at 600 rpm (27, 32, and 37 ◦C)
whereas red lines represent lysates from 1200 rpm cultivations. Whereas impurity levels are
constant, VP1 levels vary strongly, most pronounced when comparing 37 ◦C - 600 rpm as the
maximum VP1 concentration and 37 ◦C - 1200 rpm as the condition of low expression levels.
The overall optimal system point for both soluble VP1 and TSP was found for the optimum
identified in the ’Soluble VP1 fraction’ section, resulting in a TSP of 42.6% with a concentra-
tion of 1.63 mg/mL ± 0.13 mg/mL soluble VP1 (arrow in Fig. 5A). Hence, the system point
of 37 ◦C, 600 rpm, pH 6, including 2 mM magnesium sulfate, induced at OD600 nm of 0.5 AU
using 0.5 mM IPTG was selected for scale-up and downstream process development, as both
initial purity and product levels were optimal under the investigated upstream conditions.
3.2.4 Ratio of Soluble to Total Expressed VP1
Apart from the soluble VP1 fraction, also the total product fraction, including insoluble species,
was determined using a TCA protocol for total protein extraction under denaturing conditions
(Fig. 6). Fig. 7 illustrates the ratio of soluble to total expressed VP1 for each setup. For culti-
vations performed at 1200 rpm, the fraction of soluble VP1 is low, ranging from 4.6% to 39.1%
compared to experiments at 600 rpm, where the fraction ranges from 20.9% to 106.1%. The
optimal ratio of soluble to total VP1 was obtained for cells grown at 600 rpm and 27 ◦C, the
range being 67.4% to 106.1%. Under these conditions, the neutral medium condition of pH 7
was beneficial compared to pH 6. The same trend was found for cultivations at 600 rpm under
32 ◦C as well as 37 ◦C. 32 ◦C was found to be the condition of the lowest soluble to insoluble







































































































































































































































Figure 5 Impurity levels of the different lysates investigated in the BioLector R© screening. A: Ratio of
VP1 to total soluble protein, including a linear regression of data points. The different combinations of
temperature and shaker speeds are indicated as different markers and different media compositions are
highlighted as colors. B: Comparison of the impact of shaker speed and temperature on the VP1 titer and
the impurity levels shown for the media conditions of the overall optimal system point (pH 6, including
2 mM magnesium sulfate, induced at OD600 nm of 0.5 AU using 0.5 mM IPTG). Electropherograms of
these 6 combinations of temperature and shaking speed, with green lines representing cultivations at
600 rpm (27, 32, and 37 ◦C) and red lines at 1200 rpm (27, 32, and 37 ◦C) and the VP1 peak at an
aligned time of 21.7 s (49 kDa).











































































































































































































































































Figure 6 Total (soluble and insoluble) VP1 fraction shown in 3D bar plots. Separated plots are shown
for different combinations of shaking speeds (600 rpm and 1200 rpm) and temperatures (27, 32, and 37
C). Results for different media compositions (pH and magnesium sulfate concentrations), induction times
and inducer concentrations are shown for each individual sub plot. All VP1 concentrations cTCA,V P1
are normalized to the maximal concentration attained in all conditions cTCA,V P1,max.
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Figure 7 Ratio of soluble to total expressed VP1 of lysed cells shown in 3D bar plots. Separated plots
are shown for different combinations of shaking speeds (600 rpm and 1200 rpm) and temperatures (27,
32, and 37 ◦C). Results for different media compositions (pH and magnesium sulfate concentrations),
induction times, and inducer concentrations are shown for each individual sub-plot.
It was shown that a good mixing and oxygen uptake at 1200 rpm do not only result in low
soluble VP1 titers as discussed earlier, but also in the formation of aggregates and inclusion
bodies. Poor shaking at 600 rpm shaker speed, by contrast, resulted in ratios of soluble VP1 of
up to 100%, mostly for conditions of reduced temperature, as was reported by other research
groups [55, 58, 59, 56]. Note that a factor of 100% does not imply optimal conditions for yielding
high overall product titers (compare Fig. 3), but conditions of non-soluble VP1 formation. For
the condition of highest productivity of 1.63 mg/mL ± 0.13 mg/mL VP1, the ratio of soluble
product was determined to be 72.8%, indicating an economic system point for scale-up, as was
discussed earlier.
3.3 VP1 Purification & Assembly of Virus-like Particles
The development of an alternative production pathway for murine polyoma VLPs without an
affinity protein tag entails the establishment of a novel downstream process. Fig. 8 summarizes
the outcome of the purification procedure with chromatograms for the capture and polishing
step, electropherograms of VP1 process samples, and a TEM micrograph of assembled murine
polyoma VLPs.
Capturing of VP1 from clarified E. coli cell lysate was performed by anion-exchange mem-
brane chromatography. The chromatogram of the optimized salt step elution is shown in Fig. 8A.
UV absorption (blue line), conductivity signals (dashed gray line), and VP1 concentration (green
bars) are plotted against the mobile phase volume. Virtual gels for all fractions are plotted be-
low the chromatogram to track the elution of VP1 and HCPs. As shown in the chromatogram
of Fig. 8A, VP1 eluted mainly in the second salt step removing weaker and stronger charged
molecules in a low salt step at 0.09 M NaCl and a high salt step at 1 M NaCl, respectively. 69
± 4 % VP1 were recovered in the second salt step with a protein purity of 61 ± 0.9 % in the































































































































Figure 8 VP1 purification and VLP assembly procedure. A: Chromatogram of the AEX step for VP1
capturing. The UV signal is illustrated as a blue line, the conductivity is shown as a dashed line, and
the VP1 concentrations are marked as green bars. The product-containing fractions are magnified in
virtual gels of the capillary gel electrophoresis procedure, with the VP1 fraction shown at 49 kDa. B:
Chromatogram of the SEC step for VP1 polishing. The UV signal is illustrated as a blue line and
the VP1 concentrations are marked as green bars. The product-containing fractions are magnified in
virtual gels of the capillary gel electrophoresis procedure with the VP1 fraction shown at 49 kDa. C:
Electropherograms of the cell lysate (blue solid line), the pooled elution fraction after AEX (black dashed
line), and the purified product after SEC polishing (red solid line). The VP1 peak is detected at 21.6 s of
aligned time. D: TEM micrographs of the generated VLP sample after VLP assembly, showing spherical
homogeneous particles (diameter of 40-50 nm).
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pooled fractions. Fig 8B shows the chromatogram of the polishing step by size-exclusion chro-
matography for VP1 captured by anion-exchange membrane chromatography. The UV signal
(blue line) reveals four major peaks. VP1 (green bars) elutes in the major peak at a retention
volume of 15 mL, separating smaller host cell impurities (10 to 40 kDa) as displayed in the
virtual gels of the FPLC fractions. The final protein purity of the pooled VP1 fractions was
92 ± 2 % with 6 ± 1 ng DNA per 100 µg VP1, recovering 58 ± 1.5 % of VP1. In Fig. 8C
capillary gel electrophoresis analysis of clarified cell lysate (dashed black line), captured VP1
(blue line), and polished VP1 (red line) is compared in an electropherogram. The comparison
reveals the high purity achieved at the end of the two-step downstream process with only one
minor impurity left. The cell lysate obtained from the 2.5 L shaker flask-scale fermentation
showed almost the same VP1 concentration of 1.5 ± 0.2 mg/mL as in the 1 mL micro-scale
cultivation and a similar TSP value of 42 ± 2 % .
Purified VP1 at a concentration of 0.3 mg/mL was finally assembled to VLPs, as described
earlier by Middelberg et al. [19]. Fig. 8D shows the TEM micrographs of the generated VLP
sample, revealing spherical homogeneous particles with diameters of 40-50 nm. The empty par-
ticles can hardly be distinguished from those murine polyoma VLPs produced by Middelberg
et al. [19, 27] or Ewers et al. [60]. While the overall recovery of the downstream process should
still be optimized, the concept was proven by purifying non GST-tagged VP1 with a rapid and
scalable two-step purification procedure, yielding a protein and DNA purity close to threshold
values in licensed VLP-based vaccine formulations [6]. Both anion-exchange chromatography
and size-exclusion chromatography currently are the methods of choice for the purification of
numerous viral or VLP-based vaccines and vaccine candidates [61, 62, 63, 64]. Thus, an indus-
trially common downstream process setup was developed for the processing of VP1 capsomeres.
4 Conclusion
Generating high numbers of vaccine doses in short time and at low cost remains the main chal-
lenge for the vaccine industry, especially in the light of pandemic threats and arising pathogens.
VLPs represent promising nanocarriers for antigen epitopes of pathogens, but still lack straight-
forward and easily controllable upstream and downstream procedures.
In this study, we aimed at optimizing both expression and purification methods of the murine
polyoma VLP platform by using a high-throughput screening procedure for micro-scale up-
stream process development and product analysis. A novel insert and expression system was
designed and used to produce up to 1.63 mg/mL ± 0.13 mg/mL VP1. The highest product
titers were obtained at a high temperature (37 ◦C), a low oxygen supply at 600 rpm shaker
speed, and a acid pH of 6. To the best of our knowledge, this exceeds all reported VLP yields
achieved in shaker flask cultivations so far. In general, the micro-scale cultivations suggested
that induced stress during cell growth and product formation (e.g. by oxygen limitation or
acidic pH) is beneficial for high titers of soluble product. The main parameter was identified to
be the oxygen supply that needed to be low to ensure fermenting conditions.
For proof of concept, VP1 derived from 2.5 L shaker flask cultivations was purified by a simple
two-step downstream process and finally assembled into homogeneous, spherical particles. The
produced VLPs constitute an ideal potential carrier platform for the presentation of antigen
epitopes, packaging of small molecules, DNA or as a model nanoparticle or viral system. The
microbial murine polyoma VLP platform has been advanced significantly towards an industri-
ally feasible option for tailored vaccines. Future research should now focus on applying the
optimized process conditions to the production and clinical evaluation of novel chimeric VLP
constructs.
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The development and manufacturing of safe and effective vaccines relies essentially on the avail-
ability of robust and precise analytical techniques. Virus-like particles (VLPs) have emerged as
an important and valuable class of vaccines for the containment of infectious diseases. VLPs are
produced by recombinant protein expression followed by purification procedures to minimize the
levels of process- and product-related impurities. Monitoring of these impurities is mandatory
during process development and manufacturing. Especially the characterization and control of
the VLP structure and dispersity are crucial issues for a safe and effective vaccine. Currently
used methods require long analysis times and tailor-made assays. In this work, we present a
size-exclusion ultra-high performance liquid chromatography (SE-UHPLC) method to charac-
terize VLPs and quantify aggregates within 3.1 min per sample applying interlaced injections.
Four analytical SEC columns were evaluated for the analysis of human B19 parvo-VLPs and
murine polyoma-VLPs. The optimized method was successfully used for the characterization
of five recombinant protein-based VLPs including human papillomavirus (HPV) VLPs, human
enterovirus 71 (EV71) VLPs, and chimeric hepatitis B core antigen (HBcAg) VLPs pointing out
the generic applicability of the assay. Measurements were supported by transmission electron
microscopy and dynamic light scattering. It was demonstrated that the iSE-UHPLC method
provides a rapid, precise and robust tool for the characterization of VLPs. Two case studies
on purification tools for VLP aggregates and storage conditions of HPV VLPs highlight the
relevance of the analytical method for high-throughput process development and process mon-
itoring of virus-like particles.
Keywords: Virus-like particle vaccines, Size-exclusion HPLC, Papillomavirus, Aggregates,
High-throughput analytics, Process Analytical Technology
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1 Introduction
Control, prevention, and therapy of infectious diseases, cancer, and chronic diseases remain
major challenges for our global health system. In recent years, novel promising vaccination and
immunotherapy prospects for public health threats have been arising from the development of
virus-like particles (VLPs). VLPs are protein assemblages which are produced by recombinant
expression of viral structural proteins in prokaryotic or eukaryotic cells [1, 2]. Thus, the struc-
ture and morphology of highly pathogenic viruses such as HIV [3], Influenza, [4] and Ebola
[5] can be mimicked or tailor-made nanocarriers for antigen epitopes can be designed. Such
chimeric VLPs are especially interesting for the development of generic vaccine platforms [6],
the prevention of malaria (RTS,S vaccine) [7], and the immunotherapy of cancer [8], chronic
diseases [9], and Alzheimer’s disease [10].
Due to the production in genetically modified expression hosts, the analysis of product-related
and process-related impurities is crucial during development and manufacturing of VLP vaccines
[11, 12]. Process-related impurities such as host cell proteins (HCPs), DNA, and endotoxins can
be rapidly detected and assessed by methods standardized in the biopharmaceutical industry for
therapeutic proteins and antibodies such as capillary electrophoresis, ELISA, real-time PCR,
etc. [13]. In contrast, quantitative analysis of product-related impurities such as aggregates is
more challenging and mostly tailor-made for each vaccine due to the large size and complexity
of VLPs. Traditionally, VLP characterization is often done by transmission electron microscopy
(TEM) requiring high investment costs, extensive sample and instrument preparation work, and
specialized staff. In addition, sample preparations such as staining, coating on carbon grids,
and drying might affect the VLP structure and dispersity. A faster and widely used technology
for VLP characterization is dynamic light scattering (DLS) [14, 15, 16]. The method allows
the determination of hydrodynamic particle diameters and particle dispersity by measuring the
fluctuations of light scattering from particles in solution. However, DLS is less sensitive in
resolving aggregates and VLPs [17]. Hence, quantitative VLP characterization is difficult to
realize by both TEM and DLS. Currently used quantitative methods for VLP aggregates are
asymmetrical flow field-flow fractionation (AF4) [18, 19, 17], disc centrifugation particle size
analysis [20], electrospray differential mobility analysis [19], and size-exclusion chromatography
(SEC) [21]. However, these techniques are very time-consuming with typical analysis times
ranging from 30 to 60 min per sample [18, 19, 17, 21].
SEC is probably the most widely used technique for aggregate quantification in the biophar-
maceutical industry [22]. SEC methods have been successfully applied for process monitoring
during development phases of capsomere vaccines [23], recombinant fusion protein vaccines
[16], human hepatitis B virus core antigen (HBcAg) VLPs [21], and human hepatitis B virus
surface antigen (HBsAg) VLPs [24, 25, 26, 27]. In recent years, SEC columns and periphery
equipment have been constantly developed moving towards smaller adsorber particle sizes and
low-dispersion ultra-high performance liquid chromatography (UHPLC) instrumentation [28].
Rapid SE-UHPLC methods have been realized for monoclonal antibodies by performing inter-
laced sample injections instead of single injections with analysis times of 2-6 min [29, 30]. Fig.1
shows a schematic drawing of the principle of interlaced SEC (iSEC) methods. The ’informa-
tion phase’ (green) in a SEC run is the time range including the elution of relevant species
(aggregates, monomer). The longest phase in a classical SEC method run (single injection) is
the ’lag phase’ (blue) in the beginning, which is the time range from injection to elution of the
first species. The ’hold- up’ (blue) phase refers to the time from the end of the information
phase to the column’s void time defined by the elution of small molecules such as salts. In
order to reduce the total analysis time of SEC methods without changing the performance of
’information phases’ the ’lag phase’ can be eliminated by injecting subsequent samples prior to
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the complete elution of previous sample components. This operation is referred to as interlaced
injection mode.
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Figure 1 Schematic illustration of SEC chromatograms for single- and interlaced-injection mode of an
analyte containing aggregates and monomer. Information phases are marked by green colored bars, lag
and hold-up phases by blue colored bars. Timelines for the program of the autosampler (AS) and pump
and the diode array detector (DAD) are presented for two sequent injections in single- and interlaced-
injection mode.
In this work, we present the development and application of an iSE-UHPLC method for recom-
binant protein-based VLPs. The feasibility of the assay was evaluated for human papilloma
(HPV) VLPs [31], human enterovirus 71 (EV71) VLPs [32], murine polyomavirus (MuPyV)
VLPs [6], human B19 parvo (B19 VP1/VP2) VLPs [33]., and chimeric HBcAg VLPs [8]. Two
case studies are presented for the application of the iSE-UHPLC during downstream process
development and stability studies. The designed method allows a rapid assessment of VLP dis-
persity and is well-suited for high-throughput pharmaceutical process development and process
monitoring of VLPs in preclinical, clinical and postlicensing phases.
2 Materials & Methods
2.1 Disposables
For precipitation screenings, sample storage, fractionation by FPLC and UHPLC, 350 µL-
polypropylene plates (Greiner Bio-One, Kremsmünster, Austria) were used. Stability studies
with HPV VLPs were performed in 1.5 mL-polypropylene Eppendorf R© Safe-Lock Tubes (Ep-
pendorf, Hamburg, Germany). Frozen VLPs were thawed and centrifuged in the same tubes at
18,000 x g and 4◦C for 10 min. All buffer solutions were sterile filtered with 0.2 µm cellulose
acetate filters (Sartorius AG, Göttingen, Germany). Buffer exchange was performed with PD-10
desalting columns (GE Healthcare, Uppsala, Sweden).
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2.2 Chemicals & Buffers
For the SE-UHPLC method, K2HPO4 was obtained from VWR BDH Prolabo (Radnor, Penn-
sylvania, USA). MOPS was purchased from Carl Roth GmbH& Co. KG (Karlsruhe, Germany).
The SEC standard proteins thyroglobulin from bovine thyroid and uracil were purchased from
Sigma-Aldrich (St. Louis, MO, USA) and Alfa Aesor (Ward Hill, MA, USA), respectively.
All other chemicals were obtained from Merck KGaA (Darmstadt, Germany). All buffer solu-
tions were prepared with ultra pure water drawn from a water purification system provided by
Sartorius (Goettingen, Germany). UHPLC analysis was conducted with buffers composed of
0.2 M K2HPO4 and 0.25 M KCl. The pH value was set at pH 7.0 for characterization studies
with HPV VLPs and pH 7.4 for the SEC analysis of other VLPs. Semi-preparative purifications
of B19 VP1/VP2 VLPs were performed by aqueous two-phase extraction and precipitation with
PEG 4000 as described previously [34] and by anion-exchange membrane chromatography [35].
PBS buffer at pH 7.4 was used as mobile-phase buffer for chromatography experiments with a
semi-preparative SEC column. 0.2 M K2HPO4 pH 7 with 0-0.5 M KCl and 0.2 M MOPS pH 7
with 0-0.5 M NaCl were used to evaluate the stability of HPV VLPs at varying ionic strengths.
2.3 Virus-like Particles
The general applicability of an interlaced SE-UHPLC method for VLP characterization was
evaluated with several purified VLPs differing in size, morphology, expression hosts, and num-
ber of viral proteins. An overview of analyzed VLPs is given in Table 1.
Table 1 Overview of evaluated virus-like particles. BEVS/IC: baculovirus expression vector/ insect
cell system; EV: enterovirus; HBV: hepatitis B virus; HPV: human papilloma virus; MuPyV: murine
polyomavirus.







S. cerevisiae L1 (55 kDa) 40-60 nm [42,
15]
MuPyV Polyomaviridae E. coli VP1 (42 kDa) 40-50 nm [6]
HBV Hepadnaviridae E. coli core antigen (21
kDa)
30-34 nm [50]













HPV VLPs (HPV type 33 [31]) derived from yeast cells were kindly provided by Merck & Co
(Kenilworth, NJ, USA) at a concentration of 0.8 mg/mL in a formulation buffer containing
histidine and polysorbate 80 (pH 6.2). HPV VLPs were purified by several chromatography and
filtration steps as reported by Cook et al. [36]. MuPyV VLPs were produced at shaker flask
scale in Escherichia coli cells, purified using the GST affinity tag process published by Middel-
berg et al. [6], and dialyzed into PBS (pH 7.4) yielding a final concentration of 0.3 mg/mL.
Human enterovirus 71 (EV71) VLPs derived from Spodoptera frugiperda Sf 9 insect cells were
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kindly supplied by Sentinext Therapeutics (Penang, Malaysia) in a Tris buffer (pH 7.5) at a
concentration of 0.1 mg/mL. Chimeric HBcAg VLPs with fused tumor epitopes were expressed
in E.coli and generously provided by BioNTech Protein Therapeutics (Mainz, Germany) in
a Tris buffer (pH 7.2) at a concentration of 2.18 mg/mL. B19 VP1/VP2 VLPs were kindly
provided by Diarect AG (Freiburg, Germany) at a concentration of 0.5 mg/mL: VLPs were
produced in Sf 9 insect cells, purified by several ultracentrifugation steps and dialyzed into a
phosphate buffer (pH 7.4). In general, VLPs were stored at -80◦C and centrifuged (18,000 x g,
4◦C, 10 min) prior to analysis by SE-UHPLC, DLS or TEM. VLP concentrations were provided
by the project partners or, in the case of MuPyV VLPs, were determined by measuring UV
absorption at 280 nm and using the theoretical extinction coefficient for MuPyV VLP VP1
(1.36 mL/(mg*cm) [37]).
2.4 Size-Exclusion Ultra-High Performance Liquid Chromatog-
raphy
SE-UHPLC analysis was performed on an UltiMate R© 3000 RSLC x 2 Dual system provided
by Thermo Fisher Scientific (Waltham, MA, USA). The UHPLC consisted of a HPG-3400RS
pump module, a WPS-3000 autosampler, a TCC-3200 column oven, and a DAD3000 detector.
System control and peak integration was done with the software Chromeleon R© 6.80 (Thermo
Fisher Scientific, Waltham, MA, USA). Sample injection was done by full-loop injection with
a 20 µL sample loop, a 15 µL injection needle, and a 250 µL syringe. Samples were cooled in
the autosampler at 8◦C prior to column experiments which were performed at 25◦C. UHPLC
measurements were conducted in triplicates. The feasibility of a VLP aggregate separation
by SEC was evaluated with B19 VP1/VP2 VLPs and MuPyV VLPs comparing four different
columns: TSKGel G5000 PWxl [17] (Tosoh Bioscience, Stuttgart, Germany), TSKGel G6000
PWxl (Tosoh Bioscience, Stuttgart, Germany), ACQUITY UPLC Protein BEH450 (Waters
Corporation, Milford, MA, USA), and SRT SEC-1000 (Sepax Technologies, Newark, DE, USA).
An overview of column characteristics and applied flow rates is given in Table 2.












7.8 x 300 mm 13µm >1000
Å




4.6 x 150 mm 2.5µm 450 Å 310 bar 144 cm/h
(0.4 mL/min)
SRT SEC-1000 4.6 x 300 mm 5µm 1000 Å 241 bar 217-361 cm/h
(0.6-1 mL/min)
Interlaced SEC (iSEC) experiments were realized using the SRT SEC-1000 column at a flow
rate of 0.8 mL/min by shifting the ’PrepareNextSample’ (’PNS’) and the ’Inject’ commands of
subsequent samples to earlier points in time (Fig.1). As explained in detail by Diederich et al.
[30], the system was split in two virtual parts in order to record the information phase of each
sample separately. In timebase I, settings for pump, autosampler, and column compartment
were controlled, while timebase II controlled the DAD (Fig.1).
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2.5 Dynamic Light Scattering
For comparison of iSE-UHPLC results, VLP samples were analyzed by dynamic light scattering
(DLS) to determine the hydrodynamic diameter and the polydispersity index (PdI) of VLPs.
DLS measurements were performed using a Malvern Zetasizer Nano ZSP (Malvern Instruments,
Worcestershire, UK). The DLS-based aggregate content was determined by the volume distri-
bution which assumes the presence of spherical particles. Measurements were performed in
triplicates.
2.6 Transmission Electron Microscopy
Transmission electron microscopy (TEM) micrographs were taken on a Philips CM 200 FEG/ST
transmission electron microscope at 200 kV from all VLP samples to visualize the VLP structure,
dispersity, and morphology. The sample preparation procedure has been described earlier [34].
VLPs were coated onto carbon-coated grids, washed with ultra-pure water, and stained using
1% [w/w] uranyl acetate.
2.7 Purification Methods for Aggregate Removal
Size-exclusion chromatography and precipitation with polyethylene glycol (PEG) were evaluated
as potential unit operations for the separation of B19 VP1/VP2 VLPs and VLP aggregates. An
ÄKTA-purifier 10 fast protein liquid chromatography (FPLC) equipped with a pump module
P-900, UV monitor (UV-900), a conductivity monitor, and a fraction collector Frac-950 (GE
Healthcare, Uppsala, Sweden) was used for semi-preparative purifications of B19 VP1/VP2-
VLPs. The software UNICORN 5.31 (GE Healthcare, Uppsala, Sweden) allowed the control
of FPLC methods. B19 VP1/VP2 VLPs were isolated from Sf 9 insect cells by sonication and
subsequent solid-liquid separation steps as described previously [34]. Initial purification was
performed by anion-exchange (AEX) membrane chromatography using 3 mL Sartobind R© Q
membrane adsorbers provided by Sartorius AG (Goettingen, Germany). The method has re-
cently been described by our group [35]. The majority of HCPs, baculoviruses, and DNA were
separated by a bind-and-elute process with three salt steps (0.3 M NaCl (step I), 0.38 M NaCl
(step II), and 1 M NaCl (step III)). 1 mL pre-purified VLPs (pooled fractions from AEX mem-
brane step II) were finally injected on a Superose R© 6 Increase 10/300 column (GE Healthcare,
Uppsala, Sweden) at a flow rate of 38 cm/h (0.5 mL/min) to investigate the separation of VLP
aggregates. Fractions were collected in 300 µL 96-well plates and analyzed by iSE-UHPLC.
Precipitation studies with polyethylene glycol (PEG) 4000 were conducted on a robotic liquid
handling station. A Tecan Freedom EVO R©200 system (Tecan, Crailsheim, Germany) was used
as liquid handling platform and controlled using the software Evoware 2.3 (Tecan, Crailsheim,
Germany). Liquid handling calibration, set-up, and the precipitation screening method were
described earlier [38, 39]. In brief, 300 µL systems with different PEG concentrations and con-
stant VLP concentrations were prepared in 96-well plates in triplicates by mixing ultra pure
water, a 40% [w/w] PEG 4000 stock solution, and pre-purified B19 VP1/VP2-VLPs. Systems
were mixed on an orbital shaker, centrifuged, and supernatant samples were diluted four fold
with PBS prior to analysis by iSE-UHPLC.
2.8 Stability Studies with HPV VLPs
The dispersity of HPV VLPs was assessed under several stress conditions to identify critical
parameters which might trigger the formation of VLP aggregates. Chemical stress was applied
by exchanging the buffer from the formulation buffer containing stabilizing agents to phosphate
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and MOPS buffers with varying ionic strengths. Subsequently, buffer-exchanged VLPs were
stored for 3 d at 8◦C prior to analysis. Thermal stress was applied by incubating VLP samples
on an orbital shaker at 300 rpm for 1-5 h at 40◦C. Incubation at 1400 rpm, 15◦C in 1.5 mL-
polypropylene Eppendorf R© Safe-Lock Tubes with a sample volume of 300 µL was performed
to trigger mechanical stress on VLPs. Freeze-thaw stress was applied by freezing the samples
in 1.5 mL-polypropylene Eppendorf R© Safe-Lock Tubes in liquid nitrogen and thawing them at
25◦C. Prior to analysis, all VLP samples were centrifuged as described above.
3 Results & Discussion
3.1 Development of an Interlaced SEC-UHPLC Method
In the International Conference on Harmonization (ICH) guideline Q2 [40] on the validation
of analytical procedures, it is suggested to verify among others the specificity, precision, lin-
earity, and robustness of novel methods for biopharmaceutical products. The initial objective
was therefore to identify an analytical column separating VLPs and VLP aggregates in order
to develop a specific analytical method. A pre-selection of columns was done based on pore
sizes (>300 Å) and published SEC studies with VLPs [24, 25, 26, 27]. Subsequently, column
performances were compared by injecting B19 VP1/VP2 VLP and MuPyV VLP samples on
the columns in single-injection mode. Fig. 2a shows an overlay of UV chromatograms derived
from the analysis of 8 µg B19 VP1/VP2 VLPs, while Fig. 2b displays the overlay of UV chro-
matograms for SEC runs with 3 µg MuPyV VLPs. In each chromatogram, the UV absorption
at 226 nm is plotted against the mobile-phase volume. Due to different column void volumes,
the elution volumes of VLP components differ between the columns. The void volumes are
2.1 mL for the Acquity BEH 450 column (black solid line), 3.9 mL for the SRT 1000 column
(blue solid line), 12.1 mL for the TSKgel G5000 PWxl column (black dotted line), and 12.3 mL
for the TSKgel G6000 PWxl column (red dotted line). This implies a lower buffer consumption
for SEC runs with Acquity and SRT columns than with TSKgel columns. Neglecting the UV
peaks close to the void volumes, only the SRT 1000 column shows multiple peaks for the VLP
samples: The elution of B19 VP1/VP2 VLPs is split into three peak groups with two minor
and one major peak, while the elution of MuPyV VLPs reveals one minor and one major peak.
Peak fractionation and analysis by SDS-PAGE evidenced the presence of major viral proteins
in all three UV peaks of the B19 VP1/VP2 VLP sample and in the two UV peaks of MuPyV
VLPs (data not shown). Moreover, the total peak areas in the SEC chromatograms generated
with the SRT 1000 column are higher than in those generated with other columns. This sug-
gests a higher recovery and less secondary interactions of VLP components with the SRT 1000
column matrix. The weaker performance of other evaluated columns was attributed to different
base materials (methacrylate vs. silica) and pore sizes (450 Åvs. 1000 Å). It must be noted
that both peak resolution and recovery might have been higher for all columns at lower flow
rates. However, the main goal of this work was to develop a rapid analytical procedure for VLP
aggregates.
In Fig. 2c, the elution of MuPyV VLPs is compared with the elution of a protein standard
composed of thyroglobulin and uracil. The UV chromatogram of the MuPyV VLPs demon-
strates that the major peak at 3.09 mL elutes prior to thyroglobulin (3.38 mL, 17 d.nm [41])
and thyroglobulin aggregates (3.22 mL) indicating a larger size for the MuPyV VLPs and
B19 VP1/VP2 VLPs. Due to the highest selectivity and recovery, the SRT 1000 column was
selected for all subsequent experiments. In the following, the impact of the mobile-phase flow
was evaluated to test the robustness and to accelerate the method. Fig 2c shows the overlay of
chromatograms generated with 2.1 µg MuPyV VLPs at flow rates ranging from 217 to 361 cm/h
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SRT 1000 (300 mm)
TSKgel 5000 PWxl (300 mm)
TSKgel 6000 PWxl (300 mm)
(a) SEC column screening with B19 VP1/VP2
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Acquity BEH450 (150 mm)
SRT 1000 (300 mm)
TSKgel 5000 PWxl (300 mm)
TSKgel 6000 PWxl (300 mm)
(b) SEC column screening with MuPyV VLPs

























(c) Flow rate effect for SRT 1000 column





















6.0 µg MuPyV VLP
4.8 µg MuPyV VLP
3.5 µg MuPyV VLP
2.1 µg MuPyV VLP
0.8 µg MuPyV VLP
0.1 µg MuPyV VLP
(d) Interlaced SEC mode for MuPyV VLPs
Figure 2 Development steps of an interlaced SE-UHPLC method for VLPs. Chromatograms rep-
resent the mean of triplicate determinations. a) Overlaid chromatograms of 8 µg human B19 parvo
(B19 VP1/VP2) VLPs injected on an Acquity BEH450 (black solid line), SRT 1000 (blue solid line),
TSKgel G5000 PWxl (black dotted line), and TSKgel G6000 PWxl column (red dotted line). b) Overlaid
chromatograms of 3 µg murine polyomavirus (MuPyV) VLPs injected on an Acquity BEH450 (black
solid line), SRT 1000 (blue solid line), TSKgel G5000 PWxl (black dotted line) and TSKgel G6000 PWxl
column (red dotted line). c) Overlay of chromatograms of 2.1 µg MuPyV VLPs for an SRT 1000 column
at varying flow rates. The elution profile of a protein standard composed of thyroglobulin and uracil
is plotted as gray dotted line. d) Chromatogram of MuPyV VLPs injected on an SRT 1000 column
in interlaced-injection mode at a flow rate of 0.8 mL/min. Increasing VLP masses were loaded on the
column and are plotted in triplicates.
(0.6-1 mL/min). Chromatograms were hardly influenced by the flow rate in the examined range.
This allows a high-throughput of samples even in single-injection mode. For the implementa-
tion of an iSEC method, an operating flow rate of 289 cm/h (0.8 mL/min) was chosen. The
analysis time at this flow rate was 6.0 min with an initial lag phase of 3.1 min for MuPyV
VLP aggregates and 2.7 min for B19 VP1/VP2 VLP aggregates. In the iSEC method, the
start of timebase II (DAD) was triggered at 2.66 min of timebase I (autosampler and pump).
At 0.34 min of timebase II, the injection of the next sample in timebase I was triggered. The
’PrepareNextSample’ was set at 1.7 min of timebase I to ensure a total analysis time of 3.1 min
per sample. Fig. 2d shows the chromatogram of overlaid triplicate injections of varying MuPyV
VLP concentrations. The elution profile with two major peaks steadily increasing for higher
loadings does not differ at all from the chromatograms generated by the single-injection mode.
This underlines both repeatability and linearity of the iSEC method for the analysis of MuPyV
VLPs. Furthermore, it is shown that the presence and ratio of the two major peaks do not
depend on the injected VLP mass in the investigated range.
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3.2 Characterization of Virus-like Particles by iSE-UHPLC,
TEM & DLS
The developed iSEC method was evaluated for several VLPs in order to test the general ap-
plicability of the method. Moreover, an important issue was whether different peaks in iSEC
chromatograms were created by VLPs of varying sizes or by VLPs of the same size forming
VLP dimers or trimers. Therefore, samples were analyzed by iSE-UHPLC, TEM, and DLS.
Fig. 3 shows an overview of iSE-UHPLC and TEM measurements for five different VLPs, while
Table 3 lists the results obtained from DLS measurements.
Table 3 Summary of VLP characterization by dynamic light scattering (DLS) and interlaced SEC (iSEC)










[d.nm] [% v/v] [%] [min]
HPV VLP 60.8 0.134 0 5.8±0.2 0.93
MuPyV VLP 65.1 0.216 0 8.2±0.4 1.19
EV 71 55.9 0.204 0 14±3.0 1.2
HBcAg VLP 40.3 0.123 0 1.4±0.2 1.33
B19 VP1/VP2 VLP 211.1 0.467 51.5 55.8±0.5 1.42
The UV chromatograms in Fig. 3 are plotted against the measurement time of timebase II.
In the following, only UV peaks with retention times below the iSEC retention time of thy-
roglobulin (1.56 min) are discussed. The chromatogram in Fig. 3a reveals two UV peaks for
a sample containing 16 µg HPV VLPs, while the TEM micrograph displays spherical particles
with pentamer structures and a total particle size of 45-60 nm. Similar particle diameters and
structures were observed by Zhao et al. [42, 15] for HPV VLPs derived from yeast cells. In
the TEM micrographs, there were not any VLPs detected with a size larger than 65 nm, while
DLS analysis determined a mean particle size of 60.8 d.nm for HPV VLPs (Table 3). Hence,
the first peak in the iSEC chromatogram (0.52 min) is probably attributed to the formation
of VLP aggregates as reported by Deschuyteneer et al. [20]. The aggregate level in the HPV
VLP sample was 5.8±0.2% according to the iSEC method, while no aggregates were detected
by DLS measurements (Table 3). For MuPyV VLPs, the iSEC chromatogram in Fig. 3b looks
similar as for HPV VLPs with one minor (0.68 min) and one major UV peak (1.19 min). Again,
TEM micrographs display spherical particles with a similar morphology as HPV VLPs and par-
ticle sizes of 40-50 nm. The VLP aggregate level was 8.2±0.4% according to iSE-UHPLC. The
presence of aggregates in MuPyV VLP preparations has also been reported by Pease et al. [19]
and Mohr et al. [43]. Fig. 3c shows the iSEC chromatogram of 2.0 µg EV71 VLPs. The major
peak elutes at 1.2 min. The UV absorption signal is noisy and very low with a maximum at
1.2 mAU demonstrating that observed peaks are close to the detection limit of the DAD. This
impedes the exact quantification of VLP aggregates. Despite a low concentration, the presence
of spherical particles in the EV71 VLP sample is demonstrated by the TEM micrograph. In
contrast to other analyzed VLPs revealing empty particles, EV71 VLPs appeared as solid par-
ticles with diameters of 35-50 nm. A similar particle structure and morphology of EV71 VLPs
was observed by Liu et al. [44]. According to DLS measurements, the average particle size for
EV71 VLPs was 55.9 nm and no aggregates were detected. In Fig. 3d, the iSEC chromatogram
and TEM micrograph of 50 µg chimeric HBcAg VLPs are displayed. The chromatogram shows
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Figure 3 Characterization of virus-like particles by interlaced SE-UHPLC and transmission electron
microscopy (TEM). Chromatograms and TEM micrographs are arranged according to decreasing particle
sizes: a) 16 µg human papilloma (HPV) VLPs, b) 6.0 µg murine polyomavirus (MuPyV) VLPs, c) 2.0 µg
human enterovirus 71 (EV71) VLPs, 50 µg chimeric HBcAg VLPs, and e) 10 µg human B19 parvo (B19
VP1/VP2) VLPs.
a uniform dispersity with one major peak eluting at 1.33 min. The TEM micrograph illustrates
a high number of empty particles with diameters ranging from 35 to 40 nm. The mean particle
diameter determined by DLS was 40.3 nm. The aggregate level according to the iSE-UHPLC
method was 1.4±0.2%, while no aggregates were detected by DLS measurements. Fig. 3e dis-
plays the chromatogram of a sample containing 10 µg B19 VP1/VP2 VLPs. Three UV peaks
eluting at 0.6 min, 1.04 min, and 1.42 min indicate a polydisperse distribution. In contrast, the
TEM micrograph shows homogeneous icosahedral empty particles with a size of 25-30 nm. Con-
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sidering the elution times of thyroglobulin (1.56 min, 17 d.nm [41]) and HPV VLPs (0.93 min,
60 d.nm), the UV peak at 1.42 min shows probably the elution of B19 VP1/VP2 VLPs while the
other two peaks are attributed to VLP dimers (1.04 min) and larger VLP aggregates (0.6 min).
Both DLS and iSE-UHPLC analysis evidence an aggregate level above 50% (Table 3). Such an
unusually high amount of aggregates in B19 VP1/VP2 VLP samples has not yet been reported
elsewhere. Since B19 VP1/VP2 VLPs are evaluated as human vaccine candidates against dis-
eases attributed to parvovirus infections [33], the impact of aggregates on safety, immunogenicity
and reactogenicity of a VLP vaccine should be carefully evaluated in the future. Skin reactions
reported in a clinical phase study with a B19 VP1/VP2 VLP vaccine candidate [45] might have
been attributed to increased levels of VLP aggregates.
Summarizing the VLP characterization by the developed iSE-UHPLC method, it could be
demonstrated that a resolution of VLPs and VLP aggregates in the size range of 20-120 nm is
feasible. Although the DLS results listed in Table 3 indicated the presence of aggregates in the
B19 VP1/VP2 VLP sample, no aggregates were detected by the method for other VLP sam-
ples. Nevertheless, the polydispersity index (PdI) given by the DLS instrument correlates with
the aggregate level determined by the iSEC method. The lowest PdI of 0.123 was determined
for HBcAg VLPs containing 1.4% aggregates, while the highest PdI of 0.467 was identified for
B19 VP1/VP2 VLPs containing 55.8% aggregates. Comparing results from DLS, TEM and iSE-
UHPLC analysis, the iSEC method provides a precise and robust high-throughput analytical
technique for VLPs.
3.3 Purification Tools for the Separation of VLP Aggregates
In the following, the developed iSE-UHPLC method was applied for the assessment of VLP pu-
rification procedures. The characterization of VLPs has revealed the presence of aggregates in
all measured VLP samples. The propensity of aggregate formation during VLP processing can
be manipulated by adding stabilizers such as detergents, sugars or polyols into buffer solutions
of purification and storage process chains [43, 46]. However, irreversible aggregates also form
during expression in cell culture, and apart from stabilization procedures, there is a demand
for separation techniques for VLP aggregates. In this work, the highest aggregate level was
determined for B19 VP1/VP2 VLPs making these particles attractive to evaluate the effect of
downstream processing on the aggregate level. Fig. 4a shows the iSEC chromatogram of the
same VLP insect cell feedstock purified by different purification procedures. Chromatograms
are normalized to the VLP monomer peak at 1.42 min to highlight varying aggregate levels.
The residual DNA levels were below 20 ng/mL, and protein purities varied between 81% (AEX
membrane sample [35]) and 99% (ultracentrifugation sample) according to measurements by
picogreen assay and capillary gel electrophoresis (data not shown). The elution profiles demon-
strate that peaks eluting between 0 and 1.2 min show the highest UV areas for VLPs purified
by ultracentrifugation (55.8±0.5%) and the lowest for VLPs purified by a combination of AEX
membrane chromatography and SEC [35] (5.9±0.4%). Moreover, VLP samples purified by an
ATPS and precipitation procedure revealed a lower aggregate level (27.5±0.4%) than VLPs
purified by AEX membrane chromatography (30.7±0.7%). These findings suggest that a sepa-
ration of aggregates might be feasible by both chromatographic and non-chromatographic unit
operations.
Fig. 4b shows the chromatogram of a VLP aggregate separation by size-exclusion chromatogra-
phy on an FPLC system. 1500 µg B19 VP1/VP2 VLPs purified by AEX membrane chromatog-
raphy were injected on a Superose R© 6 Increase 10/300 column. VLP monomers (green bars)
and VLP aggregates (red bars) were tracked by the iSE-UHPLC method. The elution profile
displays three major peaks for the VLP sample: VLP aggregates (9.1 mL), VLP monomers
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(a) UHPLC chromatograms for VLPs purified by different
downstream processes





































(b) Separation of VLP aggregates by SEC

























(c) Separation of VLP aggregates by SEC
Figure 4 Comparison of purification tools for the separation of VLP aggregates from human B19 parvo
(B19 VP1/VP2) VLPs. a) UHPLC chromatograms for VLPs purified by ultracentrifugation (black
solid line), anion-exchange (AEX) membrane chromatography (purple dotted line), aqueous two-phase
extraction (ATPS) and precipitation (red dotted line), and AEX membrane chromatography and SEC
(rose solid line). b) Chromatogram of a B19 VP1/VP2 VLP polishing step on a Superose R© 6 Increase
column tracking VLPs (green bars) and VLP aggregates (red bars). c) Solubility curves for 0.5 mg/mL
B19 VP1/VP2 VLPs tracking VLPs (black) and VLP aggregates (blue) at increasing concentrations of
polyethylene glycol 4000.
(11.5 mL), and residual HCPs (16.4 mL). Hence, a separation of VLP aggregates was also ren-
dered with a preparative SEC resin. In Fig. 4c, iSEC UV peak areas of VLP monomers (black
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dotted line) and VLP aggregates (blue spotted line) are plotted against increasing concentra-
tions of PEG 4000. Data points are interpolated with lines to guide the eye and represent the
soluble fraction of each component at a certain PEG concentration. A decrease of solubility is
observed at different PEG concentrations for VLP monomers and VLP aggregates. While VLP
aggregates precipitated thoroughly at 10% [w/w] PEG 4000, about 81±2% VLP monomers
were detected in the soluble fraction at this concentration. Thus, a separation of irreversible
VLP aggregates might be realized by adding PEG to a VLP sample, performing a solid-liquid
separation and finally formulating VLPs in a stabilizing buffer to prevent the formation of new
aggregates. A similar approach has, for instance, been used for the separation of IgG aggregates
by Giese et al. [47].
3.4 Effect of Process Conditions on the Stability of HPV VLPs
The propensity to form aggregates varies for each VLP depending on structural characteristics
and process conditions such as pH, ionic strength, temperature, shear forces, freeze-thaw cycles
or interactions with equipment surfaces. The developed iSE-UHPLC method is a rapid assay
to evaluate the effect of such process conditions on VLPs. In a case study, HPV VLPs with
a comparably low level of aggregates (5.8±0.2%) were exposed to different stress conditions.
Fig. 5 gives an overview of iSEC chromatograms for HPV VLPs subjected to chemical, thermal,
mechanical and freeze-thaw stress conditions. Chromatograms were normalized to the VLP
monomer peak to highlight changes in aggregate levels.
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Figure 5 Characterization of human papilloma (HPV) VLPs under different stress conditions. a) The
impact of ionic strength on the formation of aggregates was assessed by storing 0.4 mg/mL VLPs in
different buffer solutions for 3 d at 8◦C. b) Thermal stress was applied by heating 0.8 mg/mL VLPs at
40◦C for 1-5 h. c) Mechanical stress was applied by incubating 0.8 mg/mL VLPs on an orbital shaker at
1400 rpm for 1-24 h. d) Stress by freeze-thawing was applied by 2-6 cycles of freezing in liquid nitrogen
with subsequent thawing at room temperature at a VLP concentration of 0.8 mg/mL. VLPs underwent
the first freeze-thaw cycle upon sample preparation.
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Fig. 5a depicts the impact of ionic strength and buffer components on the VLP aggregate
level. VLPs that were buffer-exchanged and stored for three days in a phosphate buffer without
additional neutral salt revealed the highest level of aggregates (9.6±0.2%), while the lowest
aggregate level was observed for VLPs stored in 0.2 M MOPS with 0.5 M NaCl (6.7±0.2%).
In general, there was a clear trend of a decrease in aggregate levels with increasing salt con-
centrations and with MOPS buffers instead of phosphate buffers. Both buffer components are
usually used during purification of HPV VLPs by cation-exchange (CEX) chromatography and
mixed-mode (MM) chromatography [36]. Fig. 5b shows the effect of exposure to an elevated
temperature (40◦C) on the formation of VLP aggregates. An increase in aggregate levels from
5.8±0.2% to 10.4±0.3% was observed after sample incubation for five hours at 40◦C. Aggregate
levels steadily increased with increasing heat exposure time. Thermal stability studies are es-
pecially important to assess risks arising due to interrupted cold chains or inadequate storage
conditions. The obtained results demonstrate that the investigated stabilized and formulated
HPV VLPs are prone to form aggregates when exposed to 40◦C for more than one hour. In
contrast, Fig. 5c and Fig. 5d indicate that mechanical stress such as intense mixing for up to 24
hours and numerous freeze-thaw cycles hardly change the dispersity of HPV VLPs in the used
formulation buffer. Aggregate levels vary between 5.8±0.2% and 6.7±0.2%. This confirms the
findings of Shi et al. [14] identifying the non-ionic surfactant polysorbate 80 as stabilizer for
HPV VLPs during freezing and reconstitution as well as mechanical stress conditions.
4 Conclusion & Outlook
In this work, we report the development and application of a high-throughput analytical tool
for the characterization of virus-like particles. Recently, the relevance of SE-HPLC methods
for viral vaccines has been highlighted by Yang et al. [21]. Using a low-dispersion UHPLC
system, we identified an SRT 1000 column as optimal SEC column for quantification of VLP
aggregates at low buffer consumption and high flow rates. The implementation of an interlaced
SE-UHPLC procedure allowed the characterization of VLPs within 3.1 min. To the best of
our knowledge, this represents the fastest so far reported method for the quantification of VLP
aggregates. The feasibility of the assay was proven for a variety of VLPs with total particle sizes
ranging from 20 to 120 d.nm. The VLP characterization by the iSEC method was supported
and complemented by TEM and DLS measurements. In two case studies applying the assay,
we demonstrated how aggregate levels are manipulated by both downstream processing and
storage of VLPs. Promising conditions for aggregate removal by precipitation with polyethylene
glycol were determined applying high-throughput experimentation on a robotic liquid-handling
station. The developed analytical method enables rapid assessment of suitable purification and
formulation procedures for VLPs. Future studies should focus on evaluating the impact of VLP
aggregates on product quality attributes. In order to ensure both safety and immunogenicity of
VLP vaccines, it will be important to specify acceptable and alarm limits for VLP aggregates,
identify critical process parameters (ICH Q7 [48]), and define design spaces for production
processes (ICH Q8 [49]). A well-suited process analytical technique for this purpose has been
presented herein.
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4 Conclusion & Outlook
Improving global access to biopharmaceutical drugs and vaccines and accelerating manu-
facturing processes in the light of pandemic threats represent major challenges for current
technologies. This doctoral thesis was centered on developing economic, innovative and
rapid process solutions for a novel molecular entity of vaccine, gene therapy and diag-
nostic products: virus-like particles (VLPs). Prospects, production routes and process
bottlenecks of this class of large biomolecules were described. Based on these findings,
different strategies were applied for development and optimization of VLP processes.
A key aspect of this thesis was the method development of aqueous two-phase extraction
(ATPE) processes for purification of large biomolecules. For miniaturized process develop-
ment a high-throughput screening (HTS) procedure combining ATPE and precipitation
was designed. The novel HTS tool incorporated automated precipitation, solid-liquid
separation and resolubilization steps on a robotic liquid handling station. Downstream
processes for monoclonal antibodies (mAbs) and VLPs were successfully developed with
the non-chromatographic HTS purification tool obtaining a high product recovery, ca-
pacity and purity. The HTS approach allowed the generation of a large dataset of ATPS
phase diagrams and partitioning patterns that were effectively correlated with solubility
curves of both target and contaminant components. Critical process parameters and op-
timal design spaces for ATPS partitioning of VLPs and mAbs were identified. Future
studies should focus on transferring the results obtained in miniaturized batch systems to
multi-stage and larger scale instruments. First experiments on multi-stage ATPE of mAbs
and VLPs by centrifugal partition chromatography (CPC) revealed promising results re-
garding separation efficiency and product stability. However, for an industrially relevant
process alternative, future work should focus on automating and miniaturizing multi-
stage ATPE and modeling the mass transfer with hydrodynamic and thermodynamic
approaches. Especially the establishment of a robust thermodynamic model will deter-
mine the industrial feasibility of ATPE complying with regulatory guidelines on deeper
process understanding (’Quality by Design (QbD)’). The generation of ATPS data bases
and further HTS systematization to user-friendly screening formats as in chromatography
would additionally accelerate the ongoing trend towards industrial applications.
The relevance of HTS approaches for process development was also underlined in this
thesis by the design of an alternative production process for VLPs. Application of HTS
tools such as micro-scale cultivations, capillary gel electrophoresis and micro-scale cell
lysis allowed a rapid optimization of the expression of the murine polyoma virus pro-
tein VP1 in Escherichia coli. The microbial upstream process allows a highly economic
production of murine polyomavirus (MuPyV) VLPs. These VLPs have proved to be
effective as chimeric vaccine platforms in multiple preclinical studies. Future research
should focus on the development and clinical evaluation of tailored MuPyV VLP vaccine
candidates based on the novel production process. Potential process deviations caused
by fused antigenic epitopes will be rapidly adaptable by the developed HTS methods.
In general, the applied HTS approaches for upstream and downstream processing were
especially valuable for designing processes where no physical models exist.
In order to design a more chromatographic-like purification procedure for VLPs, an anion-
exchange membrane process was developed using a hybrid approach of HTS methods and
mechanistic modeling. Mass transfer in spiral wound membrane modules was simulated
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by implementing a hydrodynamic model for radial flow. Modeling of electrostatic inter-
actions during a VLP capture step from a complex insect cell lysate was realized by UV
absorption-based modeling with scaled component specific parameters of the steric mass
action (SMA) model. Therefore, the feedstock was divided into 17 component groups
differing in AEX membrane elution behaviour. Subsequent to parameter estimation with
automated algorithms, a design space for controlling and forecasting the elution of VLPs
and impurities was developed. The in silico optimized process resulted in a high VLP
purity and demonstrated the high convenience of the novel model approach for complex
industrial feedstocks. However, drawbacks of the designed membrane process were the
high product loss due to irreversible binding and the reduced process performance at
higher flow rates. Future studies should consider the evaluation of novel membrane de-
signs and ligands as well as tracking of conformational VLP changes during processing.
Concerning VLP characterization, a novel HTS method based on size-exclusion ultra-high
performance liquid chromatography (UHPLC) was established. The developed method
allowed analysis of 20 samples per hour applying interlaced injections. Five different
VLP vaccine candidates were successfully characterized with the method. The relevance
of the novel tool as process analytical technique was highlighted by HTS case studies on
the separation of VLPs and aggregates and the stability of human papilloma VLPs at
varying stress conditions. The analytical procedure has the potential to become a novel,
rapid and robust quality control assay for viral or VLP-based vaccines.
In conclusion, this doctoral thesis has enlarged the purification and process development
toolbox for VLPs. The advanced methodologies for HTS- and model-based approaches
will facilitate manufacturing of current and future VLP products. Prospective studies
should focus on evaluating ATPE, precipitation and membrane chromatography for VLPs
with varying epitopes and lipid envelopes. Both VLP structures will be highly important
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Fischer, I., Hsu, C.-C., Gärtner, M., Müller, C., Overton, T. W., Thomas,
O. R. T. and Franzreb, M. (2013). Continuous protein purification using function-
alized magnetic nanoparticles in aqueous micellar two-phase systems. J. Chromatogr.
A, 1305:7.
Freundlich, H. (1906). Over the adsorption in solution. J. Phys. Chem, 57:385.
Garcea, R. L. and Gissmann, L. (2004). Virus-like particles as vaccines and vessels
for the delivery of small molecules. Curr. Opin. Biotechnol., 15:513.
Ghosh, R. (2002). Protein separation using membrane chromatography : opportunities
and challenges. J. Chromatogr. A, 952:13.
Gibson, T. J., Mccarty, K., Mcfadyen, I. J., Cash, E., Dalmonte, P., Hinds,
K. D., Dinerman, A. A., Alvarez, J. C. and Volkin, D. B. (2011). Application of
a High-Throughput Screening Procedure with PEG-Induced Precipitation to Compare
Relative Protein Solubility During Formulation Development with IgG1 Monoclonal
Antibodies. J. Pharm. Sci., 100:1009.
Grabherr, R. and Reichl, U. (2015). Editorial: Can modern vaccine technology
pursue the success of traditional vaccine manufacturing? Biotechnol. J., 10(5):657.
Gross, J. and Sadowski, G. (2001). Perturbed-Chain SAFT: An Equation of State
Based on a Perturbation Theory for Chain Molecules. Ind. Eng. Chem. Res., 40(4):1244.
Grudzien, L., Land Madeira, Fisher, D., Ma, J. and Garrard, I. (2013).
Phase system selection with fractional factorial design for purification of recombinant
cyanovirin-N from a hydroponic culture medium using centrifugal partition chromatog-
raphy. J. Chromatogr. A, 1285:57.
Gu, T., Tsai, G.-J. and Tsao, G. T. (1991). A theoretical study of multicomponent
radial flow chromatography. Chem. Eng. Sci., 46:1279.
Guo, P., El-Gohary, Y., Prasadan, K., Shiota, C., Xiao, X., Wiersch, J.,
Paredes, J., Tulachan, S. and Gittes, G. K. (2012). Rapid and simplified pu-
rification of recombinant adeno-associated virus. J. Virol. Methods, 183:139.
Hahn, B. T. J., Courbron, D., Hamer, M., Masoud, M., Wong, J., Taylor,
K., Hatch, J., Sowers, M., Shane, E., Nathan, M., Jiang, H. U. A., Wei, Z.,
Higgins, J., Roh, K.-h., Burd, J., Chinchilla-olszar, D., Malou-williams,
M., Baskind, D. P. and Smith, G. E. (2013). Rapid Manufacture and Release of
a GMP Batch of Avian Influenza A(H7N9) Virus-Like Particle Vaccine Made Using
Recombinant Baculovirus-Sf9 Insect Cell Culture Technology. Bioprocess. J., 12(2):1.
Hahn, T., Huuk, T., Heuveline, V. and Hubbuch, J. (2015a). Simulating and
Optimizing Preparative Protein Chromatography with ChromX. J. Chem. Educ.
Hahn, T., Huuk, T., Osberghaus, A., Doninger, K., Nath, S., Hepbildikler,
S., Heuveline, V. and Hubbuch, J. (2015b). Calibration-free inverse modeling of




Hahn, T., Sommer, A., Osberghaus, A., Heuveline, V. and Hubbuch, J. (2014).
Adjoint-based estimation and optimization for column liquid chromatography models.
Comput. Chem. Eng., 64:41.
Hansen, S. K. and Oelmeier, S. a. (2012). Meeting report: High-throughput process
development - HTPD 2012. Biotechnol. J., 7:1189.
Hanson, C. (2013). Recent advances in liquid-liquid extraction. Elsevier.
Hatti-Kaul, R. (2000). Aqueous Two-phase Systems: Methods and Protocols. Methods
in biotechnology. Humana Press.
Hayenga, K. and Valex, P. (2002). Methods for protein purification using aqueous
two-phase extraction. US Patent 6,437,101.
Herwig, C., Garcia-Aponte, O. F., Golabgir, A. and Rathore, A. S. (2015).
Knowledge management in the QbD paradigm: manufacturing of biotech therapeutics.
Trends Biotechnol., 33:381.
Holmes, K., Shepherd, D. a., Ashcroft, A. E., Whelan, M., Rowlands, D. J.
and Stonehouse, N. J. (2015). Assembly pathway of hepatitis B core virus-like
particles from genetically fused dimers. J. Biol. Chem., 290:16238.
Hopmann, E. and Minceva, M. (2012). Separation of a binary mixture by sequential
centrifugal partition chromatography. J. Chromatogr. A, 1229:140.
Hubbuch, J. (2012). Editorial: High-throughput process development. Biotechnol. J.,
7:1185.
Huuk, T. C., Hahn, T., Osberghaus, A. and Hubbuch, J. (2014). Model-based
integrated optimization and evaluation of a multi-step ion exchange chromatography.
Sep. Purif. Technol., 136:207.
Ito, Y. and Bowman, R. L. (1977). Horizontal Flow-Through Coil Planet Centrifuge
without Rotating Seals. Anal. Biochem., 83:63.
Ito, Y., Weinstein, M., Aoki, I., Harada, R., Kimura, E. and Nunogaki, K.
(1966). The Coil Planet Centrifuge. Nature, 212:985.
Josefsberg, J. O. and Buckland, B. (2012). Vaccine process technology. Biotechnol.
Bioeng., 109:1443.
Jue, E., Yamanishi, C. D., Chiu, R. Y. T., Wu, B. M. and Kamei, D. T. (2014).
Using an aqueous two-phase polymer-salt system to rapidly concentrate viruses for
improving the detection limit of the lateral-flow immunoassay. Biotechnol. Bioeng.,
111:2499.
Kaczmarczyk, S. J., Sitaraman, K., Young, H. a., Hughes, S. H. and Chat-
terjee, D. K. (2011). Protein delivery using engineered virus-like particles. Proc.
Natl. Acad. Sci. U. S. A., 108:16998.
189
REFERENCES
Karpenko, L. I., Ivanisenko, V. A., Pika, I. A., Chikaev, N. A., Eroshkin,
A. M., Veremeiko, T. A. and Ilyichev, A. A. (2000). Insertion of foreign epitopes
in HBcAg : how to make the chimeric. Amino Acids, 18:329.
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Hiller, T., Kreiter, S., Markl, J., Türeci, O. and Sahin, U. (2011). Highly
specific auto-antibodies against claudin-18 isoform 2 induced by a chimeric HBcAg
virus-like particle vaccine kill tumor cells and inhibit the growth of lung metastases.
Cancer Res., 71:516.
Lacson, E., Teng, M., Ong, J., Vienneau, L., Ofsthun, N. and Lazarus, J. M.
(2005). Antibody response to Engerix-B s and Recombivax-HB s hepatitis B vaccination
in end-stage renal disease. Hemodial. Int., 9:367.
Ladiwala, A., Rege, K., Breneman, C. M. and Cramer, S. M. (2005). A priori
prediction of adsorption isotherm parameters and chromatographic behavior in ion-
exchange systems. Proc. Natl. Acad. Sci. U. S. A., 102:11710.
Langmuir, I. (1916). The constitution and fundamental properties of solids and liquids.
Journal of the American Chemical Society, 38:2221.
Lee, C.-k., Wang, N.-h. and Ju, Y.-h. (1995). Purification of Aspartase by Aqueous
Two-Phase System and Affinity Membrane Chromatography in Sequence. Sep. Sci.
Technol., 30:509.
Lin, S.-Y., Yeh, C.-T., Li, W.-H., Yu, C.-P., Lin, W.-C., Yang, J.-Y., Wu,
H.-L. and Hu, Y.-C. (2015). Enhanced enterovirus 71 virus-like particle yield from a
new baculovirus design. Biotechnol. Bioeng., 112:2005.
Link, A., Zabel, F., Schnetzler, Y., Titz, A., Brombacher, F. and Bachmann,
M. F. (2012). Innate immunity mediates follicular transport of particulate but not
soluble protein antigen. J. Immunol., 188:3724.
Love, J. C., Love, K. R. and Barone, P. W. (2013). Enabling global access to
high-quality biopharmaceuticals. Curr. Opin. Chem. Eng., 2:383.
Low, J. G. H., Lee, L. S., Ooi, E. E., Ethirajulu, K., Yeo, P., Matter, A.,
Connolly, J. E., Skibinski, D. a. G., Saudan, P., Bachmann, M., Hanson,
B. J., Lu, Q., Maurer-Stroh, S., Lim, S. and Novotny-Diermayr, V. (2014).
Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009
vaccine: results from a double-blinded, randomized Phase I clinical trial in healthy
Asian volunteers. Vaccine, 32:5041.
190
REFERENCES
Lu, Y., Chan, W., Ko, B. Y., VanLang, C. C. and Swartz, J. R. (2015). Assessing
sequence plasticity of a virus-like nanoparticle by evolution toward a versatile scaffold
for vaccines and drug delivery. Proc. Natl. Acad. Sci., pages 1–6.
Lua, L. H. L., Connors, N. K., Sainsbury, F., Chuan, Y. P., Wibowo, N.
and Middelberg, A. P. J. (2014). Bioengineering virus-like particles as vaccines.
Biotechnol. Bioeng., 111:425.
Luechau, F., Ling, T. C. and Lyddiatt, A. (2010). A descriptive model and methods
for up-scaled process routes for interfacial partition of bioparticles in aqueous two-phase
systems. Biochem. Eng. J., 50:122.
Madeira, P. P., Bessa, A., de Barros, D. P. C., Teixeira, M. a., álvares
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